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ABSTRACT
P-glycoprotein (P-gp) is a membrane glycoprotein which can act as an efflux pump 
for certain chemotherapeutic drugs and thereby confers resistance to these drugs on the host 
cell. The P-gp isoform encoded by the human mdrl gene has been implicated as a factor in 
clinical resistance in human tumours. To investigate the role of P-gp in acquired clinical 
resistance, dogs with malignant lymphoma which were referred to Glasgow University 
Veterinary College for treatment, were given an anthracycline based protocol until first 
relapse. Tumour samples were obtained from these dogs at diagnosis and at time of disease 
progression. P-gp expression in these samples was assessed by immunohistochemistry using 
a monoclonal antibody which detects all known P-gp isoforms and by dot-blot analysis using 
a human mdrl specific probe.
Multiple members of the mdr gene family exist in every species studied and only the 
mdrl isoform(s) is implicated in drug resistance. Investigations of the canine mdr gene family 
revealed that the dog has four potential members of this family. The homologue of the human 
mdrl gene was expressed in normal canine liver, kidney and adrenal and at a lower level in 
the caudal gastro-intestinal tract. Skeletal and cardiac muscle tissue has strong P-gp 
expression but this did not appear to be of the mdrl homologue isoform.
Immunohistochemistry revealed that normal, reactive and lymphomatous nodes 
contain a P-gp positive dendritic cell population. These P-gp positive cells are 
morphologically identical to S-100 positive cells and so may represent an antigen presenting 
cell population. The presence of these cells could confound accurate interpretation of the dot- 
blot analysis and so imunohistochemistry was used as the |main criterion to determine P-gp 
positivity in the malignant cell population.
Within tumour cells, P-gp expression at time of diagnosis was a rare occurrence (less 
than 5%) but was significantly more common in drug resistant tumours (p=0.0113). 
However, even within the drug refractory tumours, P-gp expression was not ubiquitous; only 
25% of tumours were P-gp positive and therefore P-gp does not appear to be a major cause of 
treatment failure in canine lymphoma. Statistical analysis of the results revealed that P-gp 
was associated with advanced stage disease. Advanced stage at presentation seemed a more 
important predictor of subsequent P-gp expression than the amount or type of drugs received 
prior to relapse. Treatment with corticosteroids prior to chemotherapy had a profound effect 
on the ability to achieve remission but again this was not related to the presence of P-gp.
Canine T cell lymphomas are reported to have a poorer clinical performance than B 
cell tumours. T cell tumours were positively identified in this group of dogs by genotyping 
using a feline constant region probe of the T cell receptor p chain gene. 10/45 tumours were 
identified as having p chain rearrangements by this technique. The T cell genotype was a 
poor prognostic indicator by univariate analysis but none of the T cell tumours expressed P- 
gp, either before treatment or at relapse, indicating that P-gp is not a major cause of treatment 
failure in T cell lymphomas.
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1.1 NON-HODGKINS LYMPHOMAS
1.1.1 CLINICAL DRUG RESISTANCE IN NON-HODGKINS LYMPHOMA
Chemotherapy can be an extremely effective cancer treatment. Cures, 
resulting from intensive chemotherapy, are now obtainable in Hodgkin's disease, 
certain forms of non-Hodgkin's lymphoma, acute lymphoblastic leukaemia and 
testicular cancer (Chabner et ah 1984). This list of neoplastic diseases represent a 
uniquely chemosensitive group of cancers. Unfortunately though, when a relapse 
does occur in these cancers, it is usually associated with the development of clinical 
drug resistance and further response to chemotherapy is limited.
Clinical resistance to chemotherapeutic agents is complex; the drugs which 
are rendered apparently ineffective at relapse can be of divergent structure and 
function. Tumours can acquire resistance to drugs, which are usually effective in first 
line treatment, even without prior exposure (Armitage et al, 1990). The breadth and 
diversity of acquired resistance in these once chemosensitive tumours then resembles 
the inherent resistance of tumour types such as colonic and hepatic carcinomas and 
melanomas.
In the first part of this introductory chapter the heterogeneous group of 
tumours collectively known as non-Hodgkins lymphoma (NHL) will be described. 
This group contains tumours which are chemocurable yet at the other extreme 
contains indolent tumours whose natural course is undeterred by chemotherapy. The 
majority of NHL show a pattern of initial response to chemotherapy followed by 
relapses which are increasingly unresponsive to chemotherapy. This epitomises the 
problem of acquired drug resistance in clinical oncology. Socioeconomically, NHL is 
an important tumour group; it is the tenth most common cancer-related death in males 
in the U.K. (CRC Factsheet, 1988). The biological factors which contribute to the 
heterogeneity of NHL will be examined including the histologic and cytogenetic 
events which occur during the progression of certain forms of this disease.
In the second section, canine lymphomas are introduced; the clinical and 
biological similarities to NHL are highlighted. Paramount among these similarities is 
the chemosensitivity of canine lymphomas which then gives way to profoundly drug- 
resistant disease, usually within one year. Like NHL, canine lymphoma is a 
numerically important disease with an annual incidence of between 24 and 30.5 cases 
per 100,000 dogs (Dom et al 1967; Schneider, 1983). This is higher than the human 
incidence of NHL which is about 9 per 100,000 in the U.K. (Cancer Research 
Campaign, Factsheet 1988).
In the final section, the chemotherapeutic drug-resistance mechanism 
mediated by P-glycoprotein (P-gp) is discussed. Due to widespread research effort in 
the past five years, this represents one of the best defined resistance mechanisms
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applicable to clinical oncology. The activity of P-gp as a resistance mechanism can 
be successfully ameliorated in vitro using non-cytotoxic drugs (reviewed in Bellamy 
et al, 1990) and inevitably this has generated great excitement that it may be possible 
to overcome clinical multiple drug resistance using P-gp modulating drugs in 
conjunction with normal chemotherapy (Dalton et al, 1989; Salmon et al, 1991). 
This has fuelled research to identify the tumour groups which are likely to be 
amenable to modulation. Simultaneously, efforts have been directed towards 
identifying the events which lead to P-gp expression and whether this expression is 
avoidable by alterations in the existing chemotherapeutic protocols.
1.1.2 HISTOPATHOLOGICAL CLASSIFICATION OF NHL
NHL is a heterogeneous group of tumours derived from cells of lymphocytic 
origin. The natural course of NHL varies from a slow-growing indolent form, to a 
fulminating leukaemic type illness. The majority of tumours fall in between these two 
extremes and show an unremitting progression if left untreated. Histopathology is the 
traditional method of defming these different groups.
Table 1.1 Working Formulation Histopathological Grades
Low Grade small lymphocytic 
follicular small cleaved 
follicular mixed
Intermediate Grade follicular large cell 
diffuse small cleaved cell 
diffuse mixed 
diffuse large cell
High Grade 
(Burkitts)
diffuse small non-cleaved cell
diffuse immunoblastic * 
lymphoblastic
adult T cell leukaemia/lymphoma^
1. The National Cancer Institute (NCI) has adapted the WF slightly and considers 
immunoblastic tumours to be intermediate grade based on their clinical behaviour.
2. Adult T cell leukaemia!lymphoma associated with HTLV-1 infection was not 
included in the original classification scheme but is included in the NCI clinical 
schema for malignant lymphomas (DeVita et al. 1989)
The original classification system devised by Rappaport (Rappaport et al. 
1956) differentiated primarily according to the pattern of growth (follicular versus 
diffuse) rather than on cellular characteristics. It became apparent that with the 
Rappaport scheme, there was still considerable heterogeneity among some of the
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higher grades of tumour (DeVita et al. 1982; Levine et al, 1985a). Other 
classification schemes were devised, including the Lukes-Collins and Kiel systems 
which placed greater emphasis on the cellular morphology (Lukes et al. 1974; 
Lennert et al. 1975). Eventually in 1982 these schemes were amalgamated into the 
"Working Formulation" (The non-Hodgkins lymphoma pathologic classification 
system, 1982), which is illustrated in table 1.1.
1.1.3 IMMUNOPHENOTYPING NHL
(i) Basic principles
Traditional methods of immunophenotyping lymphoid malignancies were 
based on the detection of surface and /or cytoplasmic Ig on B cells and the ability of 
T cells to rosette sheep erythrocytes. Detection of heavy and light chain Ig remains 
one of the most specific determinants of B cell lineage but T cell rosetting has been 
superseded by the availability of monoclonals against lineage specific antigens.
There has been a rapid increase in the number of monoclonals against 
lymphoid markers in recent years. Knapp et al (1989), when commenting on the 
remarkable progress in this area, also noted that as surface membrane investigations 
proceed, the borders between different cell types (including myeloid cells as well as 
lymphoid cells) are being fudged rather than strengthened; many of the cluster 
determinant (CD) groups are no longer considered to be absolutely lineage specific. 
With this proviso in mind, clinical immunophenotyping depends on the use of panels 
of monoclonal antibodies rather than one or two single reagents.
It must be appreciated that because NHL is, overall, composed of relatively 
mature cell types, the role of CD 10 (CALLA) and many of the other surface antigens 
found in very early lymphoid cells (e.g. CD7) in distinguishing prognostic groups is 
not so critical as it is in ALL (Foon & Todd, 1986). These complexities plus the 
advantages and disadvantages of individual monoclonals have been discussed in 
detail by Norton & Isaacson, (1989b) and Foon & Todd, (1986). The range of CD 
groups which at present would appear critical and are most commonly used for 
lineage determination in NHL are shown in table 1.2
Table 1.2 Immunophenotyping NHL
B cell lineage T cell lineage
Ig heavy and light chain 
{surface or cytoplasmic) 
CD 19, CD20, CD40, CD72
CD2, CD3, CD7, 
CD4,
CD8
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(ii) Limitations to immunophenotypic and histopathologic classification of NHL
Immunohistochemistry and detailed histopathology are labour intensive 
techniques which require a great deal of expertise. It is difficult to provide quality 
control and reproducibility between institutes and even individuals. When the expert 
pathologists who developed the Working Formulation were tested for the 
consistencies of their diagnosis, the rate of reproducibility varied from 53-93% (NCI 
non-Hodgkins classification project writing committee).
An editorial, commenting on phenotyping of haematologic malignancies, 
(Hanson, 1991) maintains that the problem of "background” in
immunohistochemistry is frequently ignored or minimized in the literature. Low level 
expression of antigens, at the limit of the methodology, is another important limiting 
factor (Wamke et al., 1985). The loss of antigen expression, either through tissue 
handling and fixation artefacts, or through genuine downregulation of antigen 
expression can seriously hamper phenotyping. Most of the lymphocyte surface 
antigen monoclonals work best on frozen sections rather than paraffin embedded 
blocks (Norton & Isaacson, 1989a). This is much less convenient for routine work 
and also results in much poorer cellular morphology (Schlaifer et al. 1990a and 
1990b).
It would therefore appear that the problems of reproducibility and subjectivity 
inherent in histopathology and immunohistochemistry combine to limit their uses in 
adequately defining prognostic groups in NHL.
1.1.4 IMMUNOGENOTYPING NHL
(i) Use of antigen receptor gene rearrangements as a marker for clonal 
proliferations
Although an individual neoplasm may be polymorphous |as regards cell size & 
phenotype, it is increasingly evident that most neoplasias are composed of almost 
genetically identical progeny derived from a common clorjai stem cell (Farber and 
Cameron, 1980; Nowell, 1990). Abnormalities within the genome of a neoplastic 
clonal population can be manifest as gross morphological changes in the 
chromosome, such as translocations (Croce et al 1984), or subtle changes such as 
point mutations (Balmain and Brown, 1988). These genetic lesions can be used as 
unique tumour markers (Stetler-Stevenson et al. 1988). Lymphoid tumours carry an 
additional set of unique tumour markers which are the rearranged antigen receptor 
genes (ARG) of B and T lymphocytes.
Antigen receptors are expressed on B cells as immunoglobulin (Ig) and on T 
cells as T cell receptors (TCR). The genes encoding these structures are arranged as 
discontinuous DNA segments organized into variable, diversity and joining regions.
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Within each region, multiple similar but non-identical segments are found. As a 
mandatory step towards mature lymphocyte differentiation, these ARG undergo 
somatic recombination whereby the rearrangement and joining of one of each V-D-J 
segments leads to the assembly of an intact antigen receptor. The organisation of the 
human TCR p chain locus is shown in figure 1.1. The P chain contains two constant 
regions which are approximately lOkb apart; the 5' region is designated and the 
3’ region Cg2 • The coding sequences of the two constant regions are highly 
homologous having only a four amino acid difference between them. However the 
introns and the 3’ non-coding region of each constant region are not conserved 
(Toyonaga et al. 1985). The detailed arrangement of these genes and the manner in 
which recombination occur is discussed elsewhere (Tonegawa, 1983; Hedrick et al, 
1984; Honjo, 1985; Toyonaga and Mak, 1987).
Figure 1.1 T cell receptor P locus
V, variable; D, diversity; J, joining; C, constant region
During lymphocyte ontogeny an orderly pattern of gene rearrangement 
occurs. Within each gene, and where diversity segments exist, D-J joining precedes 
V-D-J joining. Incomplete V-D-J joining can lead to the production of truncated 
mRNA. Aberrant joining can also occur which produces a non-functional gene. In 
this situation it is common to find functional rearrangement of the other allele. 
Within pre-B cells, Ig heavy chain gene rearrangement precedes K light chain. If both 
k  genes are aberrant rearranged or deleted, then X light chain rearrangement 
commences (Altenburger et al., 1980; Korsmeyer et al. 1981; Heiter et al. 1981). A 
similar hierarchy of gene rearrangement occurs in T cells. Analysis of transcripts of 
murine foetal thymic cells revealed that TCR y  gene rearranges first followed by the 
p gene and lastly by the a  gene activation (Raulet et al. 1985 and Samelson et al. 
1985). The 5 gene has an unusual location between the variable and joining segments 
of the a  locus, and it appears to rearrange before the p locus. It is deleted if the a  
locus undergoes rearrangement (Chien etal 1987).
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It was Korsmeyer & co-workers (1981) who first proposed that the analysis of 
patterns of ARG rearrangements could be a powerful and useful tool to assess 
clonality. A monoclonal lymphoid population can be distinguished from a polyclonal 
population because unique restriction enzyme fragment patterns are generated by the 
recombinatorial process which are detectable on Southern blots. Polyclonal benign 
proliferations are not seen using conventional Southern blot hybridisation because the 
many rearrangements result in a wide range of fragment sizes, none of which is  
represented in sufficient quantity to be detectable.
The exception to this rule are y chain rearrangements. Rearrangements are 
detectable even among polyclonal T cells (Uppenkamp et al. 1987) because there is a 
limited number of V segments in the y gene and these give rise to a limited number of 
combinatorial joinings (Kranz et al. 1985). Therefore caution has to be exercised 
when interpreting the presence of y chain rearrangements in lymphoproliferative 
disease.
Heritable restriction fragment length polymorphisms (RFLP) exist in the 
human population which can produce patterns that can be mistaken for 
rearrangements (Lefranc, 1985; Robinson et al. 1985). This pitfall can be avoided by 
analysing tumour samples in parallel with non-lymphoid tissue from the patient (e.g. 
granulocytes from the buffy coat of a blood sample). Alternatively, multiple 
restriction enzymes can be used which will verify the rearrangement encompasses a 
region of DNA and is not simply a point mutation giving rise to a RFLP.
All mature B cells will have rearranged Ig genes and in humans the majority 
of monoclonal B cells have rearranged the k  light chain. Only about 30% of normal 
and neoplastic human B cells and 10% of mouse B cells express the X chain 
(Yancopoulos et al. 1986). Lambda expressing cells have generally rearranged (or 
deleted) their k  alleles before productively rearranging their X gene. For practical 
purposes this makes a probe of the J k  region the most specific probe for detecting 
rearrangements in Ig expressing B cell neoplasms.
The vast majority of mature T cells in man express a/p receptors (Kronenburg 
et al. 1986) and less than 5% of peripheral blood T cells are y/5 (Triebel et al. 1989). 
Malignant T cells seem to reflect the normal situation in that most mature T cell 
neoplasms have a/p receptors. The TCR a gene is an extremely large gene; the V 
segments are spread over 750,000bp and the numerous J segments (greater than 50) 
extend over another 85kb (Griesser et al, 1988). This enormous size makes it a 
difficult gene to analyze using conventional restriction fragment separation 
techniques. The difficulties of working with a probes plus the hierarchical 
rearrangement of p before a means the p chain gene probes are more widely used for 
routine immunogenotyping.
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(ii) ARG Rearrangements in lymphoid neoplasia
Virtually all B cell neoplasms have rearrangements of the Igpj regardless of 
the stage of differentiation or Ig gene expression (table 1.3). In this way common 
acute lymphoblastic leukaemia has been shown to be predominantly a precursor B 
cell neoplasm because most show Igjj rearrangement and about 50% also have k  
gene rearrangement. Most of these ALL's have yet to express fully assembled protein 
(Korsmeyer et al, 1981; Korsmeyer et al, 1983). More mature B cell neoplasms such 
as CLL, follicular lymphoma, large cell lymphoma, and Burkitts lymphoma display 
rearrangements of both heavy and light chain genes and are therefore easy to assign 
to a B cell lineage based on genotyping.
Within phenotyped T cell tumours, immunogenotyping has been equally 
confirmatory of cell lineage in both immature malignancies such as ALL and in 
mature malignancies like NHL and CLL (table 1.3). Within T-NHL, p chain 
rearrangement is almost a ubiquitous event. The small percentage which have 
retained the germline configuration of the p chain tend to be those NHL which are 
classed as "lymphoblastic" i.e. thymocytic phenotypes with a propensity for 
intrathymic growth (deVillartey etal. 1989; Williams et al. 1987).
(iii) Simultaneous Ig and TCR gene rearrangements
The use of Ig and TCR gene probes has revealed complex gene 
rearrangements in some lymphoid malignancies involving both TCR and Ig genes. 
The possibility of two different clonal populations of cells co-existing in these 
tumours has been excluded since immunocytochemically these tumours are of a 
single phenotype. In addition the equal intensity of rearranged Ig and TCR bands on 
Southern hybridisations would support the hypothesis that the rearrangement has 
occurred in cell populations of equal size.
Analysis of the literature, (table 1.3) reveals that the frequency of bigenotype 
is greater in B cells than in T cells. In up to 11% of mature B cell neoplasias, and 
24% of immature B cell tumours (ALL) the TCR genes may be simultaneously 
rearranged. Hara et al, (1987) examined 29 samples of precursor B cell ALL for 
rearrangements of all four TCR genes and found TCR 5 gene rearrangements in 20 
cases (69%), TCR a  rearrangements in 59% and TCR y rearrangements in 52% of the 
cases. TCR p was the least likely to be simultaneously rearranged with the Ig genes at 
31%. The high frequency of y/5 rearrangements in pre-B cell tumours is not 
unexpected given that y/5 rearrangement occurs early in ontogeny. In mature T cell 
malignancies, the incidence of bigenotype is much lower at only 1.5% for T-NHL.
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Table 1.3 T cell receptor |3 chain and Immunoglobulin heavy chain 
rearrangements in lymphoid malignancies.
Tumour No of 
cases
TCR B dual
genotype
References
BALL 88 20 83 24% 3,8,10,
14,16,17
B NHL 101 7 101 6.9% 10,14,18,
20,21,22
B CLL 45 5 45 11.1% 1,10,13
TALL 126 125 18/113 16% 1-14
T NHL 70 65 1/63 1.5% 2,4,9,10,14
15,18,19,20
T CLL 33 33 0/25 0% 4,8,9,10
11,15.
References for table 1.3
1. Aisenberg et al. (1987)
2. Bertness et al. (1985)
3. Davey et al. (1986)
4. Flug et al. (1985)
5. Hara et al. (1987)
6. Kitchingham et al. (1985)
7. Minden & Mak et al. (1986)
8. Minden et al. (1985)
9. O'Conner et al. (1985)
10. Pelicci etal. (1985)
11. Rabbits et al. (1985)
12. Tawa et al. (1985)
13. Waldmann etal. (1985)
14. Williams etal. (1987)
15. Isaacson et al. (1985)
16. Asuo et al. (1987)
17. Felix etal. (1987)
18. Griesser et al. (1986a)
19. Matsuoka et al. (1987)
20. Liang et al. (1990)
21. Tkachuk et al. (1988)
22. Griesser etal. (1986b)
Given that bigenotypic tumours are not uncommon, especially among 
immature and/or B cell tumours, is there any way of differentiating among these 
bigenotypic tumours? Where it has been examined there are quantitative differences 
in the patterns of ARG gene rearrangement such that only one Igjj allele is found 
rearranged in phenotypic T cell neoplasia and the light chain genes are still in the 
germline configuration. Conversely, there is a tendency for only one TCR allele to 
rearrange in B cell disorders as opposed to both alleles as seen in T cell neoplasias. It 
is very rare to find a complete V-D-J recombination of Igpj in T cell neoplasias or of 
TCR (3 chain in B cell disorders (Tawa et al 1987: Kitchingham et al. 1985; Williams 
etal. 1987).
It is generally accepted that the enzymatic processes underlying ARG 
rearrangements is very similar between T and B cells. In 1986, Yancopoulos and co- 
workers introduced T cell variable region segments into pre-B cells and showed that
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the T cell receptor gene fragment rearrangements could proceed in the B cell 
environment. It has been proposed that the accessibility of the Ig and TCR gene loci 
to the common recombinase enzyme complex (encoded by the RAG genes) could 
allow dual rearrangement (Yancopoulos et al. 1986). Davey et al. (1986) speculate 
that the high incidence of dual genotype in precursor B cell leukaemias may be due to 
the lack of signals, which are present in more mature cells, that normally terminate 
gene rearrangements. The signal to switch off recombinase activity seems to require 
the functional activation through the ARG with subsequent release of second 
messengers rather than merely the presence of mature ARG. Recombinase activity 
associated with the RAG1 and RAG2 gene products is decreased by agents which 
mimic the second messenger effects of AGR cross-linking. Phorbol esters (e.g.. 
phorbol myristate acetate) plus calcium ionophores can switch off RAG gene 
expression in both T cells and B cells. (Menetski et al, 1990; Turka et al, 1991). 
Because a functional ARG appears to be a prerequisite for stopping further gene 
rearrangement, the corollary of this is that gene rearrangement, perhaps of both Ig 
and TCR genes, may continue even after a translocation event or defective 
rearrangement has occurred on one allele.
The underlying mechanism which leads to bigenotype may take many years to 
elucidate because it is probably one of the key areas where transformation events are 
affecting normal cellular differentiation. Several practical points can be suggested to 
minimize the misinterpretation of immunogenotyping in immature phenotypic 
tumours.
Wherever possible digests and probes should be used which permit the 
assessment of the number of alleles rearranged and the extent of that rearrangement 
(i.e. D-J rearrangements versus complete V-D-J). This will reveal the quantitative 
differences discussed previously. Light chain probes should be used in conjunction 
with IgH probes to determine the likelihood of complete Ig assembly taking place. 
The presence of complete or truncated mRNA for the TCR genes will also help to 
assess the completeness of gene rearrangement. In this way it can be determined 
whether the TCR genes or the Ig genes are closer to producing a mature receptor 
molecule.
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1.1.5 KARYOTYPIC ABNORMALITIES AND TRANSLOCATIONS IN NHL
Recurring cytogenetic abnormalities have been identified in NHL and 
significant correlations have been made between these abnormalities and NHL 
morphology, immunophenotype and in some cases, prognosis. Despite the large 
number of NHL cases which have been karyotyped, the conclusions arc not always 
consistent. This is probably due to a combination of the complexity of these 
karyotypes plus the non-uniformity of morphologic classifications and treatment 
schedules between institutes.
A comprehensive account of the translocations found in NHL is not 
attempted; reviews of these translocations and the mechanisms leading to them are 
available elsewhere (Levine and Bloomfield, 1990; Tycko and Sklar, 1990). Instead 
attention is focussed on a few abnormalities which have established association with 
certain morphologic and phenotypic NHL groups. Some of the recurring cytogenetic 
abnormalities within histologic subtypes are listed in table 1.4 which is adapted from 
Levine and Bloomfield (1990).
Correlations of chromosomal abnormalities can be made with 
immunophenotype. The t(14; 18) and t(8; 14), which involve Ig gene translocations, 
occur in B-cell NHL. Analogous to this, T cell NHL chromosomal abnormalities can 
affect the T cell receptor genes. The a  locus at 14ql 1-13 is disrupted in tumours with 
morphologies usually associated with T cell phenotype i.e. diffuse mixed, 
immunoblastic and diffuse intermediate sized with nuclear polymorphism (Fifth 
International Workshop, 1987; Maseki et al 1987). However, the frequency of 
translocations involving TCR genes does not seem to be as frequent as Ig 
translocations are in B cell lymphomas (Levine et al. 1986; Levine et al, 1990; 
Maseki et al, 1987). In fact, both arms of chromosome 1, 2p and 6q are equally or in 
some studies more commonly involved with T cell lymphomas than the TCR gene 
sites (Levine et al, 1986; Berger et al , 1988; Fifth International Workshop, 1987; 
Maseki etal, 1987).
Molecular dissection of some of the translocations has already shed light on 
the oncogenic mechanisms contributing to lymphomagenesis. The activation of c-myc 
by ARG (TCR and Ig) gene translocations in some of the high grade lymphomas has 
highlighted the role of the c-myc family in malignant transformation. This subject has 
been reviewed recently by DePinho et al, (1991) and Klein (1991).
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Table 1.4 Recurrent cytogenetic abnormalities within NHL histologic subgroups.
*
Lymphoma type Associated abnormalities
Follicular small 
cleaved cell
t(14;18), del(6q)
Follicular, mixed small 
and large cell
+8, t(14;18), del(2q), +3/3q, 
10q23-25
Follicular, large cell +7, t(14;18), 17q21-25
Diffuse, small cleaved 
cell
del(8p), del(20q)
Diffuse, mixed small 
and large cell
+3, +5,1lp
Diffuse large cell +4, +7, -8, -13, +21, +X, lq, 2q, 
3q21, del(6q), 4q, 7q, 9q, 14q, 18q
Immunoblastic +5, +18, +X, del(3p), del(5q), 
del(6q), 5p, 5q, I3q, 16, 19p
Small noncleaved cell t(14; 18)
* Lymphoma type is classed according to the Working Formulation.
Significant insights into the functional role of the t(14; 18)(q32;q21) 
translocation has emerged in recent years. In this translocation, the putative oncogene 
bcl-2 is fused to the joining region segment of the IgH gene. There is accumulating 
evidence that the constitutive expression of bcl-2 protects B-cells from apoptotic 
death (Nunez et al, 1990; Hockenberry, et al, 1990). The ability of the bcl-2 gene to 
confer a survival advantage to B cells is thought to be an initiating event (Rabbitts, 
1991) which allows time for other mutations or physiological events to contribute to 
the neoplastic process, as shown in a transgenic mouse model (McDonell and 
Korsmeyer, 1991).
One of the problems in karyotypic analysis of NHL and the interpretation of 
the results is the separation of abnormalities into those present at diagnosis versus 
those acquired at relapse. The evolutionary cytogenetic changes are, like the primary 
abnormalities, non-randomly distributed within histological classes. Among these 
sequential changes are deletions of all or part of 17p and acquired changes in 
chromosomes 1 and 2 (Levine et al, 1990; Sanger et al, 1987; Fukuhara et al, 1983). 
Duplication of part of lq occurs significantly more often in tumours with t(8;14) than 
with t(14; 18) (Fifth International Workshop, 1987; Fukuhara et al, 1983). The 
opposite frequency is found with acquired trisomy 7 or duplication of 7q. This is 
more commonly in tumours with preexistant t(14; 18) than t(4;8) tumours. Trisomy 7 
is also more commonly associated with diffuse rather than follicular morphology
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(Bloomfield et al, 1983). Armitage et al, (1988) examined a total of 69 tumours with 
t(14;18) and found trisomy 7 in 52% of the tumours with a diffuse histology but only 
15% of the tumours with follicular histology.
Some acquired abnormalities are not confined to a particular histologic type 
of tumour. The del(6q) abnormality is significantly associated with progression of 
follicular forms, small cleaved cell, diffuse large cell and immunoblastic lymphomas 
(Bloomfield et al, 1983; Levine and Bloomfield, 1990). Del(6q) has also been 
described in other tumour types and may be a prevalent abnormality associated with 
general tumour progression (Vogelstein et al, 1989; Fountain et al, 1990).
From this brief overview, it is apparent that the morphologic heterogeneity of 
NHL is reflected in the heterogeneity of karyotypic abnormalities. The underlying 
difference in oncogenic events between, for instance t(14,18) follicular tumours 
versus t(8;14) small non-cleaved tumours helps to explain the difference in the 
natural history of these two diseases (Klein et al, 1991). It is also evident that NHL 
not only have different cytogenetic origins, they progressively acquire different 
genetic alterations.
1.1.6 PROGNOSTIC FACTORS IN NHL
The Working Formulation histopathologic classification scheme identified 
three major prognostic groups based on survival; the terms "low-grade", 
"intermediate grade" and "high grade" were used to define patients with favourable, 
intermediate and unfavourable prognosis. This classification scheme is based on the 
natural history of the tumour groups. However, with the advent of effective 
combination chemotherapy, the survival of complete responders in the intermediate 
and high grade NHL groups in the long term (over 15 years) can be greater than for 
low-grade tumours (Rosenberg, 1985).
Once NHL is classified into low-, intermediate- or high-grade, the influence 
of histopathologic sub-type on prognosis is often minimal compared to other 
prognostic factors. Hayward et al (1991) analysed the survival data on over nine- 
hundred patients with intermediate or high-grade lymphomas and found that in this 
unselected group, the histologic sub-type did not influence survival. Leonard et al, 
(1983) using the Kiel classification system to divide 199 cases of NHL into low or 
high grade also found that the sub-type within the two grades was not a prognostic 
indicator.
The influence of immunophenotype on prognosis is still an area of debate. 
Some analyses did not find cell lineage to influence outcome (Homing et al, 1984 
and 1986; Shimoyama et al, 1988) but others have found that T cell phenotype does 
have a poorer prognosis (Greer et al, 1984; Coiffer et al, 1988; Armitage et al, 1989).
13
In the study reported by Armitage et al. (1989), the influence of phenotype was 
profound. In a total of 110 uniformly treated patients, stage IV B-cell patients had a 
higher complete response rate than stage IV T-cell tumours (67% versus 0%) as well 
as a four year survival of 44% compared to 0%. So although it is not universally 
detected, T cell phenotype may adversely affect prognosis.
Hayward et al (1991) defined a poor prognostic group using multivariate 
analysis which showed the following factors to be important (in declining order of 
power): advanced age (over 70 years), worsening performance status, central nervous 
system/liver involvement, abnormal white count, systemic symptoms ("B" 
symptoms) and advanced clinical stage. The importance of age as a prognostic 
indicators over some of the other factors is in agreement with Leonard et al (1983), 
Danieu etal, (1986), Homing etal, (1984) and Al-Katib etal, (1984).
Poor physiological reserve, as indicated by poor performance status and "B" 
symptoms, have repeatedly been associated with poor prognosis in NHL (Leonard et 
al, 1983: Homing et al, 1984; Al-Katib et al, 1983). The tendency for randomized 
trials of new chemotherapy regimes to use younger, fitter patients, either through 
deliberate exclusion or through the inevitable bias of the referral population at a 
tertiary centre, can lead to serious difficulty in the interpretation of the results of these 
trials (Armitage and Cheson, 1988).
The importance of clinical stage, often based on the Ann Arbor classification, 
(Carbone et al, 1971) as a prognostic tool is equivocal. Hayward et al, (1991) did 
identify stage III and IV as having a poorer survival than stage I and II but Leonard et 
al, (1983) found that apart from stage I having a better prognosis than more advanced 
stage, the difference in survival between the more advanced stages were minimal. 
Danieu et al, (1986), Al-katib et <2/,(1983), Shimoyama et al, (1988) and Armitage et 
al (1982) did not find stage a significant prognostic factor in the intermediate and 
high grade tumours in their studies. This inability for clinical stage to accurately 
predict clinical outcome is not unexpected. In the lucid article "Staging of 
lymphomas:Practical thoughts on impractical practices" written by Raubitscheck et 
al, (1990), it was emphasized that the anatomic definition of each stage is 
fundamentally arbitrary and that the main purpose for staging patients is to allow 
meaningful comparisons of treatment results from multiple institutions. It was 
emphasized that within any one staging category, there will be heterogeneity of 
prognosis depending on patient and tumour characteristics. This is in contrast to 
many solid tumours, for example, cervical cancer, where patients of a certain stage 
represent a fairly homogeneous population.
Attempts at direct measurement of tumour cell proliferation in NHL has also 
produced prognostic information. Overall a high proliferative index is associated with
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the poor prognostic categories (as reviewed by Child, 1991). Unfortunately, because 
of the technical variations and the small number of tumours assessed, it is 
impossible to incorporate this information into a useable prognostic index (Coiffer et 
al, 1991).
The effect of specific chromosomal abnormalities is equally difficult to 
include in a prognostic index. The common abnormalities t(14; 18) and t(8:14) 
correlated with histologic phenotype and are not independent factors over and above 
morphology. Levine and Bloomfield (1990) summarized the evidence for correlating 
genetic abnormalities with clinical outcome. Abnormalities in 17p or q have been 
identified as adversely affecting prognosis in three studies (Levine et al, 1990; Yunis 
et al, 1989; Rodriguez et al, 1991). Yunis et al, (1989) also identified trisomy of 2p 
or dup2p as having a negative impact on survival whereas dup3p or +3 gave an 
improved prognosis. Levine et al. (1988) found that breaks in 2p was associated with 
better survival; chromosome 2 would therefore appear to affect prognosis differently 
according to whether loss or gain of information occurs. Cabanillas et al (1989) 
related abnormalities in chromosome 7 to poor response and survival in lymphoma. 
The basis for these prognostic factors in terms of genes affected by the karyotypic 
abnormalities are unknown although sparse data may suggest that losses and 
mutations in p53 may account for the poor prognosis of the tumours with 
chromosome 17 abnormalities (Rodriguez et al, 1991).
Because of the inadequacy of the existent staging based prognostic schemes, 
editorial comments by Bunn (1988) and Child (1991) both called for a replacement of 
the currently used system. The first workshop on prognostic factors in large cell 
lymphomas was reported by Coiffer et al, (1991). In this workshop the prognostic 
indices developed by independent cancer groups were described. These schemes were 
broadly similar, all involved certain aspects of tumour mass and distribution plus 
some reflection of tumour growth characteristics such as LDH or Z?2 niicroglobulin 
(Jaganneth et al. 1986). The conclusions of the international workshop was that a new 
Prognostic Index was needed for NHL and that this index should take account of the 
major tumour factors described above plus patient factors such as performance, 
symptoms and age. It is therefore hoped that in the near future a common prognostic 
scheme will be used for reporting NHL trials and hence facilitate the identification of 
risk groups and treatment benefits.
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1.2 CANINE LYMPHOMA
1.2.1 INTRODUCTION
Canine lymphosarcoma (alternatively known as malignant lymphoma) is the 
most common haematological malignancy in the dog. All breeds can be affected by 
lymphoma but there are certain breeds which appear to be at higher risk of 
developing the disease. Carter et al (1987) identified a greater preponderance of 
medium and large breed dogs within their series of 41 lymphomas. German Shepherd 
dogs and boxers are overrepresented in surveys (Priester, 1967; MacEwan etal, 1987 
and Squire, 1973) and a variety of other "at risk" breeds have also been identified 
including Poodles and Scottish terriers (MacEwan et al, 1987). A prospective study 
of three households of bull-mastiffs revealed that 9 out of 59 bull mastiffs died of 
lymphoma within a three year period (Onions, 1984). This corresponds to an annual 
incidence of 5000 cases per 100,000 dogs. The aetiologic significance of this familial 
predisposition is still unknown. This time-space clustering could suggest an 
infectious origin (such as a retrovirus) but attempts to identify a causative retrovirus 
have failed (reviewed by Squires, 1990).
The dog shows an increasing incidence of lymphoma with age (Schneider, 
1983) and although very young dogs can occasionally be affected, lymphoma is 
mainly a disease of middle to old age. Male dogs are more commonly affected than 
females and the difference is comparable to male/female incidence in humans for 
NHL. Schneider (1983) estimates that entire male dogs have a 20% increased 
incidence of the disease compared to female dogs whereas human males have 10- 
20% greater incidence than women (Scottish Cancer Registration Scheme, 1984), but 
in certain small studies the disparity between men and woman can be considerably 
greater (Slymen et al, 1990).
Malignant lymphomas can be classified according to their anatomical 
location. The most common forms are multicentric, thymic, cutaneous and 
gastrointestinal. The work in this thesis primarily pertains to the multicentric form of 
lymphoma (MLSA). In the remaining sections o f this introductory chapter, the MLS A 
(and occasionally thymic forms) are discussed rather than the other types of 
lymphoma.
Like NHL, MLSA is a chemosensitive malignancy which relapses with 
chemoresistant disease in virtually all cases. The time-scale is inevitably shortened 
compared to humans; the majority of dogs will relapse within one year (Squire et al, 
1973; Weller et al, 1980; Postorino et al, 1989; Greenlee et al, 1990). Tumour 
progression is rapid; if left untreated, the majority of cases will die or be presented for 
euthanasia within one month of diagnosis although from owner history 
lymphadenopathy can have been present for several weeks prior to presentation
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(Bloom and Meyer, 1945; Squire et al, 1973) Relapse can be equally swift and 
devastating. Within a two or three week period between treatments, dogs can progress 
from clinical remission to large bulk disease. The clinical history of this group of 
tumours is therefore similar to intermediate and high grade NHL. It has been used as 
a model for human NHL in the past (Appelbaum et al, 1985; MacEwan, 1990; 
Greenlee et al, 1990).
The remainder of this section will describe some of the similarities of canine 
lymphoma to NHL with particular emphasis on the efforts to understand the 
heterogeneous response of these tumours to treatment.
1.2.2 HISTOLOGIC CLASSIFICATION
The Rappaport classification scheme has been applied to canine MLSA but 
has been disappointing in its ability to identify prognostically useful groups (Squire et 
al, 1973; Holmberg et al, 1976; Weller et al, 1980 and Greenlee et al, 1990). This 
may be due to the emphasis which the Rappaport classification places on diffuse 
versus follicular patterns of tumour growth. In the dog, the percentage of tumours 
which have a follicular pattern is low (see table 1.5)
Table 1.5 Follicular histology in MLSA
Reference Follicular
Number
lymphomas
%
Squires etal, 1973 1/100 1%
Weller era/,1980 7/72 9.7%
Appelbaum etal, 1984 1/40 2.5%
Greenlee et al, 1990 10/176 5.6%
Holmberg et al, 1976 8/24 33%
The paucity of follicular tumours in the dog may be due to the bias created by 
only being able to obtain lymph nodes at a biologically advanced stage of disease. 
Compared to humans most dogs present with more widespread disease. Careful 
examination of longitudinal sections from multiple lymph nodes has suggested that 
about one third (8/24 cases) may be follicular (Holmberg et al, 1976). Holmberg et al
(1976) admitted that the canine nodular pattern was less obvious than in humans and 
that it was not always recognizable in all parts of the node nor was it found in all 
nodes at necropsy. Thus it is not unreasonable to propose that some of the diffuse 
tumours may have initially been nodular in pattern and had progressed to a more 
diffuse form by the time the biopsy (or necropsy) was performed. Progression from 
follicular to diffuse forms is reported in humans (Hubbard et al, 1982).
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Taking into consideration that histological grade is not a static situation and 
that it is not possible to take multiple lymph node biopsies merely to ensure that an 
underlying follicular pattern is not overlooked it is obvious that alternatives to the 
Rappaport scheme are needed. Greenlee et al (1990) undertook a comprehensive 
comparison (involving 176 lymphomas) of the merits of four major classification 
systems; Rappaport, Lukes-Collins, Kiel and the Working Formulation. The Kiel 
system appeared to be best able to accommodate canine cellular morphologic types 
and at the same time provide some correlations between morphology and clinical 
performance.
1.2.3 IMMUNOPHENOTYPIC CLASSDFICATION
The panels of monoclonals used to type human leukaemias/lymphomas do not 
commonly cross-react with canine lymphocytes. Immunophenotyping MLSA out of 
necessity is still based on the presence or absence of surface/cytoplasmic 
immunoglobulin (slg or clg) and the use of a few putative T cell markers. The 
incidence of B cell tumours based on slg has been in broad agreement for over 10 
years: using an indirect method of detecting slg based on resetting techniques Onions
(1977) found only 51% (17/33) of tumours but when slg is detected using anti­
immunoglobulins reagents, 70-80% of the tumours appear to be slg positive (table 
1.6).
Table 1.6 Immunoglobulin positive MLSA
Reference slg positive tumours 
number %
Holmberg et al, 1976 8/11 73%
Appelbaum et al, 1984 31/40 77.5%
Ladiges et al, 1988 42/54 78%
Greenlee et al, 1990 48/64 75%
Teske etal, 1992 52/66 79%
Positive identification of phenotypic T cells has not been so straightforward. 
The presently available T cell monoclonals such as DT2 and LQj, commonly react 
with slg positive B cell tumours. Appelbaum et al (1984), Ladiges et al (1988) and 
Greenlee et al (1990) all report a sizeable proportion of slg positive tumours to also 
stain with either DT2 or LQ1. These dual staining tumours represented 67%, 68% 
and 44% respectively of the total tumour populations. The frequency of this dual 
staining is beyond that which could be believably explained by "lineage promiscuity" 
and would more likely represent (excluding technical problems) the fact that the 
antigens recognized by DT2 and LQ1 are not confined to T cells. Using these pan-T
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cell monoclonals (but excluding those tumours which are both pan-T/sIg positive), 
the percentage of tumours which are phenotypically T cells falls in the range of 9- 
20% (Ladiges era/,1988; Greenlee etal, 1990).
Greenlee identified a correlation between immunophenotype and 
morphologic features using the Kiel classification. All of the tumours with 
immunoblastic morphology were slg positive and conversely most of the tumours 
with a significant small cleaved cell population (the centrocytic and 
centrocytic/centroblastic forms) were identified as T cells. Teske et al (1992) has also 
identified a correlation between small cleaved cells and T cell phenotype.
1.2.4 IMMUNOGENOTYPING CANINE LYMPHOMAS
There are no published results of genotyping canine lymphomas. However 
Greenlee et al (1990) allude to unpublished genotyping which yielded results 
consistent with their phenotyping in the few cases in which it was performed. This 
lack of genotyping information would seem a fairly serious deficit in the 
classification of canine lymphomas given the problems which have been encountered 
with the pan-T cell markers. None of the canine specific T cell monoclonals currently 
available recognize components of the TCR/T3 complex and hence will not be 
inherently limited to cells containing TCR gene rearrangements. The proportion of 
tumours which stain for both slg and pan-T cell markers has already been described 
as suspicious. Given that these markers may not be truly T cell specific, there is the 
possibility that some of the slg positive, pan-T cell positive tumours may not be 
phenotypic T cells but could indeed be B/pre-B cells which do not express slg. Thus 
it would seem prudent to assume that the current proportion of tumours identified as 
T cell lineage represents the uppermost limit. Genotyping would help clarify this 
situation.
1.2.5 TREATMENT OF CANINE LYMPHOMA
(i) First Line Treatment
Combination chemotherapy protocols are generally considered more effective 
than single agent therapy. Treatment with prednisolone with or without 
cyclophosphamide produces a temporary response (usually less than 3 months) in less 
than half of the treated dogs (Brick et al, 1968; Squire et al, 1973). The introduction 
of more intensive regimes has not only increased the length of remissions but has also 
improved the percentage of dogs which attain a complete response. Using a relatively 
simple protocol of cyclophospamide vincristine, and prednisolone (COP) it is 
possible to achieve remissions in more than 80% of cases (Cotter et al, 1983). 
Reviews of the treatment of canine lymphomas are available (Madewell, 1985;
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Cotter, 1986) and indicate that of the plethora of currently available protocols, no 
single protocol has gained uniform acceptance as the most efficacious. Median 
remissions remain in the 5-8 month range with overall survival times of 10 -14 
month. Little improvement has been made in remission rate or length or in survival 
times since the early reports of COP protocols (Squire et al, 1973). However it is 
notoriously difficult to compare protocols between institutions since selection and 
staging of patients plus methods of calculating results varies between establishments. 
With these caveats in mind, there is some evidence that the addition of doxorubicin 
into the basic COP protocol does improve remission lengths (Carter et al, 1987; 
Cotter and Goldstein, 1986). Indeed single agent cytotoxic therapy with doxorubicin 
alone achieved response rates, remission durations and survival times which compare 
favourably with the COP protocol (Postorino et al, 1989).
Chemotherapy for MLSA is still largely palliative. Given that cure is 
impossible for the majority of patients, then quality of life for both the patient and the 
owner are an important goal. In this regard, single agent treatment with an 
anthracycline does offer the advantage of infrequent out-patient attendance (once 
every three weeks) and freedom from complicated oral dosing of drugs.
(ii) Rescue therapy following relapse
Chemotherapy in canine lymphoma is usually given throughout the remission 
period. Depending on the exact protocol, there may be a more intensive induction 
course of drugs followed by chronic maintenance treatment until clinical signs of 
relapse are apparent. In other protocols (Postorino et al, 1989) the same protocol is 
given for induction and maintenance. For historical reasons (Squire et al, 1973), 
canine lymphoma is usually treated with maintenance chemotherapy throughout the 
lifespan of the animal. A recent retrospective survey suggests that chronic treatment 
gives no improvement in remission or survival over short term administration of 
anthracycline single-agent chemotherapy (Hahn et al, 1992). This has yet to be tested 
in a randomised prospective trial.
Most protocols give first remissions of about 6 months. The chance of 
obtaining a second remission is less than for the first, and if achieved, is usually 
shorter. The length of the first remission often correlates with the length of the second 
remission; achieving a long first remission gives a greater chance of obtaining a 
durable second remission (Cotter, 1986). This clinical impression emphasizes the 
profound inherent biological variability within canine lymphomas such that some 
tumours fail multiple drug treatment rapidly and then fail subsequent alternate drug 
protocols (Hohenhaus and Matus, 1990).
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The importance of achieving a solid first remission means most drugs are used 
during induction and consequently, at relapse, there is a limited number of new drugs 
available. Dogs which have received variations on the COP protocol can be rescued 
with doxorubicin (Calvert and Leifer, 1981) but despite doxorubicin having a 
different mechanism of action from cyclophosphamide, vincristine or prednisolone, 
Calvert and Leifer (1981) could only obtain responses in 4 out of 12 dogs. 
Dacarbazine can also induce second remissions in dogs resistant to doxorubicin (Gray 
et al, 1984) but again in only a limited number of cases. Hohenhaus and Matus (1990) 
reported disappointing results using etoposide to rescue dogs relapsing after a 
vincristine containing multi-drug protocol. However Carter et al (1987) remarked that 
dogs which relapsed following doxorubicin treatment were more likely to achieve a 
second remission than dogs which had received the COP protocol. Therefore the 
extent of clinical multiple drug resistance may be greater in the COP treated dogs. 
Asparaginase, which has a unique mechanism of action compared to the other 
commonly used cytotoxic drugs, is a useful drug in relapse and can induce remissions 
in dogs resistant to both COP and anthracycline protocols (personal clinical 
experience; N.T.Gorman, personal communication). The limited success of "rescue" 
therapy highlights that multiple drug resistance in relapsed canine lymphomas is just 
as prevalent as in human NHL.
1.2.6 PROGNOSTIC FACTORS IN CANINE LYMPHOMA
The use of histologic classification as a prognostic indicator in human NHL is 
not easily emulated in canine NHL. It has been difficult to identify sub-groups with a 
consistent clinical outcome. This may not only be because canine lymphomas do not 
exactly "fit" the human cellular descriptions (as discussed by Greenlee et al. 1990). It 
was already mentioned that in NHL, there is considerable heterogeneity of 
performance within any of the three grades (low, intermediate and high) of the 
Working Formulation . In the most comprehensive study of canine MLSA histology 
yet undertaken, Greenlee et al, (1990) established that 60% of canine lymphomas are 
intermediate grade, 29% are high grade and only 11% are low grade. In this study, the 
high grade (immunoblastic) tumours had longer remissions and survivals than other 
histologic types, but this difference was not statistically significant. Carter et al
(1987) also found a trend towards a longer remission in dogs with high grade 
tumours, but this trend was not statistically significant. Both Greenlee and Carter 
remarked that the high grade tumours were a more homogeneous group in terms of 
response than the intermediate or low-grade tumours. Histiocytic type tumours have 
been associated with good responses (Squire et al, 1973: Weller et al, 1980) but have 
also been reported to respond poorly to single agent doxorubicin (Gray et al, 1984). If
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the human NHL experience is also relevant for MLSA, it is probably unlikely that 
histology alone will be sufficient to reliably detect prognostically useful subgroups 
within these intermediate grade tumours. Given that this group makes up the 
majority of MLSA, this is a disincentive for undertaking detailed histological 
examinations of canine lymphomas.
Clinical staging is commonly performed in canine MLSA, predominantly by 
non-invasive means. Depending on the exact scheme used, patients are divided into 
four or five stages with stage V representing disseminated disease. An example of a 
staging scheme is given in chapter 7. The dogs can then be sub-classified according 
to the severity of the clinical signs and history of illness at time of presentation. 
Assignment according to clinical signs does inevitably involve a degree of 
subjectivity but has actually been of use in providing prognostic information. Cotter 
et al (1983) found that dogs with severe clinical signs were less likely to achieve a 
complete response; for stage IILA and IIIB dogs the CR was 91% and 60% 
respectively. These workers did not identify an effect of clinical signs on the 
remission length but other groups have suggested dogs with severe clinical signs do 
have shorter remissions (Greenlee et al, 1990).
Staging according to disease extent has had mixed success in predicting 
response. Greenlee et al (1990) and MacEwan et al (1987) did not find stage to be 
predictive of response whereas Squire et al (1973), Cotter et al (1983) and Carter et 
al (1987) showed that stage III dogs did perform better than stage IV/V dogs. The 
consensus takes the view that there is a loose correlation of stage with prognosis but 
it is by no means clear whether the poorer prognosis of advanced stage tumours is due 
to inherent drug resistance or due to the susceptibilty of these dogs to the toxic effects 
of the treatment. Cotter's results (1983) would|imply that stage IV tumours are less 
drug sensitive than stage III tumours (CR rates of 47% and 83% respectively). Squire 
et al (1973) and Carter et al (1987) also found that stage IV tumours were less likely 
to obtain a complete response but the difference was not so marked.
Does phenotyping contribute to the ability to identify different prognostic 
groups? Unfortunately remarkably little is published on this point; Ladiges et al
(1988) could not correlate immunophenotype with subsequent response but Greenlee 
et al (1990) did reveal significant correlation of shorter remissions and 
hypercalcaemia with the T cell phenotype. Hypercalcaemia has been recognized as a 
poor prognostic factor by other groups (Weller et al. 1982). The numbers of treated 
dogs in the B cell/T cell categories established by Appelbaum et al (1984) were too 
small to make meaningful comparisons but rather curiously they did identify a 
tendency for T cell tumours to have smaller peripheral lymph nodes than B cell 
tumours.
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A myriad of other clinical factors have also been proposed to influence 
response including age, sex and weight. The clinical impression that small dogs 
survive longer (probably due to relative overdosing in comparison to large dogs) is 
not statistically significant nor is age a significant factor (MacEwan et al, 1987). 
However females can have a significantly prolonged remission compared to males in 
some studies (MacEwan et al, 1987). Cytogenetic studies in canine MLSA have not 
been carried out, presumably due to technical difficulties, and so no prognostic 
information is available from this source.
In summary, advanced clinical stage, severe clinical signs, hypercalcaemia 
and T cell phenotype are all (to a variable extent) associated with poor prognosis. 
Other factors, including age, sex and body size may have minor effects.
1.3 MULTIDRUG RESISTANCE
1.3.1 MUTATIONAL BASIS FOR DRUG RESISTANCE
Failure of a chemotherapeutic protocol to cause tumour remission may be due 
to many factors. Physiological and pharmacological factors undoubtedly play a large 
role in the absorption, distribution and metabolism of chemotherapeutic drugs. In 
relapsing haematological malignancies, a substantial portion of the tumour burden is 
in the bone marrow and peripheral circulation. In these malignancies, it is difficult to 
envisage pharmacologic factors which can alter drug serum concentrations sufficient 
to result in treatment failure. Research on acquired and inherent clinical resistance in 
these malignancies has therefore focussed on cellular factors which could account for 
resistance to chemotherapeutic drugs.
Malignant cell populations are characterised by a genetic instability which 
leads to the spontaneous generation of variant forms with diverse phenotype and 
genotype; the genetic origin of cellular resistance to a variety of drugs has been 
shown (reviewed by Goldie and Coldman, 1984). The dependence of resistance on 
mutations at drug resistance genes suggest that the higher the mutation rate in a given 
tumour population, the earlier in its growth curve resistant variants may appear 
(Goldie and Coldman, 1985).
Albertini et al (1990) compiled the results from numerous studies on somatic 
cells mutation rates and illustrated that the normal mutation rate was between 10"^' 
10‘6 at a given gene locus per generation. The implications of this somatic rate of 
mutation on models of multi-stage carcinogenesis are discussed by Stein et al, (1991) 
and Loeb (1991). The latter emphasizes that most human malignancies contain a 
multiplicity of genetic abnormalities which would seem to indirectly suggest that the 
mutation rate within tumours may be greater than the frequency calculated for normal
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cells in vivo. Loeb (1991) also highlights the deficiencies in the current data directly 
assessing mutation rates in tumours. Most of the work has been performed in rodent 
models which because of the differences in DNA repair capacity may not be directly 
relevant to human neoplasms. If Loeb's prediction that part of carcinogenesis involves 
the induction of a "mutator phenotype" is correct, then this would lend greater 
credence to the original Goldie-Coldman hypothesis on the genetic origin of drug 
resistance.
The likelihood of a resistant cell arising in a population is not merely 
dependant on the mutation rate but also on the number of cell doublings. When the 
stem cell population in a tumour is low, the tumour must undergo many more cell 
doublings to reach a clinically detectable size. Added to this is the selection pressures 
occurring during this prolonged slow-growth phase; some cell lineages will have died 
due to environmental pressure. The surviving fraction in these slow-growing tumours 
will have a higher likelihood of having undergone mutations towards resistance than 
a tumour of similar mass with a higher growth fraction because of the extended 
environmental selection pressure. This mutational hypothesis could help explain the 
intrinsic chemoresistance of the slow-growing indolent NHL in comparison to the 
potentially curable higher grade tumours. It would appear that the mutational events 
underlying inherent versus acquired resistance need not be different. In the former 
case, the resistant variants represent the majority of the cell types in the tumour mass 
whereas in the chemosensitive group they only represent a tiny fraction of the total 
cell population at the start of chemotherapy. Ultimately, the ability to completely cure 
patients will depend on the ability to kill the tumour stem cells. The pessimistic 
clinical implications of this fact are discussed by Butturini and Gale (1991) and 
Jasmin (1988).
1.3.2 DISCOVERY OF P-GLYCOPROTEIN
The characterisation of in vitro derived drug resistant cell lines has been 
fundamental in discovering resistance mechanisms with clinical relevance. Foremost 
among these discoveries were the observations of Kessel et al> (1968), Biedler and 
Rheim (1970), Bech-Hansen et al, (1976) and other groups, that chronic in vitro 
selection with a single agent (for example actinomycin D or colchicine) could result 
in resistance to a wide range of lipophilic drugs which do not share a common 
structure or target. This in vitro phenomenon, which became known as pleotropic or 
multi-drug resistance (MDR) was intensively investigated because it seemed to 
reflect the complexity observed in clinical resistance.
In 1974, Ling and Thompson observed that MDR cells which had been 
selected in colchicine did not accumulate the drug to the extent of the parent cell line.
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Two years later, these colchicine resistant cells were shown to overexpress an integral 
membrane protein of approximately 170,000 daltons (Juliano and Ling, 1976). 
Roninson et al, (1984) and others (Riordan et al, 1985; Scotto et al;1986; Gros et al, 
1986c) noted that MDR cells contained amplified DNA. These amplified sequences 
were found to contain a small family of genes (Van der Bliek et al. 1986); one of 
these genes, termed mdr 1 encoded a 4.5 -5.0kb mRNA which in turn coded for the P- 
glycoprotein (Riordan et al, 1985; Ueda et al, 1987b).
The nucleotide sequences of human mdrl (Chen et al, 1986), and what were 
designated mouse mdrl (Gros et al, 1986b) and hamster Pgpl (Gerlach et al, 1986a) 
became available in rapid succession. The complete sequences of all these genes 
showed that the genes encode proteins of between 1276-1280 amino acids. The 
sequence of the mdr genes placed mdr encoded P-gp in the ABC (ATP Binding 
Cassette) superfamily of transport proteins. Other members of this family include a 
number of bacterial transport proteins and the "shock" sensitive nutrient uptake 
systems found in gram-negative bacteria (Gros et al, 1986b). The closest homology is 
to Haemolysin B, a self contained membrane protein which mediates the energy 
dependent extrusion of the protein haemolysin A. Proteins of the haemolysin group 
include a hydrophobic region with six transmembrane segments and a nucleotide 
binding domain, thus resembling one half of P-gp. This general homology to bacterial 
permeases, provided a potential mechanistic basis for the MDR phenotype. From 
sequence homology, it would appear likely that P-gp could act as an energy 
dependant drug efflux pump, lowering the intracellular drug concentration and 
thereby permitting cell survival.
The functional significance of the mdr-1 encoded P-glycoprotein (P-gp) in 
the multi-drug resistance phenomenon was later confirmed by transfection 
experiments. Full length P-gp cDNA transfected into sensitive cells could confer the 
MDR phenotype following drug selection of recipient clones (Gros et al, 1986a; 
Croop et al, 1987; Ueda et al, 1987a) and even without drug selection (Guild et al, 
1988). The postulated structure of P-glycoproteins has been deduced from the 
nucleotide sequence and is shown in figure 1.2.
The coding sequence of P-gp comprise two halves (which are almost a direct 
repeat of each other) connected by a linker of about sixty amino acids. Each half can 
be divided into two domains of functional significance: an N-terminal domain which 
has little similarity between the halves, and a C-terminal domain which contains 
nucleotide binding sites and is largely identical between the two halves. Upstream of 
the nucleotide binding sites in both halves of the molecule are six hydrophobic 
segments which are predicted to span the membrane as shown in figure 1.2. It has 
been postulated that these membrane loops could form a membrane channel through
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which drugs are extruded. In conjunction with the results of Hamada and Tsuruo
(1988) demonstrating that isolated P-gp containing membranes have ATPase activity, 
all of the evidence is compatible with the postulated role of P-gp as an ATP-driven 
pump which removes drug from the cell and thereby prevents cytotoxicity.
Figure 1.2 Proposed P-glycoprotein structure.
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NBS, nucleotide-binding sequence consensus region.
The potential N-linked glycosylation sites are indicated by the branches sprouting 
from the polypeptide. Dashed lines indicate the linker region. (Adapted from 
Kirschner et al. 1992)
Over five years later, the supra-molecular structure of P-gp has still not been 
resolved. Freeze fracture electron microscopic studies suggest that mdrl probably 
exists as a higher oligomer, most likely a dimer or a trimer (Arsenault et al., 1988; 
Sehested et al., 1989; Weinstein et al., 1989). These findings would be consistent 
with other integral membrane transporters such as Band 3, the anion transporter of 
red blood cells (Jay and Cantley, 1986). This raises the possibility that mdrl 
monomers may need to organize into higher oligomers for the formation of transport 
pores that are large enough to accommodate lipophilic drugs moving out of the cell.
1.3.3 MDR GENE FAMILY
The manner by which the coding sequences for two human, three mouse mdr 
genes, and two complete hamster P-gp genes were obtained is summarised by Van 
der Bliek and Borst, (1989). A single gene has been cloned and sequenced in the rat 
(Silverman et al, 1991). All of these genes have strong homology to each other.
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The nomenclature of the mdr gene family in different species is confusing. 
The mouse genes were originally named according to the chronological order in 
which they were isolated (Gros et al, 1986b; Gros et al, 1988; Devault et al, 1990). A 
second group led by Horwitz adopted a functional based nomenclature (table 1.8) in 
which the two murine genes which were most closely related to each other were 
called mdr la  and mdr lb  (Hsu et al, 1989). Both of these genes are capable of 
conferring the MDR phenotype by gene transfection. The remaining gene, known as 
mdr2 by both Horwitz and Gros, does not confer drug resistance in transfection 
experiments. The second human mdr gene was called mdr3 by Van der Bliek's group 
(1987) because of its homology to the third hamster gene. The human mdr3 gene 
also fails to confer resistance in transfection experiments and is more homologous to 
the mdr2 gene of the mouse than the murine mdrl genes. The sequence homology 
between the different mdr genes is given in table 1.7 which is adapted from 
Silverman et al, 1991 and the different nomenclatures in table 1.8.
Table 1.7 mdr gene homologies (% nucleotide homology)
Gene Hamster
mdrla mdrlb
Mouse
mdrla mdrlb mdr2
Human
MDR2
Human
MDR1 83.5 75.7 82.2 78.7 71.1 74.9
MDR2 64.2 47.7 71.6 70.6 86.1 100
Mouse
mdr2 65.0 77.9 71.1 69.4 100
mdrlb 77.9 83.4 84.2 100
mdrla 89.3 76.8 100
Hamster
mdrlb 82.0 100
mdrla 100
The sequence comparison in table 1.7 shows that the human mdrl gene is 
analogous to the mdrla gene in rodents. The mdrla and mdrlb of rodents are closely 
related and have been suggested to have arisen by a gene duplication event which is 
presumed to have arisen after the divergence of rodents and primates. It is also 
noteworthy that the mdr2 genes are more closely related to each other than they are to 
the mdrl genes of the same species. The conserved nature of the mdr2 gene indicates 
that the protein probably has an important cell function, which is as yet unknown.
27
Table 1.8 mdr gene nomenclature
Suggested
Designation
Current
Human
Designation
mouse hamster
mdrla MDR1 mdr3 pgpi
mdrlb mdrl Pgp2
mdr2 UDR2/mdr3 mdr2 Pgp3
Along the length of the gene, the degree of cross-species and cross-isoform 
homology varies. The areas sunounding the nucleotide binding sites are the best 
conserved; generally the homology increases towards the 3' end of each half of the 
gene. The linker region, which joins the two duplicate halves of the gene, is poorly 
conserved (Hsu et al, 1989). This has implications for the ability to generate gene 
specific probes.
1.3.4 DRUGS AFFECTED BY MDR
Some of the drugs which are generally considered to be affected by mdr 
encoded P-gps are listed in table 1.9. These drugs have diverse cellular targets and 
structure (Bowman and Rand, 1980) . The common feature of these drugs is there 
hydrophobicity and, in the majority of cases, their flexible planar ring structure (Beck 
and Qiang, 1992). The sensitivity to hydrophilic drugs such as bleomycin and 
cisplatin is generally unaltered or even slightly decreased in MDR cells (Schurr et al., 
1989; Keizer et al., 1989). In this regard, the MDR phenotype falls short of being a 
complete mimic of clinical multiple drug resistance in that it is not uncommon for 
clinical drug resistance to be accompanied by resistance to drugs such as 
methotrexate, cisplatin and bleomycin (Armitage etal, 1990).
The MDR phenotype has been most studied in drug selected cell lines. These 
mdrl expressing cell lines often show a quantitative variation in the degree of cross- 
resistance to the MDR spectrum drugs (Akiyama et al, 1985; Gekelar et al.,1990). 
Generally resistance is highest to the selecting drug (Akiyama et al, 1985) but this is 
not universal (Guild et al, 1988). A notable exception is the colchicine selected 
Chinese hamster ovary cell line CHpC5, which is 180 times resistant to colchicine but 
is 5000 fold resistant to gramicidin D (Geriach et al. 1986b). In the chronically 
selected cell lines it is difficult to exclude other resistance mechanisms contributing 
to this variation. However after transfection of functional P-gp cDNA among a series 
of recipient clones (Shen et al., 1986b; Ueda et al., 1987b) variation still exists in the 
quantitative resistance, even in the absence of drug selection (Guild et al, 1988).
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Table 1.9 MDR phenotype drugs
doxorubicin
vincristine
daunomycin
colchicine
actinomycin D etoposide
epirubicin
vinblastine
puromycin
colcemid
mitoxantrone
azidopine
taxol
gramicidin D 
valinomycin
Because the primary interest in P-gp stems from the field of cancer 
chemotherapy, most of the drugs commonly used to screen MDR cell lines are 
chemotherapeutic drugs rather than some of the membrane perturbing agents used 
originally in the characterisation of these lines (Bech-Hansen et al., 1976). This 
concentration of effort is understandable from a clinical viewpoint. Of the drugs 
included in the MDR spectrum, the anthracyclines, podophyllotoxins and the 
vinca alkaloids are of major importance in many treatment protocols. Doxorubicin has 
formed the crux of many lymphoma treatment regimens since the efficacy of the 
CHOP protocol (cyclophosphamide, doxorubicin, vincristine and prednisolone) was 
demonstrated in the seventies (McKelvey etal, 1976).
In those studies which have not been confined to a cancer perspective, 
interesting results regarding potential P-gp substrates have been found. Early work 
suggested that some MDR cell lines have altered sensitivity to certain steroids (Bech- 
Hansen et al., 1976) and in addition, P-gp is present at high levels in the steroid 
producing adrenal cortex (illustrated by Bradley et al, 1990). This possible 
connection with normal P-gp function spawned an interest in steroids as substrates 
for the P-gp pump. Naito et al., (1989) and Yang et al (1989) examined the ability of 
different steroids to inhibit vincristine and azidopine binding to MDR cell 
membranes. Progesterone, of the steroids tested, inhibited drug binding most 
efficiently. Curiously, subsequent work has suggested that the two mdrl genes in the 
rodent can be differentiated by their differential binding of progesterone. Mdrlb, the 
isoform found in adrenal and gravid uterus, binds progesterone more effectively than 
the mdrla isoform. However, effluxing of progesterone by the mdrlb expressing cell 
line could not be shown (Yang et al, 1990). Thus although there is a link between P- 
gp and endogenously occurring steroids, there is still no definite proof of efflux of 
endogenous substrates via P-glycoprotein.
1.3.5 HOW DOES P-GP RENDER CELLS DRUG RESISTANT?
There is ample evidence that MDR cells avoid cytotoxicity by keeping the 
intracellular drug concentration low (Ling and Thompson, 1974; Fojo et al, 1985a; 
Willingham et al., 1986). Numerous studies have demonstrated that MDR drugs can 
bind to P-gp containing membranes (Cornwell et al, 1986; Naito et al, 1988; Safa et
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al. 1989) and in the inverted vesicle model of Horio et al (1988) some of these drugs 
have been shown to be transported across the membrane. Agents, such as verapamil, 
which are known to reverse the MDR phenotype, also bind to P-gp and can 
competitively block MDR drug binding (Safa et al, 1987; Foxwell et al, 1989). These 
findings all support the general model of P-gp active transport, which was based on 
the nucleotide similarities between mdrl and the ABC superfamily. However, 
despite the acceptance of the active drug transport model in its' broadest sense, there 
are still many uncertainties about the system. Firstly, what is the biochemical basis of 
the diverse substrate specificity of P-gp? Secondly, how can P-gp confer resistance to 
a large fold increase in external drug concentration yet reduce the intracellular 
concentration by a much smaller fold difference (Fojo et al, 1985a)? Until these two 
points are adequately answered, it is unlikely that the full benefits or limitations of 
mdr modulator drugs will be understood.
West (1990) speculated about the mechanistic basis of P-gp substrate 
specificity and discussed whether P-gp could be a transport system for diverse 
xenobiotics which are recognised via a common chemical tag placed on them by 
enzymatic drug-conjugating systems such as glutathione transferase. However, the 
inverted vesicles of Horio et al. (1988) could accumulate vinblastine without any 
exogenously added glutathione. Therefore, even if P-gp does transport glutathione- 
conjugated xenobiotics, the glutathione moiety is not an absolute requirement and 
would seem unlikely to be the major recognition feature.
West (1990) also drew attention to some of the inexplicable aspects of the 
data on drug binding and transport in MDR cells. Horio et al, (1988) noted that 
daunomycin effectively blocked vinblastine binding. However neither colchicine nor 
puromycin were particularly effective inhibitors. Earlier work by Cornwell et al, 
(1986) had illustrated the same phenomenon; colchicine was a poor inhibitor of 
vinblastine binding to MDR cell membranes. This led West to propose that there 
were possibly separate and non-interacting drug binding sites on the P-gp for 
different drugs.
The idea of binding site specificity affecting drug interactions was 
strengthened by the work of Choi et al, (1988) who demonstrated that an alteration in 
a single amino acid can have marked effects on the cross resistance profile of MDR 
cells (Choi et al, 1988). A cluster of point mutations in the human mdrl gene which 
resulted in a glycine to valine substitution was associated with increased resistance to 
colchicine relative to the vincaalkaloids. The altered amino acid (residue 185) was 
located immediately adjacent to the cytoplasmic side of the third transmembrane 
segment (TM3) and was therefore proposed to be involved either in initial drug 
binding or at some point in the translocation of the drug (figure 1.3). To resolve these
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alternatives, Safa et al, (1990) compared the binding of photoactive drug analogues to 
the wild-type versus mutant P-glycoprotein. This work suggested that this mutation 
did not affect initial drug binding but did affect the ability to translocate vincristine 
across the membrane.
P-gp is a protein of two virtually identical halves and hence one would expect 
the homologous cytoplasmic loop in the other half of the molecule to also contribute 
to drug binding and efflux. Georges et al, (1991) proteolytically cleaved P-gp into its 
two halves and showed that both halves labelled with azidopine. They then used 
monoclonal antibodies against specific regions of P-gp to perturb drug and ATP 
binding. The positions of the binding sites of these monoclonals on the intact protein 
are shown in figure 1.3. C219 binds in both halves of the molecule whereas the 
binding sites of C494 and C32 are limited to the C-terminal half of the protein. 
Despite this large separation in the linear drawing of P-gp, C494 and C32 effectively 
inhibited ATP binding to both halves of P-gp suggesting cooperativity between the 
two domains, perhaps as a result of close proximity in the native protein. This work 
has given intriguing insights into P-gp tertiary structure but still does not define the 
biochemical basis of substrate specificity.
The group led by Philippe Gros approached the question of P-gp substrate 
specificity by exploiting their knowledge of the murine mdr genes. Transfection 
experiments had shown that the mdrla/lb genes could confer the MDR phenotype 
(but that this resistance was not identical) whereas mdr2 could not transfer drug 
resistance (Gros, et al, 1988; Devault and Gros, 1990). Initially they created chimeric 
proteins where regions of the mdrlb protein was replaced by regions from the 
inactive mdr2 protein. When mdrlb transmembrane domain regions were replaced 
by the equivalent regions of mdr2, biological activity was abolished. Replacement of 
as few as two TM regions (e.g.. TM5-6 or TM7-8) was sufficient to destroy activity 
(Buschman and Gros, 1991). The group then went on to investigate whether 
differences in the TM segments between mdrla and mdrlb could account for the 
difference in drug-resistance spectrum of transfectants. A comparison of the 
aminoacid sequence of the two genes revealed a difference in TM11. Site directed 
mutagenesis of a single amino acid at position 941 (Ser to Phe) in TM11 altered the 
degree of drug resistance. For mdrlb, the substitution produced a mutant protein 
which had retained the ability to confer resistance to vinblastine but had lost the 
ability to confer doxorubicin or colchicine resistance. This segregation of vinblastine 
resistance from colchicine resistance in the mutant validates the biochemical 
observations of competitive binding and drug efflux carried out by Horio et 
a/,(1988), Cornwell et al, (1986), Safa et al, (1989) and others, which suggested that
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the binding sites for VBL may be non-overlapping with the colchicine and 
doxorubicin binding sites.
Figure 1.3 P-gp illustrating some functionally critical sites.
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Arrow marks position of the glycine/valine substitution
As a way of unifying some of the apparently divergent information on the 
binding and efflux capabilities of P-gp and its structural implications, Higgins and 
Gottesman (1992) have proposed an alternative view of the P-gp pump. Rather than 
basing P-gp substrate specificity on some "enzyme-like" recognition site somewhere 
on the cytoplasmic side of the protein, Gottesman proposes that drugs initially 
interact with the plasma membrane and then interact with the P-gp transporter from 
the lipid phase. After interaction has occurred, the substrates are "flipped" either into 
the outer leaflet of the membrane or directly to the exterior. This model assumes that 
substrates partition themselves into the lipid phase: it is well recognised that despite 
the size variation, MDR drugs are all cationic, lipid soluble planar molecules which 
would be expected to intercalate into membranes (Beck and Qian, 1992). In this way, 
the primary determinant of substrate specificity would be the ability to insert into the 
lipid membrane in a recognisable fashion, and only secondarily would come the 
ability to bind to a substrate site on the molecule. Substrate specificity based on lipid 
membrane intercalation would help explain the P-gp mediated resistance to the 
hydrophobic peptides gramicidin D and valinomycin which would not seem likely to 
interact with a binding site positioned in an aqueous part of the molecule.
The "flippase" model could also explain some of the complexities of kinetic 
data in that the amount of drug available for transport will depend on the amount
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partitioned into the membrane at any one time and not on the external or 
intracytoplasmic concentration. If P-gp acts in a sentinal role, intercepting and 
expelling drugs prior to entry into the cytoplasm, P-gp would be a particularly 
effective resistance factor. However, although this "flippase" model is very 
attractive, it still does not explain the second question posed at the start of this 
section. This question relates to how the presence of P-gp can give cells a large fold 
resistance relative to the parental cell line and yet still allow considerable intracellular 
drug accumulation.
Confocal microscopy of daunorubicin distribution in sensitive and resistant 
cell lines show that both drug sensitive lines and their resistant counterparts have a 
similar rapid distribution of drug from the plasma membrane to the perinuclear region 
within the first two minutes of drug exposure (Gervasoni et al, 1991). It is only in the 
subsequent redistribution that resistant and sensitive cells differ. In the sensitive cells, 
drug redistributed to the nucleus and cytoplasm in a diffuse pattern. In contrast, in the 
resistant cell lines, daunorubicin redistributed from the perinuclear region into 
vesicles distinct from the nucleus, which gave the cell a punctate pattern. This altered 
sub-cellular distribution of MDR drugs into a punctate pattern begs the question of 
whether P-gp is present in internal membrane structures as well as the external 
membrane.
Remarkably little is known about the sub-cellular distribution of P-gp. In the 
tumour cell line KB-C4 (which is a high expressor of P-gp), Willingham et al, (1987) 
localised P-gp to the external plasma membrane but also to the lumenal side of the 
Golgi stack membranes. A small amount was also located in the endoplasmic 
reticulum. However, the distribution in normal cells, and in tumour cells in situ, may 
be considerably different from cultured cells. Numerous studies (discussed in chapter 
5) have described P-gp in what would appear to be the Golgi region of cells or in a 
punctate distribution. In the hamster and human adrenal, the pattern of staining with 
anti-P-gp monoclonals suggests that P-gp is distributed throughout cytomembranes 
and is not localised to the cell surface (Bradley et al, 1990).
In summary, P-gp appears to act as a hydrophobic vacuum cleaner expelling 
hydrophobic drugs which interact with transmembrane portions of the protein. 
Certain regions within the intracytoplasmic loops are also essential for effective 
efflux. MDR cells can have an altered intracellular distribution of MDR drugs but the 
role of P-gp in this redistribution is unknown.
1.3.6 NORMAL TISSUE DISTRIBUTION OF THE MDR GENE FAMILY
Fojo et al (1987b), reported the first large survey of normal human tissues for 
the expression of mdrl. They measured total mdrl mRNA in blocks of normal tissue
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and found high expression in liver, kidney, adrenal and colon. Expression in most 
other organs was low. Using the mdrl specific monoclonal antibody MRK16, 
Theibaut et al,(1987) found P-gp localised to the apical surface of colonic epithelium, 
brush border of proximal tubular epithelium in the kidney and the canalicular surface 
of hepatocytes. Suguwara et al, (1988) also used MRK16 and confirmed expression 
of P-gp in the adult (but not neonate) adrenal glands. Mdrl encoded P-gp has also 
been localised to the surface of endothelial cells of capillaries in the brain and testes 
(Cordon-Cardo et al 1989, Thiebaut et al. 1989). Van der Valk et al, (1990) 
surveyed normal human tissue using three monoclonal antibodies (C219, JSB-1 and 
MRK16) and found endothelial staining not only in the brain and testes but also in the 
lung, prostate, stomach, intestine and glomeruli.
Because of the existence of the human mdr3 gene, whose tissue distribution 
was unknown, some confusion arose over the use of the monoclonal antibody C219. 
This antibody detects a conserved epitope in P-gp which is conserved in all known 
isoforms (Georges et al, 1990). When immunohistochemical analysis of human 
muscle tissue revealed a strong reactivity which was not detected with mdrl specific 
monoclonals nor with mdrl gene probes, this muscle tissue reactivity was considered 
to be a spurious cross-reactivity. Immunoblotting of electrophoresed protein gels with 
C219 suggested that the protein detected in muscle tissue was of a higher molecular 
weight than the other tissue P-gp and so this cross-reactivity was reputed to possibly 
be to a myosin protein. Reassessment of this work in the light of subsequent 
information would suggest that C219 does not cross react with myosin but that the 
reactivity in muscle is detection of the mdr3 gene product. Detailed examination of 
the distribution of P-gp isoforms in the hamster using a panel of isoform specific 
monoclonals (Bradley et al, 1990) showed that hamster muscle tissue expresses the 
equivalent of the human mdr3 gene. N-linked glycosylation of P-gp in normal human 
tissue can alter the apparent size of the protein by up to 15kD (Ichikawa et al, 1991), 
this coupled to the poor resolution of large proteins on the gel system used by 
Thiebaut et al (1989) could account for the size discrepancy between liver and heart 
muscle P-gp.
There are reports of mdrl encoded P-gp in human ureter (Weinstein et al, 
1990a) and in certain epithelium of the female reproductive tract (Finstad et al,
1990). This work, and other work using C219 and JSB-1, is now open to 
reinterpretation following the revelation that certain batches of these monoclonal 
antibodies may be contaminated with antibodies which react with blood group 
antigens, in particular blood group A antigens (Finstad et al, 1991). Blood group 
antigens can be expressed by a variety of epithelia and endothelia so it is not
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inconceivable that some of the reported P-gp expression in epithelia (and epithelial 
tumours) and endothelia, may not be genuine.
The detailed immunohistochemical analysis of P-gp isoform tissue 
distribution in the adult hamster by Bradley et al, (1990) showed that rodents have a 
very similar tissue distribution to humans, with the major exception that P-gp could 
not be unequivocally demonstrated in the kidney. This point is discussed further in 
chapter 5.
Rodents have two mdrl isoforms, and judging from the results of Croop et al,
(1989) and Bradley et al, (1990), the normal function of the mdrlb protein is likely 
to be quite distinct from the mdrla function. Mdrlb is localised to the adrenal cortex 
and to the epithelium of the uterus in mid to late stage of pregnancy. In the adrenal, 
reactivity was localised to the zona fasciculata and z. reticularis; there was no 
expression in the medulla or z.glomerulosa. This strong adrenal cortex staining was 
limited to males; females showed only weak staining of the z.glomerulosa. This 
would suggest that the expression of mdrlb is under tight and probably complex 
control.
Inevitably, the tissue distribution of P-gp has led to speculation about the 
normal physiological role of the different isoforms. The association of the mdrla 
isoform with secretory and excretory epithelial surfaces such as liver, gastro­
intestinal tract and kidney, has invoked the idea that mdrla is an efflux pump for 
noxious xenobiotics or potentially harmful lipophilic endogenous substances. There is 
remarkably little direct evidence to further substantiate this hypothesis. There are a 
number of in vivo and in vitro models that show that mdrl may increase in response 
to various noxious stimuli (Thorgeirsson et al, 1987; Burt and Thorgeirsson, 1988; 
Hill et al, 1990, Marino, et al, 1990; Chin et al, 1990a and 1990b; Gant et al, 1991), 
but these studies have not succeeded in identifying the normal substrates for mdrl. 
The putative role of the mdrlb isoform in rodents has centred around vague ideas 
about steroid transport and metabolism but again although binding of progesterone to 
P-gp has been demonstrated in vitro and in vivo, it is by no means clear if these 
substances are actually transported (Yang et al, 1989 and 1990).
The function of the mdr2 isoform is even less clear. Immunohistochemistry 
shows that it is present in a complex striated pattern in both cardiac and skeletal 
muscle fibres. In skeletal muscle, only certain fibres are P-gp positive; these appear to 
be the Type 1 fibres (slow twitch fibres) identified by their alkaline labile, acid- 
resistant ATPase activity (Thiebaut et al, 1989). The potential substrates of the mdrl 
isoform are completely unknown. Recent evidence suggests that the mdrl isoform 
may be a volume-regulated, chloride-selective channel (Valverde et al. 1992); this 
makes it similar to the cyclic AMP regulated chloride channel encoded by the cystic
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fibrosis transmembrane regulator (CFTR) gene (Tabcharani et al, 1991). It is 
interesting to speculate that the mdrl isoform may also have ion channel properties 
that participate in the complex ion fluxes which occur during muscle contraction and 
relaxation.
1.3.7 P-GP/A/DR EXPRESSION IN HUMAN TUMOURS
(i) Methodological considerations
P-gp represents a resistance mechanism which can be detected in tumour 
material using standard techniques. Naturally numerous studies have examined P-gp 
in tumours and attempted to relate this to inherent or acquired resistance. Before 
proceeding to the results of some of these studies, some methodological 
considerations have to be discussed. In a recent editorial Baer and Bloomfield (1991) 
commented "studies of MDR1 expression are of great potential significance in cancer 
therapeutics, and it is imperative that methodologic problems be conquered". It is a 
reflection of the quality of work in this field that this comment was still necessary six 
years after the first measurement of mdrl in clinical samples (Bell et al, 1985). Some 
of the technical problems and misunderstandings which have arisen (plus ways of 
avoiding them) are outlined in the first half of this section.
In broad terms it is possible to divide the clinical studies into mdr mRNA 
versus protein measurement studies. The methodologies can be further subdivided 
into those which use homogenates of tumour tissue versus techniques which allow 
assessment of P-gp distribution within a tumour sample such as 
immunohistochemistry (IHC) and in situ hybridisations. Historically, mdr gene 
probes became available more rapidly than monoclonal antibodies directed against P- 
glycoprotein. Consequently, the majority of the earliest studies used dot-blot and 
Northern hybridisations to measure mdr mRNA to categorise tumours into 
high/intermediate/low expressors of P-gp. Now that IHC information is available on 
cellular distribution of P-gp some of the generalities which arose from the dotblot 
work must be reassessed (see below).
A second level of misinterpretation arose because initial studies were carried 
out before the implications of the mdr gene family were appreciated. One of the first 
antibodies widely available was C219 (Kartner et al, 1985) which is not isoform 
specific (Georges et al, 1990). Many studies (predominantly of haematological 
malignancies) have used C219 alone, even since this potential source of inaccuracy 
has become apparent (Carulli et al, 1990a, 1990b, 1990c; Kuwazuru et al, 1990a, 
1990b; 1990c; Ma etal, 1987; Weide etal, 1990; Kato etal, 1990; Musto etal, 1990; 
Musto et al, 1991; Epstein et al, (1989). These authors, if they make reference at all 
to this source of error, have justified their experimental design with the comment that
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this particular normal tissue does not express mdr2. In many tissues this may be true 
but it has certainly not been unequivocally shown. One of the few studies of mdr2 
expression in normal human tissues (using per analysis) did not examine peripheral 
blood but did detect mdr2 in spleen homogenate (Chin et al. 1989). Given that spleen 
is part of the lympho-reticular system and a site of blood storage, it would seem 
unsafe to conclude that peripheral blood leucocytes and leukaemias will be mdr2 
negative.
Misinterpretation of mdrl/mdr2 can be avoided using mdrl specific probes. 
Fortunately, most mdr mRNA studies (with a few exceptions such as Holmes et al,
1990) have used probes which were mdrl specific under the conditions employed. In 
IHC, the use of a panel of antibodies (as recommended by Grogan et al 1990) 
including mdrl specific monoclonals such as MRK16 and JSB-1 (Schinkel et al,
1991) minimizes the risk of misinterpretation.
Characterisation of mdr cell lines has indicated that only a little surface P-gp 
in an otherwise P-gp negative cell type, can alter drug resistance (Noonan et al, 1990; 
Chan et al, 1988; Bradley et al. 1989). The realisation that a low level of P-gp is 
relevant in vitro, has focussed attention on the threshold sensitivity of the techniques 
employed to analyse clinical samples. Generally it is accepted that Northerns and 
mRNA slotblots are more sensitive than Western immunoblots but these techniques 
do have the advantage of being quantifiable, whereas IHC is more subjective. Many 
of the papers analysing mdrl mRNA have adopted the use of the KB drug resistant 
cell line series as their positive and negative controls (Goldstein et al, 1989: Noonan 
et al. 1990; Fojo et al, 1987a and 1987b; Kakehi et al, 1988; Lai et al, 1989; 
Rothenburg et al, 1989; Kanamuru et al, 1989; Herweijer et al, 1990). KB8-5, the 
most widely used P-gp positive cell line, has a low level of resistance to MDR drugs 
(approximately four fold to doxorubicin) and has a reproducible amount of mdrl 
mRNA on dotblot or northern blot. Mdrl mRNA from both normal and tumour 
samples can yield values greater than KB8-5 (Goldstein et al, 1989; Fojo et al, 
1987a) thus it is a realistic control. The mdr mRNA in KB8-5 is then used as a 
threshold between "intermediate" and "high" expressing tumours.
Chan et al (1988) and Grogan et al, (1990) have established that certain 
immunocytochemical techniques can be equally sensitive as mRNA detection 
techniques. Both groups have used cell lines other than the KB8-5 to determine the 
detection threshold of their IHC but both have established that their technique can 
detect P-gp on cells with a low fold resistance to MDR drugs. Unfortunately not all 
studies have determined a meaningful threshold for their methodology and this makes 
the comparison of results difficult. Some authors do not stipulate what they use as a 
positive control (Rubin et al 1990) and others use highly drug resistant cell lines with
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gross overproduction of P-gp well above that in the tumour samples (Keith et al. 
1990a; Schneider et al. 1989; Wishart et al. 1990; Schlaifer et al, 1990 ), making it 
impossible to judge the limit of their sensitivity.
The quest for improved sensitivity has led to mdrl mRNA analysis by per 
technology (Noonan et al 1990) and this has shown that low-level mdrl expression, 
undetectable by conventional assays, is common in most tumour types. Given that 
normal endothelia and tissue macrophages can have P-gp (Van der Valk et al 1990), 
it remains to be proved whether per based studies can produce clinically meaningful 
results.
The problem of comparing between studies is not a trivial one. Often a very 
small number of samples are analysed and hence it is difficult to determine if 
variation in results is because of differences in technique sensitivity, biological 
variation between small sample groups or even due to artefact. Artefacts may be 
prevalent in this work because very few papers validate their findings by repetition 
(Chan et al, 1990; Marie et al, 1991) and hence conclusions are often formed from a 
single dot-blot reading or on a single IHC section (Goldstein et al, 1989; Pirker et al, 
1991; Solary et al, 1991; Ito et al, 1988; Musto et al, 1991; Weide et al, 1990; and 
many others).
(ii) Mdrl in solid tumours
The possible sources of error in clinical P-gp work are many and in reviewing 
the publications, it is not possible to exclude all papers which do not meet high 
technical standards; in many tumour types this would reduce the number of properly 
analysed samples to a mere handful. Table 1.10 divides solid tumours into three 
groups according to the frequency and amount of P-gp found in pre-treatment 
samples. This table is adapted from Nooter and Herwiejer (1991) but includes only 
malignancies which have had at least twenty independent samples analysed by at 
least two different groups of researchers.
From this table it is apparent that tumours which arise from P-gp expressing 
normal tissue like the liver, kidney and gastrointestinal tract, have a tendency to 
retain P-gp following neoplastic transformation. It is also accepted that the tumours in 
Group 1 tend to fall into the clinical category of intrinsically resistant; i.e. 
chemotherapy rarely produces complete remission. It is important to note that Group 
3, the tumour group which is invariably P-gp negative at time of diagnosis, does not 
symbolise a group of chemosensitive tumours. Non-small cell lung cancer and head- 
and-neck tumours have a fairly poor response to chemotherapy; both ovarian tumours 
and small cell lung cancer often relapse with chemoresistant disease.
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Table 1.10 Expression of mdrl in solid tumours
References in bold type used immunohistochemical techniques
Group I High mdrl expression levels at a high frequency
Renal cell carcinoma Fojo et al, 1987b 
Goldstein et al, 1989 
Kakehi et al, 1988 
Kanamura et al, 1989 
Schlaifer et al, 1990
Colon cancer Fojo etal, 1987a 
Goldstein et al, 1989 
Weinstein et al, 1991 
Schlaifer et al, 1990
Hepatocellular carcinoma Goldstein etal, 1989 
Schlaifer et al, 1990
Adrenocortical tumours Fojo etal, 1987a 
Schlaifer et al, 1990
Group II Intermediate mdrl expression levels at a lower frequency
Neuroblastoma Fojo etal, 1987a 
Goldstein et al, (1989) 
Bourhis et al, (1989a) 
Chan et al, 1991
Soft tissue sarcomas Gerlach et al, 1987 
Chan et al, 1990 
Noonan etal, 1990 
Schlaifer et al, 1990
Phaeochromocytoma Fojo etal, 1987a 
Goldstein et al, 1989 
Schlaifer et al, 1990
Breast cancer Goldstein et al, 1989 
Moscow etal, 1989 
Salmon et al, 1989 
Keith et al, 1990a 
Schneider et al, 1989 
Schlaifer et al, 1990 
Wishart et al, 1990 
Verelle et el, 1990
Table 1.10 (continued)
Group IH Almost always low/undetectable mdrl expression
Ovarian cancer Gerlach et al, 1987
Goldstein et al, 1989
Bourhis etal, 1989b
Moscow etal. 1989
Rubin et al, 1990
Lung tumours (small cell Goldstein et al, 1989
and non-small cell) Moscow et al, 1989
Lai et al, 1989
It must be appreciated that within the three groups, it is possible to select a 
study which gives results divergent to the rest. Some studies of Group 1 tumours have 
failed to detect P-gp in tumour cells. Goldstein et al (1989) remarked on the variation 
in dotblot values for this tumour type whereas Moscow et al, (1989) failed to find 
mdrl in 10/12 colon samples by slot blot analysis. IHC studies are revealing that this 
variation between individuals (and presumably between studies) may be a genuine 
biological phenomenon. Schlaifer et al, (1990a) examined two colonic carcinoma 
samples using immunohistochemistry; neither had P-gp positive tumour cells but did 
have P-gp positive macrophages. Other IHC studies have also revealed that colonic 
tumours are not uniformly positive: Weinstein et al (1991) found 30 out of 95 
tumours were P-gp negative.
IHC analysis in addition to showing inter-patient variability, is also showing 
that intra-tumour P-gp distribution is heterogeneous (Rubin et al, 1990; Finstad et al, 
1990; Wishart et al 1990; Weinstein et al, 1991). Eventually this may necessitate 
regrouping the tumours in table 1.10. The heterogeneous distribution of P-gp in 
tumour cells is usually described in terms of the potential for selection of a pre- 
existant drug refractory sub-population by subsequent chemotherapy. However it is 
still unclear if P-gp positivity in relapsing tumours is due to a drug selection 
mechanism, as suggested by the Goldie and Coldman hypothesis. For ethical reasons, 
patients receive drug combinations which are not limited to MDR drugs. 
Consequently, even if the expression of P-gp does increase at time of relapse in an 
individual tumour it is not possible to state that this is due to drug selection of mutant 
phenotypes by MDR drugs.
Determining the frequency of P-gp in relapse tumours versus pre- 
chemotherapy tumours is still not adequately established for most tumour types. The 
inter-patient variability of P-gp expression at time of diagnosis necessitates the use
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either of large cohorts of pre-treatment and post-treatment samples or preferably the 
use of paired samples from the same patient before treatment and at relapse. This has 
not been achieved in most tumour types because of the difficulties of sample 
procurement.
In those tumour types that are not uniformly P-gp positive at diagnosis, there 
is accumulating evidence that P-gp may be a poor prognostic indicator, even when 
non-MDR drugs are included in the treatment protocols. In a collection of solid 
tumour papers, small numbers of tumours which are P-gp positive at diagnosis are 
associated with poor clinical response in a variety of tumour types including breast 
cancer (Salmon et al, 1989; Verelle et al, 1991), neuroblastoma (Bourhis et al, 
1989a) and ovarian cancer (Rubin et al, 1990). No multivariate analyses was 
attempted in any of these studies to take account of other prognostic factors.
Chan et al, (1990) performed a longitudinal study of 30 cases of childhood 
soft tissue sarcoma, including twelve patients sampled after treatment. This IHC 
study is important for various reasons. Firstly, it meets all the technical criteria 
mentioned previously. Secondly, it provides patient details and actually uses this 
information to assess whether the presence of P-gp is of prognostic importance 
independent of other factors. It would appear that in this group of childhood sarcomas 
the presence of P-gp at diagnosis, or subsequent to treatment, was associated with 
poor survival. The difference in survival between the P-gp positive group (9/30) and 
the 21 negative tumours was profound. No statistical analysis of clinical response was 
attempted (which bypasses the difficulties inherent in objectively assessing solid 
tumours) but there was a definite trend for the P-gp positive group to be clinically 
chemoresistant.
(iii) Mdrl in haematological malignancies
Many of the early studies of leukaemias and lymphomas analyse only a few 
patients (often with sub-standard methodology) and inevitably, there is a large range 
of positive tumours before treatment and at relapse between studies even within each 
individual leukaemic type (table 1.11). However, the availability of clinical material 
has brought more rapid results in this area of oncology than in solid tumours.
It is possible to correlate P-gp positivity with poor response (or short duration 
of response) in most haematologic malignancies (Weide et al, 1990; Ito et al, 1989; 
Musto et al, 1990; Carulli et al, 1990b; Ubezio et al, 1989). Unfortunately it is 
difficult to determine if this is due to drug resistance imparted by P-gp or due to the 
co-segregation of P-gp with other poor prognostic variables, as discussed by the 
editorial comments of Dalton (1991) and Baer and Bloomfield, (1991). Table 1.11 
shows that post-chemotherapy myeloma samples are more likely to be P-gp positive
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at relapse but that P-gp expression in AML and ALL is very variable even in relapse 
samples.
Compiling the results of the NHL studies, P-gp has been found in about a 
tenth of the tumours at diagnosis whereas about one half have acquired P-gp at 
relapse. The vast majority of the drug resistant samples were from patients who had 
received complex drug protocols so it has not been possible to correlate P-gp 
expression at relapse to one particular drug or drug regime (see references in table 
1.12).
Table 1.11 mdrl expression in haematologic malignancies.
Acute Myeloid Leukaemia
Untreated Treated
List etal, 1991 in
Goldstein et al, 1989 3/24
Ito etal, 1989 0/14 0/11
Pirkcretal, 1991 45/63
Noonan etal, 1990 27/51
Marie etal, 1991 12/19 5/7
Suguwara et al, 1989 1/6
Herweijer et al, 1990 13/17
Kuwazuru etal. 1990c 9/17
Acute Lymphoblastic Leukaemia
Untreated Treated
Musto et al. 1990 5/11 8/9
Fojo etal. 1987a 0/9
Rothenburg etal. 1989 1/9 3/15
Goldstein et al. 1989 2/15
Ito etal. 1989 1/3 3/5
Kuwazuru etal. 1990c 4/11
Marie etal. 1991 1/2 * 1/3Herweijer et al. 1990 8/11
Ubezio et al. 1989 0/5 0/5
Myeloma
Untreated Treated
Salmon etal. 1991 10/15
Carulli et al. 1990c 5/10
Epstein et al. 1989 6/10 10/12
Salmon et al. 1989 4/7
Dalton etal. 1989 4/6
Musto et al. 1990 0/5 2/5
Solary etal. 1991 3/12 2/4
* Treatment status not stated
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Five of the NHL papers used techniques which allowed direct visualisation of 
the lymphoma samples. However, Umeda et al, (1990) used flow cytometry of 
peripheral mononuclear cells, without making reference to the leukaemic state of the 
NHL patients. Their criteria for positivity was to have a higher percentage of positive 
cells in the peripheral blood from NHL patients than in samples from normal healthy 
volunteers. The normal range was 0-1.5% positive; all of the NHL positive samples 
were in the range 1.5% to 5.4%. The authors stated that ICC was used to show P-gp 
in tumour (blast) cells but this data from NHL patients was not presented. It is very 
unclear from Umeda's flow cytometry work how prevalent P-gp is in the actual 
tumour cell population.
Several of the studies of leukaemic samples use flow cytometry to document 
P-gp in blood samples and the criteria for defming positive varies (Epstein et al. 
1989; Cumber et al. 1990; Suguwara et al. 1989). Many of these "positive" samples, 
even from drug-resistant tumours, do not have more than 50% positive cells (Epstein 
et al. 1989; Cumber et al. 1990; Suguwara et al. 1989; ). This is in contrast to the 
IHC work of Miller et al, (1991) and Dalton et al, (1989) who categorically state that 
P-gp is present in essentially all of the tumour cells in a "positive" tumour. Whether 
this difference in prevalence of P-gp positive cells is a genuine phenomenon or 
created by the difference in technique is not clear. However, the reservations 
forwarded by Hanson (1991) regarding flow cytometry and the inability to match 
staining results with cell morphology is a valid criticism of the P-gp work.
Table 1.12 mdrl in non-Hodgkins Lymphomas
Non-Hodgkins Lymphoma
Untreated Treated Method
Goldstein et al, 1989 4/18 3/5 dotblot
Dalton et al, 1989 1/1 m e
Salmon etal, 1989 1/2 2/4 m e
Suguwara et al, 1989 0/2 Flow
Musto et al, 1990 0/2 1/2 ICC
Noonan et al, 1990 0/1 per
Umeda etal, 1990 1/2 5/12 Flow
Schlaifer et al, 1990a 0/6 0/9 m e
Miller et al, 1991 1/39 5/9 m e
Total 7/72 19/42
Methods: dotblot=mRNA quantitation with MDR5A.
IHC = immunohistochemistry with multiple P-gp monoclonal antibodies (except 
Musto et al,who used C219 alone).
Flow = flow cytometry using MRK16
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Attempts to link acquisition of P-gp with particular NHL subgroups have not 
been successful. Potentially relevant tumour and patient information such as 
histologic type, stage etc are not automatically given in the papers, perhaps because 
the small numbers in each study do not appear to merit such detail. Schlaifer et al, 
(1990a) provide the working formulation classification of their NHL samples but 
since all of the tumour cells in their study were negative, this information is of limited 
use. The P-gp positive relapse sample in Dalton et al, (1989) was a diffuse large cell 
lymphoma but in the larger study from the same group (Miller et al, 1991), the 
tumours were divided into low, intermediate and high grade without giving further 
detail. All of their positive samples were in the intermediate-grade subgroup, which is 
likely to include other diffuse, large cell lymphomas.
The immunophenotype of the relapse samples is unknown. It is therefore 
unknown if the incidence of P-gp expression in the relapsing T cell tumours and B 
cell tumours is equal. Adult T cell leukaemia/lymphoma, associated with HTLV-1 
infection, is a subgroup of lymphoid malignancies which is categorised as a high 
grade lymphoma in the NCI modified version of the Working Formulation. These 
lymphomas are exclusively T cell neoplasms. Four studies (table 1.13) have shown 
that the incidence of mdrl /P-gp in ATL is higher both in untreated and treated cases 
compared to other forms of NHL. The numbers involved, especially in the relapse 
samples is still too small to make firm conclusions.
Table 1.13 mdrl expression in ATL
Adult T-cell leukaemia/lymphoma
Untreated Treated
Su etal. 1991 4/7
Umeda etal. 1990 0/3
Kuwazuru etal. 1990a 8/20 6/6
Kato etal. 1990 4/6 4/5
Total 16/33 10/14
So at this time it is only possible to state that more NHL express P-gp at 
relapse than before treatment. Several lines of indirect evidence suggest that drug 
selection may not necessarily be the underlying mechanism for P-gp expression in 
these relapse samples.
Nooter and Herweijer (1991) remarked that in most types of leukaemias, 
elevated mdrl levels can be found and that this is in discordance with normal 
haemopoietic cells which do not express mdrl. Unfortunately, the latter half of this 
statement, often repeated, is based on old data, from the slot-blot and Northern
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analysis data of a handful of unpurified blood samples (Fojo et al. 1987a; Holmes et 
al, 1990). Once more sophisticated techniques were applied to this complex group of 
cell types, Chaudury and Roninson (1991) demonstrated that haemopoietic stem cells 
in bone marrow express a functional P-gp. That an extremely primitive cell type 
within the bone marrow expresses P-gp is significant because it helps rationalise the 
results of the leukaemic samples. P-gp expression in untreated samples could reflect 
the retention of part of the primitive stem cell (as indicated by concomitant CD34 
expression) phenotype due to neoplastic transformation (List et al, 1991).
CLL and multiple myelomas have a more mature phenotype than the ALL 
group and so it is less easy to attribute their P-gp to a stem cell phenotype. However it 
is important to remember that P-gp in mature white blood cells has not been 
addressed in any detail in pathologic states. Indirect evidence suggests that the 
presence of P-gp in lymphocytes should not be discounted. McGown et al, (1991) 
measured daunorubicin uptake in the (normal) lymphocytes of ovarian cancer patients 
who were randomly sampled during the course of their MDR/non-MDR drug regime. 
The accumulation of drug in the lymphocytes from the chemotherapy patients could 
be increased by up to 123% by the addition of verapamil whereas accumulation in 
samples from healthy volunteers remains unchanged. These lymphocyte populations 
were not analysed for P-gp expression but it does raise the possibility that the cellular 
stress of chemotherapy could (temporarily) elevate P-gp in normal lymphocytes.
In one of the few published examples of a (mouse) B-lymphocyte population 
(presumed to be a cell line) examined by Northern analysis, Teeter et al (1990) 
detected strong mdrlb expression. However, Weide et al.(1990) and Suguwara et al.
(1989) failed to detect P-gp in the peripheral blood of 30 healthy individuals using 
immunocytochemistry and flow cytometry respectively. It would therefore appear 
that P-gp in normal healthy lymphocytes is rare. However, the lymphocytes from 
people receiving lymphotoxic /immunosuppressive drugs have not been studied in 
detail. If mature lymphocytes can express P-gp (perhaps only under certain 
circumstances), this would not only provide a normal tissue precedence for P-gp in 
fairly mature lymphocytes, it would also emphasize the importance of sorting 
leukaemic from normal cells prior to analysis of bulk samples. In the work by 
Herwiejer’s group (Herwiejer et al. 1990 and 1991; Nooter et al. 1990), unsorted 
peripheral blood samples were analysed by RNAse protection assay. The authors 
state that all samples contain at least 50% leukaemic cells, but the opposite view 
would say they could contain 50% normal cells! It is curious that their technique has 
detected the highest incidence of mdrl in both AML and ALL.
Returning to the question of MDR drug selection of P-gp positive mutants, 
there is interest in the work with CML and CLL. These malignancies can undergo a
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blast crises which is characterised by an enormous production of a cell type which is 
morphologically dissimilar and more primitive than the original neoplastic cell. Some 
of the oncogenic events that accompany this transformation have been determined 
(Gale and Butturini , 1989; Daley and Ben-Neriah, 1991; Klinken, 1991). The blast 
crises of these diseases are not infrequently P-gp positive. Blast crises can occur even 
in untreated patients and although sufficient numbers of these drug naive patients 
have not yet been analysed, it would appear that prior drug treatment is not a pre­
requisite for P-gp expression (Marie et al, 1991; Tsuruo et al, 1987; Goldstein et al, 
1989; Carulli etal, 1990b, Weide etal, 1990).
Further work with leukaemic samples will help unravel the crucial question of 
whether P-gp in relapse samples is drug selected or an unfortunate event arising from 
progressive genetic events which are an inherent part of the disease process.
1.4 SUMMARY
Both NHL and canine MLSA represent a heterogeneous group of tumours 
which overall are chemosensitive but are often associated with a high incidence of 
drug-resistant relapse. In NHL, certain morphologic types are associated with specific 
oncogene-activating translocations and these affect the natural history and treatment 
response of the disease. Canine histologic types parallel human NHL except there is a 
preponderance of intermediate and high grade tumours. The histologic progression 
from follicular to diffuse forms is less evident in the dog compared to humans, 
perhaps because dogs present with biologically more advanced disease. Cytogenetic 
studies have revealed that NHL progressively acquire non-random genetic lesions, 
some of which are associated with a poor prognosis. Other prognostic factors 
influencing remission and survival in both humans and dogs are broadly similar. 
Advanced stage, poor performance status, "B" symptoms and T cell phenotype are all 
associated with poor prognosis in some studies.
Mdrl encodes a membrane spanning glycoprotein (P-gp) which acts as an 
ATP-dependant efflux pump lowering the intracellular concentration of a variety of 
chemotherapeutic drugs and allowing cells to survive drug exposure. The drugs 
affected include clinically important agents such as some anthracyclines and the 
vinca-alkaloids. P-gp is a normal tissue protein and tumours which arise from tissues 
which express the mdrl isoform are generally chemoresistant. The currently available 
evidence suggests that normal lymphocytes do not express P-gp and many 
haematological malignancies which are drug-sensitive are also P-gp negative.
The role of P-gp in contributing to the heterogeneous response of NHL 
tumours is unclear. P-gp is rare in untreated tumours but is acquired in about 50% of 
relapse samples. The influence of drug treatment, in particular MDR drug treatment,
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in selecting P-gp expressing subclones is not known; all of the relapse patients have 
received multiple agent protocols. High grade T cell lymphomas may have a higher 
incidence of P-gp expression than other NHL groups. Indirect evidence from other 
haematological malignancies suggest that events unconnected with drug selection 
may influence P-gp expression in lymphoid malignancies.
1.5 STUDY DESIGN AND THESIS AIMS
Determining the role of MDR drugs in the selection of P-gp positive tumour 
cell populations cannot be properly studied in humans because it is not ethically 
possible to give humans single agent protocols of MDR (or non-MDR) drugs. The 
inability to obtain adequate clinical samples from patients has further hindered the 
study of P-gp in clinical oncology. Within human NHL studies, basic biological 
factors (such as immunophenotype) have not been incorporated into study design.
MLSA in dogs is a naturally occurring tumour which displays acquired 
resistance to MDR and non-MDR drugs. In dogs, it is already known that single agent 
treatment of MLSA with an anthracycline such as doxorubicin (which is an MDR 
drug) can give acceptable disease free survival times (Postorino et al, 1989). This 
study was designed to take advantage of the efficacy of the anthracyclines in MLSA 
to study the role of P-gp in contributing to acquired anthracycline resistance in 
intermediate and high grade lymphomas.
Dogs with MLSA were actively recruited into the study from referral cases 
and treated with a simple chemotherapy protocol which is detailed below. Epirubicin 
is a derivative of doxorubicin which is still part of the MDR drug spectrum (Mirski et 
al, 1987). Dogs were scheduled to receive this anthracycline until relapse was 
evident. Epirubicin is less cardiotoxic than doxorubicin (Young et al. 1989), hence 
decreasing the likelihood that the MLSA dogs would show dose-limiting cardiac side 
effects prior to relapse.
Table 1.14 Epirubicin chemotherapy protocol
MLSA Chemotherapy Protocol
Epirubicin 25mg/m^ intravenously, every three weeks 
until relapse.
Prednisolone 2mg/kg per os, daily for seven days 
1 mg/kg, daily for seven days 
1 mg/kg, every other day until relapse
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Lymph node samples were collected from these dogs at time of diagnosis and 
then at relapse for analysis of P-gp/mdrl expression. Samples from a smaller number 
of dogs which had received a standard multi-drug protocol prior to relapse were also 
obtained. P-gp expression in lymph node sections was assessed by 
immunohistochemistry using the non-isoform specific monoclonal antibody C219. A 
human mdrl probe was used to confirm the presence mdrl isoform in P-gp positive 
nodes using slot-blot analysis.
The lymphomas were genotyped; rearrangements in the T cell receptor (3 
chain were used to positively identify potential T cell tumours. Genotyping of the 
canine tumours was carried out using a feline TCR p chain constant region probe. 
The most appropriate restriction enzyme digests, with a low incidence of restriction 
fragment length polymorphisms, was determined from the digestion of a 
phenotypically immature canine T cell line and normal germline samples.
Clinical performance, tumour characteristics (ie P-gp status and TCR gene 
rearrangement) plus relevant host factors were statistically analysed by multivariate 
analysis to determine the important prognostic factors in the anthracycline treated 
dogs.
The main aim of this thesis was to use canine lymphomas as a means of 
determining the relevance of P-gp as a potential resistance mechanism to 
anthracyclines in a clinical setting. The most cited hypothesis on acquisition of drug 
resistance suggests that drug selection is a major factor influencing the nature of the 
resistance mechanisms in tumours. The chronic treatment with epirubicin would be 
expected to favour the acquisition of P-gp more than treatment with a multi-drug 
regime (i.e. COP) which contains a smaller MDR drug component. The frequency of 
P-gp expression in the epirubicin treated dogs would therefore be expected to 
approach the maximum likely in a lymphoma population. From the percentage of 
treated lymphomas which express P-gp following epirubicin administration it will be 
apparent whether P-gp modulation or MDR drug avoidance is worth pursuing as part 
of salvage treatment of resistant lymphomas.
The basis for the poor clinical performance of T cell tumours relative to B cell 
tumours is unknown. The combination of the genotyping and the P-gp expression 
information will help establish if this difference is due to a propensity for T cells to 
express P-gp.
The relative importance of P-gp as a prognostic factor in NHL is unclear; 
other factors may identify poor risk groups more effectively and easily. The statistical 
analysis of clinical performance taking into account both patient and tumour details
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should identify if P-gp is a critical prognostic indicator. Through statistical analysis, it 
may also be possible to identify groups which are "at risk" of expressing P-gp.
In summary, it is hoped to establish the role of P-gp in contributing to 
acquired drug resistance by building up a reasonably complete picture of P-gp in 
canine lymphomas, without excluding other biological factors, and without excluding 
the possibility that mechanisms other than simple drug selection may result in P-gp 
expression.
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2.1 MATERIALS
The following section lists routinely used materials. Less frequently used 
materials are described in the appropriate Methods' section.
2.1.1 CHEMICALS
All chemicals were of the highest available quality and were obtained from 
BDH Chemicals Ltd, Gibco BRL, Pharmacia LKB or Sigma Chemicals except the 
following;
2.1.2 RADIOCHEMICALS
(a^^P)dCTP, (y 32p)ATP plus (a32p)UTP for labelling probes were obtained 
from Amersham International pic.
2.1.3 EQUIPMENT
Routine equipment which would be an integral part o f any laboratory is not listed.
1. Dotblot manifold: BRL
2. Electroblotting System: Milliblot SDE, Millipore, Watford.
3. Gel Tanks: tanks for agarose & acrylamide gels were from IBI Ltd, Cambridge & 
Biorad Labs Ltd, Watford, Hertfordshire.
5. Hybridisation membranes: Genescreen, NEN, Boston. Hybond-N, Amersham 
International. Nitrocellulose 0.45um, Schleicher & Schuell via Anderman Lab 
Supplies, Kingston-upon-Thames.
6. Hybridisation Oven & Bottles: Hybaid Ltd, Middlesex.
7. Laser densitometer: autoradiographs were analysed at a SUN workstation using a 
Molecular Dynamic Densitometer and PDI Quantitation 1 software.
8. Microdismembranator: Braun, Germany
9. Plate reader: Biorad Labs Ltd, Watford.
Acrylamide 
Bacto Agar 
Doxorubicin 
Epirubicin 
Formamide
Methocell MC4000 
Phenol
RNAzol B 
Vinblastine
Severn Biotech, Kidderminster 
Difco, Detroit, USA 
Farmitalia Carlo Erba 
Farmitalia Carlo Erba 
Fluka, Buchs, Switzerland 
Fluka, Buchs, Switzerland 
Rathbum, Walkerbum, UK 
Biogenesis Ltd 
Eli Lilly, Basingstoke
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2.1.4 RESTRICTION ENDONUCLEASES & OTHER ENZYMES 
Restriction Enzymes
The majority of restriction endonucleases (RE) were from Pharmacia Ltd, 
Boeringer Mannheim Corporation or Northumbria Biologicals. Bulk ordering of 
RE's by the Department meant that the same "brand" of RE could not be used 
throughout this work.
Other Enzymes
DNAse 1 (RNAse free)
RNAse A 
RNAse Ti 
RNAse Inhibitor 
T4 Polynucleotide kinase 
Proteinase K
2.1.5 SIZE MARKERS
DNA size markers;
(i) Hind III digested phage X, BRL
(ii) Eco Rl/BamHl digested Adenovirus, IBI Ltd.
RNA size markers; 0.24 - 9.5kb RNA ladder, BRL 
Protein size markers; Prestained standards, 14,300-200,000, BRL.
2.1.6 BUFFERS, SOLUTIONS & MEDIA
Where mentioned, autoclaving was carried out at 121°Cfor 20 minutes.
General Buffers & Solutions
Denhardts (xlOO)
2% Ficoll
2% polvinylpyrrolidone 
2% bovine serum albumin.
Aliquoted & frozen at -20^C.
MOPS (x 10)
200mM MOPS (3-[N-morpholino}propanesulphonic acid) 
lOmM EDTA 
50mM Na Acetate
Made to pH 7.0 with glacial acetic acid then autoclaved.
RBC Lvsis Buffer 
8.3g Ammonium chloride 
O.037g EDTA
lg Potassium carbonate. Make up to 1 litre with distilled water.
Pharmacia LKB 
Pharmacia LKB 
Boerhinger Mannheim 
Pharmacia LKB 
Northumbria Biologicals 
Boerhinger Mannheim
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RNA Lvsis buffer 
0.3M Na acetate 
0.5% SDS
5mM EDTA. Made to ph8 with 10M NaOH then autoclaved.
IAE(lx) pH8 
40mM Tris base 
2mM EDTA 
20mM NaCl 
20mM NaAc
IBE(lx) pH8 
89mM Tris borate 
89mM Boric acid 
2.5mM EDTA
TBS(1 Ox') pH7.6
116.9 NaCl 
24.2g Tris base
6.7g EDTA. Make up to 2 litres at pH7.6.
Loading Buffers
Dve loading buffer 
125mM Tris HCL (autoclaved)
20% w/v Glycerol 
5mM EDTA (autoclaved 
0.25% w/v Bromophenol blue 
0.25% w/v Xylene cyanol
Northern Loading Buffer 
lx MOPS buffer 
50% v/v formamide 
2.2M formaldehyde 
0.5ug/ml ethidium bromide
Acrylamide Gel Loading Buffer (RNAse Protection Assays)
80% Formamide 
lxT B E  
ImM EDTA 
0.1% Xylenecyanol 
0.1% Bromophenol blue
Western Loading Buffer^ ' )
60g Urea
20mls "Solubilisation " buffer. See below 
33.7mls distilled water.
This urea buffer is then aliquoted & stored at -70^C.
Solubilisation buffer 
25 g Sucrose 
0.3g Tris base 
1.54g Dithiothreitol
0.005M EDTA Make to Ph8 with HC1 and final volume
5g SDS of 50mls with distilled water.
2.5mg Pyronin Y
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Transfer solutions
Phosphate buffer ,lGenescreen,Y20x>) used to transfer both RNA & DNA.
Electroblotting solution used to transfer proteins.
48mM Tris base 
39mM Glycine 
0.037% (vol/vol) SDS 
20% methanol
Hybridisation solutions & Wash solutions
Formamide hybridisation mix (makes lOOmls)
50mls formamide 
25mls SSC(x20) 
lOmls "Genescreen"(x20)
5mls Denhardts(xlOO)
10% SDS
8mls distilled water
lml salmon sperm DNA (boiled 5 mins then cooled on ice)
Non-Formamide hybridisation mix
50mM Pipes
lOOmM Nacl
50mM Na2P04
50mM Nah2P04
ImM EDTA
5% SDS
Hybridisation Mix for PolvdfD 
2.5mls Denhardts (xlOO) 
lml "Genescreen" (X20)
12.5mls SSC(x20)
34mls distilled water
Standard Saline CitratefSSCD (20x)
700g NaCl
353g tri-Sodium citrate. Make to 4 litres with distilled water.
Tissue culture media 
RPMI
88 mis RPMI-1640 from Gibco BRL 
800mls sterile distilled water 
26.6mls Na carbonate 
lOmls Na pyruvate 
lOmls L-glutamine 
lml lMNaOh
Dulbecco's Modified Eagles media fDMEM^
50mls Dulbecco's MEM (1 OX) from Gibco BRL
400mls sterile distilled water
5mls Na pyruvate
5mls Glutamine
25mls Na bicarbonate
.54
2.1.7 CELL LINES
3132
This cell line was derived from the ascitic fluid of an adult male Belgian Shepherd 
dog with multicentric lymphoma (Strandstrom & Rimaila-Pamanen, 1979). This cell 
line has been reported to produce a retrovirus (Strandstrom, personal communication 
reported in Squires, 1990) but subsequent attempts to induce retroviral expression 
have been unsuccessful (Squires, 1990). 3132 expresses surface immunoglobulin 
(slg) and Fc receptors (Holmes, 1989). This cell line was maintained in RPMI 1640 
plus 20% foetal calf serum and grows in suspension forming small spheroids of about 
10 cells. Every 3-5 days, 80% of the media was removed and replaced with fresh 
media.
CL-1
This cell line was obtained from Dr.Hajime Tsujimoto, Department of Veterinary 
Internal Medicine, University of Tokyo. It was established from a spontaneous case 
of thymic lymphosarcoma in a dog. FACS analysis of CL-1 carried out by Dr. Ryo 
Goitsuka, also of Tokyo University, suggested that Cl-1 is immunophenotypically an 
immature T cell reacting with the monoclonals DT-2 (Wulff et al, 1982) and E ll  
(Szer et al 1985). This information was made available from Dr.Tsujimoto by 
personal communication. Cl-1 grows as a single cell suspension in RPMI 1640 plus 
20% foetal calf serum. Every 3-5 days 80% of the media was removed and replaced 
by fresh media.
KB3-1, KB-ChR-8-5, KBV-1
This series of cell lines was derived from human KB epidermoid carcinoma cells. 
The lines were obtained from the European Collection of Animal Cell cultures, 
Porton Down, Salisbury. KB3-1, the parent cell line for the drug resistant mutants, 
was derived from a single clone of human epidermoid carcinoma cells after two 
subclonings. The drug resistant mutants, KB-CH^-8-5 (also known as KB8-5) and 
KBV-1 were obtained after chronic selection in colchicine and vinblastine 
respectively (Akiyama et al, 1985; Shen et al, 1986c). All three cell lines grow as 
monolayer cultures in DMEM and are split using 0.125% Trypsin. KB8-5 is 
maintained in lOng/ml of colchicine and is 3-6 fold more resistant to colchicine than 
the parent. KBV-1 is grown in DMEM plus lug/ml of vinblastine.
AuxBl & CHr C5
AuxBl is a drug sensitive Chinese hamster ovary cell line from which the drug 
resistant line CHrC5 was derived (Ling & Thompson, 1974; Bech-Hansen et al, 
1976). CHrC5 was obtained following chronic selection in colchicine and is 
approximately 150 fold resistant to colchicine: it is grown in DMEM plus lOug/ml
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colchicine. CHr C5 overexpresses Pgpl in comparison to the parental line and is used 
as a positive control in the western blots.
3201
This cell line is derived from a specific pathogen free kitten which developed an 
intrathoracic tumour following inoculation with the FeLV negative thymic tumour 
cell line. 3201 has a paucity of lynmphocyte surface markers but does rosette guinea- 
pig erythrocytes (Rojko et al 1989). It has P chain rearrangements (J Neil, personal 
communication) and is used as a positive control for p chain expression on northern 
blots. RNA from this cell line was kindly donated by J Neil, Glasgow University.
2.1.8 MONOCLONAL ANTIBODIES & IMMUNOLOGICAL REAGENTS 
Monoclonal Antibodies
C219 This IgG2a monoclonal antibody was produced following immunization of 
mice with drug-resistant hamster & human cell lines (Kartner et al, 1985) and detects 
all known isoforms of P-gp in all the species studied so far. It has been epitope 
mapped to a hexapeptide sequence (VVQEAL) in a conserved, cytoplasmic portion 
of P-gp (Georges et al, 1990). Synthetic peptides containing this hexapeptide 
sequence have been used to block specific C219 binding (Georges et al ,1990). It is 
obtained from CIS UK Ltd, High Wycombe.
MAC 387 This IgGl monoclonal was raised against purified human blood monocyte 
components. It reacts with a cytoplasmic antigen in many cells of the 
monocyte/macrophage series including infiltrating & reactive histiocytes, tumour 
infiltrating macrophages and sinus histiocytes (Flavell et al 1987). However other 
macrophage populations are not labelled including germinal centre macrophages. It 
can also react with human granulocytes. MAC 387 is obtained from Dako Ltd, High 
Wycombe.
MRK 16 is an IgG2a monoclonal that was raised against the human leukaemia cell 
line K562/ADM. It reacts with an external epitope on the human mdrl encoded P-gp. 
This monoclonal does not react with the human mdr3 gene product nor with rodent 
isoforms. MRK-16 was obtained from Dr. Tsuruo, Cancer Chemotherapy Center, 
Toshima-ku, Tokyo.
S-100 This is a rabbit polyclonal sera raised against ox brain. It was obtained from 
Dako and they claim it recognizes both a  and P chains of S-100.
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Immunological Reagents
10 amino acid peptide (spanning C219 epitope)
V-V-Q-E-A-L-D-K-A-R was obtained from Peptide & Protein Research, University 
of Reading. The peptide was purified to "immunological grade purity" of over 80%.
15 amino acid peptide (spanning C219 epitope)
V-V-Q-E-A-L-D-K-A-R-E-G-R-T-C was obtained from Biomac, Department of 
Biochemistry, Glasgow University. This was screening grade (70%-95% pure) 
quality.
Clonab LNC was described by the manufacturers as "a murine antibody against an 
unrelated antigen and is provided as a control to assess the degree of non-specific 
binding of the primary antibodies of the Clonab product range. Clonab LNC is a 
mouse immunoglobulin of class IgG" (Biotest Product Information sheets, 1991). It 
was used as a negative control primary antibody in the early work with C219. Curious 
results were obtained with this product and subsequent requests for further 
information on this product revealed that this was actually a 5ug/ml IgA solution, and 
not an IgG product as initially published (Anita Baker, Biotest UK, personal 
communication). Clonab LNC was obtained from Biotest UK , Solihull, West 
Midlands.
Rabbit anti-mouse Ig Alkaline Phosphatase conjugate
This was obtained from Dako Ltd and was used at a 1 in 50 dilution in routine 
immunohistochemistry.
Sheep anti-mouse Ig Horseradish peroxidase conjugate
This was obtained from Amersham International and was used at a 1 in 5000 dilution 
in Western immunoblots.
Vectastain ABC Elite Kit
This kit contains all the reagents necessary for a peroxidase, avidin/biotin based 
detection system for murine primary monoclonals. Details of its use are given in later 
sections. It was purchased from Vector Laboratories, Peterborough, UK.
Vector Blocking Kit
This kit contains reagents which are used to block nonspecific binding of the 
Biotin/Avidin components of the Vector ABC kit. It was purchased from Vector 
Laboratories, Peterborough, UK.
Normal sera
Normal dog, rabbit & mouse serum was obtained from Sigma chemicals.
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2.1.9 MOLECULAR PROBES 
MDR5A
The MDR5 A clone represents a portion from the middle third of human mdrl 
(Ueda et al, 1987a). The 1383bp produced by EcoRl digestion of the pHDR5A 
cDNA clone (corresponding to positions 1178 -2561 of the full length cDNA) was 
subcloned into pGEM4 (Promega, Biotech). This plasmid was kindly supplied by Dr. 
M Gottesman, National Cancer Institute, Bethesda. The pGEM4 plasmid permits 
production of riboprobes from SP6 or T7 RNA polymerase transcription start sites. 
Riboprobes for use in RNAase protection assays were produced following 
linearisation of the MDR5A construct with Xmn 1 (figure 4.1). Detailed sequence 
maps of this probe are provided in chapter 4. Riboprobes for Southern blots were 
linearised with BamHL All dot-blots and Northern blots were hybridised with full 
length MDR5A which had been released from pGEM4 with EcoRl digestion and 
then gel purified prior to random prime labelling of the DNA.
pEXl/172
This 172 base pair probe encodes the last exon of the hamster Pgp2 gene (Ng et al, 
1989). This exon was described as exon 1 in this original paper but it is the equivalent 
of exon 27 or 28 (depending on species) in later publications. This short sequence 
does not contain any recognition sites for any of the common 6bp restriction 
enzymes. This exon has a high homology to other mdr genes; 98% to Pgpl and Pgp2, 
94% and 95% to murine mdrla. and mdrlb, 92% and 91% to human mdr 1 and mdr3. 
Ng et al (1989) have used this conserved sequence to identify mdr gene family 
members in the hamster.
7S
This probe is a clone of the murine abundant cytoplasmic 7S ribosomal RNA 
(Balmain et al, 1982) which is highly conserved across species. It hybridizes to a 
0.3kb band in the mouse, human and dog. The 7S probe is used to normalize for 
loading on Northern transfers.
POLYd(T)
Polyd(T) hybridizes with polyadenylated RNA and therefore provides an 
estimate of total mRNA loading. It is used on dot-blot hybridisations to assess RNA 
loading. It was obtained from Pharmacia LKB.
ACTIN (y)
A Bam -Hind III fragment of a clone of human y  actin (Gunning et al, 1983) 
was previously subcloned into psP64. This clone is linearised with Hinf 1 to generate 
a template for transcription with SP6 Polymerase. Human y  actin protects an 145 base 
pair fragment of this probe (Enoch et al, 1986).
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FELINE TCR |3 CHAIN REGION PROBE
This clone represents V, D, J & C sequences of the feline TCR P chain which 
had become transduced by Feline Leukaemia virus (FeLV). This viral-rcr was 
isolated from field case of thymic lymphosarcoma in a young adult cat, code name 
T17 (Fulton etal, 1987). The clone was obtained by screening a T17 genomic library 
using the human constant region probe pB400 (Collins et al, 1985). The intronless 
FeLV transduced p chain has been partially sequenced within the constant region and 
is identical to the normal feline constant region within the sequenced portion (Neil et 
al, 1988). The transduced P chain was subcloned into pUC18; digestion of this 
construct with Bgl II releases a 390bp fragment which encompasses part of the 
constant region (from nucleotide 584 to 974 in the map provided in Fulton et al. 
1987). The position of this fragment relative to the four constant region exons is 
illustrated in figure 6.1. The 5' Bgl II site is 58bp downstream of the start of exon 1. 
The 390bp fragment therefore spans the majority of the large first exon, all of the 2nd 
exon and part of the third exon. The 3' part of the 3rd exon, which encodes the 
transmembrane segment of the polypeptide, is not included in the Bgl II fragment.
The purified Bgl II fragment of the feline p chain was used in the majority of 
the Southerns in this study. Occasionally, the unpurified construct containing V-D-J 
sequences was used. Where this is the case it is mentioned in the text.
2.1.10 CANINE TISSUE SAMPLES
Samples of normal canine tissue were obtained from freshly euthanased dogs 
at the local Dog Home. Samples were snap frozen in liquid nitrogen and stored at - 
70°C until use. Lymphomatous nodes were primarily collected from canine patients 
presented to the Department of Veterinary Surgery at Glasgow University. Excisional 
lymph node biopsies were carried out for diagnostic purposes; part of these biopsies 
were snap-frozen for future use. Dogs which were treated for lymphoma but 
subsequently relapsed were euthanased & the appropriate samples collected 
immediately after death. Samples were collected from dogs which died either at home 
or at the referring veterinary surgery as soon as was logistically possible but 
sometimes a delay of up to 12 hours had occurred. Some samples came direct from 
referring veterinarians or from cadavers brought in for necropsy. Limited clinical 
information is available on these cases.
2.2 EXTRACTION OF NUCLEIC ACIDS & PROTEINS
All work with RNA & DNA was carried out using autoclaved solutions & 
where appropriate DEPC treated solutions & equipment. Disposable gloves & 
plasticware were used throughout. DNA & RNA quantitation was performed using a 
combination of visual assessment on an agarose gel when run against known 
standards and spectrophotometrically using O D .260
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2.2.1 MICRODISMEMBRANATING TISSUE SAMPLES
Tissue samples used for nucleic acid or protein extraction were first powdered 
using the microdismembranator. The samples and the dismembranator chamber were 
kept frozen using liquid nitrogen during the procedure.
2.2.2 RNA EXTRACTION
RNA was extracted from powdered tissues & cells using RNAzol B. 
Monolayer cultures were lysed in the flasks with RNAzol. Suspension cultures were 
spun down & pelleted before extraction. The extraction procedure followed the 
manufacturers instructions. RNA for use in RNAse protection assays was 
reprecipitated following ethanol precipitation using 0.2M NaCl plus isopropanol. All 
of the normal tissues & cell line RNA was prepared using RNAzol B. However some 
of the earliest lymphoma samples underwent simultaneous DNA & RNA extraction 
detailed in 2.2.3, the section below.
2.2.3 DNA EXTRACTION
Powdered tissues & cell lines were prepared as above then lysed with 0.3M 
Na Acetate equilibrated phenol pH7.6. Blood samples (usually about 8mls) were 
prepared for DNA extraction by first lysing red blood cells using a five fold excess of 
RBC Lysis Buffer. After mixing for 10 minutes, the intact WBC were pelleted by 
centrifugation (1500g, lOmins). Approximately 0.5-lg of tissue was extracted with 15 
mis of phenol; about lOmls of phenol was used per 175cm^ tissue culture flask or for 
blood samples. An equal volume of lysis buffer and chloroform isoamyl alcohol was 
added & the samples mixed for 20 minutes. The samples were then spun at 3000g for 
20 minutes at room temperature. The upper aqueous phase was collected & 
precipitated with an equal volume of isopropanol at 4^C for at least one hour. The 
DNA was spun down at 3000g 20 minutes at 4^C, airdried then resuspended in sterile 
water. This procedure simultaneously extracts DNA & RNA.
When RNA was the prime requirement, the procedure was essentially as 
above except the phenol was equilibrated with 0.3M Na Acetate at pH7.0 rather than 
pH7.6, the initial spin was carried out at 4^C and the first ethanol precipitation was at 
-20^C. These samples were then resuspended in TNM (0.14M NaCl, 0.01M Tris 
pH7.4,1.5mM MgC^) to facilitate the use of RNAse free DNAse 1 at a future date.
2.2.4 PROTEIN EXTRACTION FROM TISSUES & CELL LINES
Tissues were powdered as described in 2.2.1 & the powder transferred into a 
15ml Falcon tube. 2mls of protein lysis buffer was added, mixed thoroughly and put 
on ice for 15 minutes. The samples were then spun at 3,500g for 10 minutes to pellet 
debris. The supernatant was collected & protein estimation was carried out using the 
Biorad Kit method.
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Protein Ivsis buffer.
O.IMTris pH8 
10% glycerol 
0.5% Nonidet P40 
lug/ml pepstatin 
lug/ml aprotinin 
lug/ml chymostatin
2.3 PREPARATION OF 32P RADIOLABELLED PROBES
With the exception o f end labelled polyd(T), all other probes were separated 
from unincorporated & P-labelled nucleotides using disposable Sephadex containing 
"NICK" columns from Pharmacia. An aliquot was removed to measure incorporation 
in a scintillation counter.
2.3.1 EXTRACTION OF DNA FROM LOW MELTING POINT GELS
Plasmid DNA fragments for use as probes were prepared by digestion with 
the appropriate restriction enzyme followed by separation in a 1% Low Melting Point 
agarose gel made with lxTBE containing 0.5ug/ml ethidium bromide. The DNA 
fragments were visualized on a UV transilluminator & the bands of interest were 
excised from the gel and placed in an clean tube. The gel slice was melted at 65^C 
and approximately 3 volumes of TBE added. The DNA solution was maintained at 
37^C where an equal volume of equilibrated phenol was added & mixed thoroughly. 
The upper aqueous phase was removed following centrifugation at 13,000g for 5 
minutes. The samples were then reextracted with phenol and chloroform before 
precipitation with 2 volumes of ethanol plus 0.1 volume of 3M Na acetate at -20^C 
for at least one hour. The DNA was recovered by centrifugation at 13,000g, 15 
minutes, washed, dried and finally resuspended in TE.
2.3.2 RIBOPROBE PRODUCTION
Radiolabelled single-stranded RNA probes (riboprobes) were prepared using 
the SP6/T7 Transcription Kit from Boehringer Mannheim. Riboprobes of the mdr5a 
plasmid for filter hybridisation used lug of template DNA which was linearised with 
BamHl and labelled according to the kit instructions for 90 minutes. Riboprobes for 
the RNAse Protection Assays used lug of Xmn I linearised mdr5a template DNA 
which was labelled for 30 minutes. In both cases, the DNA template was removed by 
DNAse 1. Riboprobes for the RNAse Protection Assays were phenol & chloroform 
extracted prior to use.
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2.3.3. RANDOM PRIMING OF dsDNA
32P labelled dsDNA probes were produced with the aid of the "Prime-it" 
random primer kit from Stratagene. Between 25ng and lOOng of template DNA was 
used & the protocol followed Stratagene's recommendations.
2.3.4 POLYMERASE CHAIN REACTION LABELLED PROBE
The probe pEX/172 (Ng et al, 1989) was obtained from Dr. Ling of the 
Ontario Cancer Institute, Toronto. The pEX/172 DNA template was provided, at an 
unknown concentration, in conjunction with per templates of an unidentified length. 
Labelling was performed exactly as detailed by Dr. Ling.
Labelling instructions:
5ul Template
2.5ul primer "A" (lOOng/ml)
2.5ul primer "B" (lOOng/ml)
5ul dATP, dGTP, dTTP mix. (2.5nM each)
5ul cold dCTP, 5uM 
5ul 32P-dCTP 
20ul distilled water 
5ul 10 x PCR buffer*
0.5ul Taq 1 Polymerase*
(* supplied from Northumbria Biologicals)
The mixture was covered with 2 drops of sterilised mineral oil. 25 per cycles were as 
follows;
Denature 94^C, 30secs 
Anneal 48^C, 30secs 
Extend 72°C, 1 min
2.3.5 LABELLING POLYD(T)
Polyd(T)2o (Pharmacia) was labelled using T4 Polynucleotide Kinase (PNK) at 37®C 
for 45 minutes as follows;
15ul polyd(T)20 lug/ul
2.5ul "One-Phor-All" buffer (Pharmacia)
2u ly32P-ATP 
4.5ul water 
lul T4 PNK
The reaction was terminated by 20ul of 0.5M EDTA; the resultant labelled 
oligonucleotide was used without further purification.
62
2.4 SEPARATION & HYBRIDISATION OF NUCLEIC ACIDS
2.4.1 DIGESTION, SEPARATION & SOUTHERN TRANSFER OF DNA
Separation and transfer of DNA was essentially as described by Southern 
(1975). 20ug of genomic DNA was digested for at least 16 hours in a total volume of 
150ul using 15ul of the required restriction enzyme. The digested DNA was then 
precipitated with 0.1 volume of 3M Na Acetate and an equal volume of isopropanol 
at -20°C for 1 hour. The DNA was pelleted by centrifugation at 13,000g for 15 mins 
followed by air-drying and resuspension in 25ul of sterile water. Resuspension 
continued overnight at 37°C and then transferred to 4°C until use (usually within one 
week). 5ul of Dye Loading Buffer was added to the DNA and then run on a 0.6%- 
1.0% TAE gel. Gels were run overnight at about 40mA using a buffer recirculation 
system. The next morning, gels were stained with Ethidium bromide for 20 minutes 
to allow polaroid photography on a transilluminator. DNA was denatured for 20 
minutes in 1.5M NaCl/0.5M NaOH followed by neutralization in 3M NaCl/0.5M 
Tris-HCl pH7.0 for 30 minutes. The gel was then rinsed in Genescreen buffer & 
transferred onto either Genescreen or Hybond N membranes overnight using 
Genescreen buffer. The membranes were rinsed in Genescreen prior to baking at 
80°C for 2 hours to fix the DNA on the membrane. Occasionally filters were UV 
fixed onto Hybond membranes.
2.4.2 SEPARATION & NORTHERN TRANSFER OF RNA
Methodology for separation and transfer of RNA followed instructions in 
Maniatis et al, (1982). 1% (w/v) agarose gels were prepared by dissolving 3g of 
agarose in 216mls of water then cooling to 60^C. 54mls of 37% formaldehyde plus 
30mls of MOPS(lOx) was then added, mixed and immediately poured. 20ug of total 
RNA was freeze-dried to give a volume less than 5ul then redissolved in 15ul of RNA 
loading buffer plus 2ul of Dye Loading buffer. The samples were heated to 65°C for 
10 minutes then chilled on ice before loading on the gel. Gels were electrophoresed 
for 6-16 hours at 30-60mA. The gels were photographed then soaked in 50mM 
NaOH/lOmM NaCl for 30 minutes prior to transfer onto Hybond N using Genescreen 
as the transfer buffer. Membranes were rinsed & baked as previously described.
2.4.3 RNASE PROTECTION ASSAY
Riboprobe production from Xmn I  linearised MDR5A is detailed in section 
2.3.2. The method is adapted from Melton et al, (1984).
Hybridisation: 20ug of total RNA plus 500,000cpm of riboprobe were dried in a 
speedi-vac & then dissolved in 20ul of hybridisation solution;
80% Formamide
400mM NaCl Hybridisation
40mM Pipes pH6.4 buffer
ImM EDTA
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The samples were incubated at 85°C, then the water bath thermostat was turned down 
to 45°C and held at 45°C for 3 hours. The water bath was then allowed to cool to 
room temperature overnight.
Digestion: Digestion was carried out at 30°C for 30 minutes in 300ul digestion 
buffer;
lOmMTris pH7.6
5mM EDTA Digestion
0.3M Na acetate buffer
2ug/ml RNAse A 
30U/ml RNAse Tj
Following digestion, the samples were incubated with 2.5ul Proteinase K (lOmg/ml) 
plus 3.2ul SDS (20%) at 37°C for 15 minutes. The samples were phenol/chloroform 
extracted, precipitated with ethanol in the presence of lul of glycogen (Pharmacia) 
and dried in the speedi-vac.
Acrvlamide gel electrophoresis:
The products of the above hybridisation/digestion were run on an 8M urea denaturing 
acrylamide gel prepared as follows;
37g Urea
15.98mls Acrylamide (30% acrylamide/0.8% bis acrylamide)
8mls TBE(lOx)
Make up to 80mls once urea is dissolved.
Degas, add 30ul TEMED (Biorad) & 300ul Ammonium persulphate 
Dried samples were resuspended in 4ul of RNAse loading buffer, heated to 95°C for 
5 minutes, chilled on ice and then electrophoresed at 30mA until the gel had run the 
desired distance. The gel was peeled off the plates onto blotting paper, wrapped in 
clingfilm and exposed to radiographic film. Occasionally, gels were dried under 
vacuum prior to autoradiography.
2.4.4 DOTBLOTTING OF RNA
20ug of RNA in TNM buffer (total volume of 150ul) was pipetted along the 
1st and 51*1 rows of a 96 well plate. The RNA was DNAsed for 30 minutes to remove 
any trace DNA in the samples. One third titrations of the samples was then performed 
in the microtitre plates; the final volume of each well was lOOul. The contents of each 
well was then transferred onto Hybond N using a dotblot manifold.
2.4.4 HYBRIDISATION IN FORMAMIDE SOLUTIONS
Hybridisations in formamide were performed in a shaking water bath for a minimum 
of 16 hours.
Northern blots were initially hybridised in formamide hybridisation mix (see 
section 2.1.5) at 56®C but this method was found to be less sensitive than non-
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formamide hybridisation at 65°C and hence was abandoned in favour of the latter 
methodology for the Northerns shown in this thesis and all dot-blot hybridisations.
Southern blots were routinely hybridised in non-formamide solutions. 
However one Southern blot using the MDR5A probe was hybridised at 42°C in 
formamide hybridisation solution. This Southern is indicated in the text.
2.4.6 HYBRIDISATION IN NON-FORMAMIDE SOLUTIONS
Hybridisations in non-formamide solution (recipe in section 2.1.6) were 
carried out at 65°C (for a minimum of 16hours) using a Hybaid oven and Hybaid 
roller bottle system.
2.4.7 DOT-BLOT HYBRIDISATIONS
Dot-blot hybridisations with the MDR5A probe were carried out in non- 
formamide hybridization solutions as detailed in 2.4.6. Hybridisation with polyd(T) 
was carried out in polyd(T) hybridisation solution for 1 hour at room temperature.
2.4.8 WASHING FILTERS
Following formamide hybridisations, filters were initially washed in 1 x SSC plus 1% 
SDS (60 minutes) followed by a 65°C wash with 0.1 x SSC, 1% SDS for 30 minutes.
Following non-formamide hybridisation, membranes were washed at 65°C using 1 x 
SSC plus 5% SDS for at least 90 minutes with a minimum of 5 changes of wash 
buffer.
Following room temperature polyd(T) hybridisation, dot-blots were washed at room 
temperature in 1 x SSC/5%SDS for 1 hour with 4 changes of wash buffer.
2.4.9 STRIPPING FILTERS
Stripping filters, especially northern blots, was avoided where possible. When 
necessary, blots were stripped by agitating briefly in 1% boiling SDS and allowing to 
cool in the SDS solution.
2.4.10 AUTORADIOGRAPHY
Following washing, filters were blotted dry, wrapped in clingfilm and exposed 
to Kodak AR film in a film cassette with fast tungstate intensifying screens. Loaded 
film cassettes were held at -70°C until developed. Southern blot hybridisations 
required up to 3 weeks exposure time whereas RNA hybridisations with mdr5a 
probes required 2-7 days. 7S and polyd(T) probes gave adequate exposures within 
hours.
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2.5 SEPARATION & IMMUNODETECTION OF PROTEINS
2.5.1 SAMPLE PREPARATION
Protein extracts were prepared & quantified as detailed elsewhere. 150ug of 
total protein in 50ul was mixed with an equal volume of 2 x Protein loading buffer 
and loaded without boiling.
2.5.2 GEL & RUNNING CONDITIONS
Denaturing protein gels were cast & run in the Protean gel tank system 
(Biorad). Gels were prepared as follows;
54g Urea
18.6mls Acrylamide(30% Acrylamide with 0.8% bis acrylamide) 
lOmls Electrophoresis buffer 
5mls SDS(20%)
23.7mls water.
The mixture was degassed & then set with 1ml of 15% ammonium persulphate plus 
25ul Temed (Biorad).
Gels were run overnight at 25mA in electrophoresis buffer containing 1%
SDS.
2.5.3 ELECTROBLOTTING
Electroblotting was performed using a millipore semi-dry electroblotter. The 
membrane was wetted in Electroblot Transfer Buffer, 6 sheets of 3M Whatmans filter 
paper was sandwiched next to the anode & cathode with the membrane & gel layered 
in between. Transfer took place over 1 hour at 200mA. The membrane & gel were 
then stained in Poinceau's stain for 5 minutes and destained in 5% acetic acid. This 
allowed a visual assessment to be made of the evenness of the transfer and the 
integrity of the proteins.
2.5.4 IMMUNODETECTION OF PROTEINS ON WESTERN BLOTS 
Biotin/iodinated streptavidin method
Blocking 3% BSA in TBS with 0.05% Tween 20 was used as a blocking solution. 
Membranes were blocked for at least 1 hour at room temperature with 3 changes of 
block solution in the first 30 minutes to remove any acetic acid residues.
Primary antibody (C219) was used at lug/ml in a 3%BSA/TBS/0.05% Tween 
solution. The membrane was sealed in a plastic bag and incubated overnight at 4^C 
on a shaker. The membrane was washed in TBS for 15 minutes with 3 changes of 
wash. Anti-mouse IgG Biotin conjugate (Sigma) was applied at a 1 in 20,000 dilution 
in block solution for 1 hour. A second TBS wash of 30 minutes with 3 changes of 
wash preceded the final readout system. The membrane was incubated for 30 minutes 
at room temperature with 50uCi of ^^1 Streptavidin (Amersham International) in
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50mls of block. The filter was then washed extensively for three hours with numerous 
changes of buffer before autoradiography.
Chemiluminescence method
Blocking, and all antibody dilutions, were in 10% Marvel, TBS/0.05% tween 20. 
Washes were in TBS/0.05% tween. All procedures were carried out at room 
temperature. Block was applied for 1 hour prior to C219 (lOug/ml) for 2 hours. The 
first wash in TBS was for 15 minutes with 3 changes of buffer. The second antibody, 
anti-mouse IgG Horseradish peroxidase conjugate (Sigma), was diluted 1 in 5000 and 
applied for 15 minutes. The second wash for 30 minutes had a further 3 buffer 
changes. The membrane was then incubated with a chemiluminescense substrate 
(ECL kit from Amersham) as per manufacturers instructions & exposed to 
radiographic film.
2.6 IMMUNOHISTOCHEMISTRY
2.6.1 PREPARATION OF SLIDES & SECTIONS
Slides were pre-coated with Vectabond (Vector Labs). Frozen tissue sections 
were cut at 5uM by Mr. Ian McMillan of the Veterinary Pathology Department & Mr. 
Angelo Kyriakides of the Veterinary Surgery department. Cytospins of 3132 & Cl-1 
cells were prepared using approximately 200,000 cells per slide. The KB cells were 
grown on coverslips and then the coverslips were stuck onto slides using DPX 
mountant. Fixation was in acetone at room temperature for 10 minutes.
2.6.2 ALKALINE PHOSPHATASE CONJUGATE STAINING
All lymph nodes, cell lines and the majority of canine normal tissues were stained 
using this methodology, which was adapted from Wishart et al, 1990. The evolution 
of this particular protocol is discussed in the relevant results section. The procedure 
was carried out at room temperature as follows;
Wash: TBS/0.05% tween
Block: 1.5% rabbit serum, 1.5% dog serum in TBS/0.05% tween, 20 mins.
Primary Antibody: C219 5ug/ml in block solution.
Wash: 2 x 2mins in TBS/tween
Second Antibody: Rabbit anti-mouse Ig Alkaline Phosphatase conjugate (Dako), 1 in
20 dilution in block solution
Wash: 2 x 2mins in TBS/tween
Fast Red substrate: (see below) 20 mins
Wash: 2 x 2mins in water
Counterstain: Haematoxylin.
Sections were then mounted in Glycergel (Dako)
67
Substrate Solution
A batch of substrate (without Fast red salt) was prepared in advance and then 
aliquoted & frozen. First Veronal Acetate buffer was made;
0.97g Na acetate(trihydrate)
1.47g Na barbitone 
2.5mls 0.1MHC1
247.5mls water. Final pH is 9.2 
To make 20 x 5ml aliquots;
50mg Napthal AS Bj was dissolved in 20 drops of dimethyl formamide. Add lOOmls 
of Veronal Acetate buffer plus lOOul of 1M levamisole.
The 5ml aliquots were defrosted as needed and 2.5mg of Fast Red TR salt added 
within 10 minutes of use. The substrate solution is filtered through a 45um disposable 
filter (Gelman) before use.
2.6.3 ABC PEROXIDASE STAINING
This methodolgy was used for tissues such as the gastrointestinal tract plus 
central nervous system which gave unacceptable background with alkaline 
phosphatase staining. This was carried out at room temperature using the Vectastain 
elite ABC kit. The procedure was as outlined in the manufacturers instructions with 
some modifications. Prior to application of primary antibody, non-specific 
avidin/biotin binding was blocked using the Blocking Kit provided by Vector Labs. 
After the biotinylated second antibody was washed off, endogenous peroxidase 
activity was quenched using 0.3% peroxide in methanol for 30 mins. This was 
washed off before proceeding with the rest of the protocol. The final substrate was 
diamminbenzidine tetrahydrochloride (DAB).
2.6.4 AUROPROBE STAINING
This system is based on the reaction between a biotinylated secondary antibody and 
streptavidin coated gold spheres. The protocol was identical to the Alkaline 
phospatase method until the secondary antibody:-
Second antibody: Goat anti-mouse Ig biotinylated antibody (Sigma) at 1 in 10,000 
dilution in block solution.
Wash: 2 x 5  mins TBS
Streptavidin-Gold: 1 in 50 dilution in TBS, 2 hours.
Wash: 2 x 5  mins TBS then 2 mins in water.
Silver Enhance: 15 mins
Rinse in water then counterstain with safffenin.
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2.7 DRUG SENSITIVITY ASSAYS
2.7.1 TETRAZOLIUM BASED ASSAY (MTT)
This assay is based on the principle that live cells (but not dead cells) can 
reduce the tetrazolium dye, MTT, to a coloured product that can be read in an ELISA 
plate reader and follows the protocol suggested by Plumb et al, (1989).
Cells were plated at 500 per well in RPMI onto triplicate 96 well plates 
(leaving the first row blank as a control) and left to acclimatize overnight in the 
incubator. Cytotoxic drug was then added at different concentrations per row and left 
for 24 hours. Drug was then removed and replaced by fresh media. (3132 and CL-1 
grow in suspension so before any media changes, the 96 well plates were spun at 
lOOOg for 10 minutes to pellet the cells.) The cells were left for 3 days (which is 
approximately 2 doubling times for these cell lines) before replacing the media with 
fresh RPMI containing lOmM Hepes buffer . MTT was then added at a concentration 
that was predetermined to give maximal absorbence without cellular toxicity in this 
system. Plates were wrapped in foil & incubated for a further 4 hours. The media was 
then carefully removed & the insoluble formazan crystals dissolved in DMSO plus 
Sorenson's buffer (0.1M glycine, 0.1M NaCl pH10.5). Plates were then read in an 
ELISA plate reader at 570nm.
2.7.2 SOFT AGAR CLONOGENIC ASSAY
Cells were plated at 500 cells per 6cm plate in 3% Bacto agar/RPMI 20% 
foetal calf serum. Prior to plating, 3132 cells were gently pipetted up & down to 
disaggregate cell clumps. Cytotoxic drugs at different concentrations were 
incorporated into the soft agar mixture, each concentration was in triplicate. The 
plates were then incubated for 3 weeks before colonies were counted. A colony was 
defined as a group of 50 or more cells.
2.7.3 METHOCELL CLONOGENIC ASSAY
Clonogenic assays in methocell were essentially as detailed for Bacto agar 
except the cells were plated in 0.9% methocell.
2.7.4 CONDITIONED MEDIA PRODUCTION
Cells were scaled up to roller bottle quantities. 150mls of fresh media was 
added and left for three days. The media was then harvested, cleared of cells by 
centrifugation and filter sterilized. It was frozen at -20°C in aliquots.
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CHAPTER 3 
DEVELOPMENT OF AN IMMUNOHISTOCHEMICAL 
TECHNIQUE FOR THE DETECTION OF P-GLYCOPROTEIN
3.1 C219 DETECTS P-GP IN CANINE TISSUE
3.2 TECHNICAL PROBLEMS WITH C219IMMUNOHISTOCHEMISTRY
3.3 USE OF C219 EPITOPE SPECIFIC PEPTIDES IN COMPETITIVE 
IMMUNOHISTOCHEMISTRY AND WESTERN BLOTTING
3.4 USE OF COMPETITIVE IMMUNOHISTOCHEMISTRY TECHNIQUE 
TO DETECT P-GP IN NORMAL CANINE TISSUE.
3.4.1 RESULTS
3.4.2 DISCUSSION
3.5 SUMMARY
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3.1 C219 DETECTS P-GP IN CANINE TISSUE
Monoclonals against P-gp have been easily available for several years. 
MRK16 (Hamada and Tsuruo, 1986) JSB1 (Scheper et al, 1988) and C219 (Kartner 
et al, 1985) represent three of the most widely used reagents.
MRK16 is commonly used in human cancer research and has the advantage of 
being mdrl specific. The external epitope recognised by MRK16 is thought to be 
human specific because it does not react with rodent cells (Tsuruo et al, 1989). There 
is no published work mentioning the reactivity of MRK16 in species other than 
human and rodents. Despite its' lack of reactivity with rodent tissue, it was felt that it 
should be established whether or not this reagent could be useful in the dog. The 
MRK16 epitope is known to be best preserved in unfixed or formalin fixed tissue 
(Grogan et al, 1990) so MRK16 was tried on both unfixed and formalin fixed canine 
liver tissue using an alkaline phosphatase/fast red methodology (detailed in section 
2.6.2) and lOug/ml of MRK16. Liver was selected as the test tissue because it has 
expression of an mdrl isoform in every species studied (Fojo et al, 1987a; Bradley et 
al, 1990; Gant et al, 1992) including canine (chapter 4). No positive staining was 
found in the canine sections (data not shown) which supports the view that MRK16 is 
not suitable for analysing canine lymphomas.
Of the two other monoclonal antibodies JSB-1 is also mdrl specific and is not 
species specific (Scheper et al, 1988). Unfortunately JSB-1 was reported to be less 
dependable than C219 in immunohistochemistry (Krishan et al, 1991; Van der Valk 
et al, 1990; G. Wishart, personal communication) and was particularly sensitive to 
most tissue fixation techniques (Pavelic et al, 1991). It was not used in canine tissue.
C219, which detects all known P-gp isoforms, has already been shown to 
detect P-gp in canine tissue (Lieberman et al, 1989) and was considered dependable 
(Grogan et al, 1990; Krishan et al, 1991). Using the alkaline-phosphatase 
immunohistochemical technique described by Wishart et al (1990) (and adapted in 
section 2.6.2), C219 produced staining localised to the canalicular surface of the 
canine hepatocyte (figure 3.1a). A concentration of lOug/ml of C219 was used in 
these first slides. In the negative control (figure 3.1b), a 1 in 20 dilution of Clonab 
LNC (see section 2.1.8) showed a complete absence of reactivity.
A western immunoblot (methodology given in section 2.5) using C219 and an 
iodinated biotin-streptavidin system, confirmed that canine liver and kidney contain 
a protein recognized by C219 (fig 3.2). This protein is slightly smaller than the 
human and hamster P-gp (figure 3.2). Lieberman et al (1989) also reported the canine 
renal protein to be smaller than the human counterpart; 160kD compared to 170kD. 
Accurate sizing on the upper portion of the gel shown in figure 3.2 was not possible,
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but the sizes would appear to be similar to Lieberman's. The canine lymphoma cell 
lines CL-1 and 3132 were negative for P-gp on Western immunoblot.
Figure 3.1 Canine liver C219 immunohistochemistry (AP)
(AP alkaline phosphatase)
a Canine liver plus C219, x40 magnification (Top picture) 
b Canine liver plus Clonab LNC, x20 magnification (Bottom picture)
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3.2 TECHNICAL PROBLEMS WITH C219 IMMUNOHISTOCHEMISTRY 
(IHC)
The initial success with the first IHC protocol (based on Wishart et al9 1990) 
led to its use in subsequent IHC. This original protocol exposed sections to C219 
before exposure to any other protein products i.e. there was no "blocking" step using 
normal serum prior to the application of the primary antibody. This protocol relied on 
the use of a Clonab product "LNC" as a negative control. Clonab supply this reagent 
specifically to act as a control for their monoclonal products. The LNC product was 
described as a mixture of IgG's suitable for use as a negative control in IHC.
During the investigation of the P-gp content of a canine sarcoma, it became 
apparent that there were problems with the use of the Clonab product. The sarcoma, 
shown in figure 3.3a, gave very intense cytoplasmic staining with C219 in a spindle 
shaped cell population. The Clonab negative control was completely negative (figure 
3.3b). However, serial sections which had been exposed to 5% normal human serum 
instead of Clonab, gave the same positive result as the C219 section (figure 3.3c). 
The positive reactivity with normal human serum suggested that both the C219 and 
the serum staining was spurious, possibly through binding to Fc receptors. If this 
was the case, it seemed curious that the Clonab reagent did not show up this effect.
C219 is an IgG2a monoclonal and the normal serum would contain a mixture 
of isotypes. Given that within the Clonab range of monoclonals, there are IgM, IgGl, 
IgG2a and IgG2b products, one would expect the LNC reagent to have a mixture of 
all of these isotypes. The manufacturers were contacted to confirm the Ig content of 
their LNC product. After testing this product, they found it was a 9ug/ml solution of 
IgA. Thus, once Clonab LNC had been diluted 1 in 20 prior to use (following the 
protocol of Wishart et al, 1990), an IgA solution of 0.45ug/ml was being matched as 
a negative control for a lOug/ml solution of an IgG2a monoclonal. Negative controls 
should ideally use isotype and concentration matched "irrelevant" monoclonals 
(Hanson, 1991). Clonab LNC obviously fails to meet these criteria. Isotype matching 
is important because Fc receptors can vary in their ability to bind monomeric IgG of 
different subclasses (Fanger et al, 1989) hence use of unmatched isotypes in controls 
can lead to spurious results.
Clonab LNC was abandoned and alternate negative control reagents were 
investigated (see below).
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Figure 3.3 Sarcoma immunohistochemistry with C219 and controls
3.3a Sarcoma plus C219, xlO (Top picture)
3.3b Sarcoma plus Clonab LNC xlO {Middle picture)
3.3c Sarcoma plus 5% normal human serum, x 50 (Bottom picture)
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3.3 USE OF C219 EPITOPE SPECIFIC PEPTIDES IN COMPETITIVE 
IMMUNOHISTOCHEMISTRY AND WESTERN BLOTTING
Georges et al, (1990) determined the C219 recognition sequence using a 
series of overlapping hexapeptides covering the entire 211 amino acid fragment of the 
C-terminal of hamster Pgpl. C219 reacted most strongly with the sequence 
VQEALD and had very little activity with the adjacent overlapping peptides.
The different mdr isoforms in human and rodents were examined for the 
presence of this hexapeptide sequence in the C- and N- terminal halves of the P-gp. 
There was some variation in the exact hexapeptide sequence at the different sites 
between species (see table 3.1); new peptides representing these subtle variations 
were then examined for reactivity in the C219 ELISA based binding assay (Georges 
et al, 1990). The results, are illustrated in table 3.1.
Table 3.1 C219 binding to peptide analogs of recognition epitope
C-terminal domain Peptide Signal
Classes I, II, III (Rodent VQEALD ++
Classes I and III (Human) VQEALD ++
N-terminal domain
Classes I, II, III (Rodent) VQAALD ++++
Class DI (Human) VQAALD ++++
Class I (Human: mdrl) VQVALD +
Non-conserved amino acid residues are in bold script
From the results of Georges et al, (1990), several predictions can be made 
about the use of C219. Firstly, the combined signal from the N- and C-terminal 
binding sequences of the rodent class I and II isoforms would appear to be stronger 
than the human class I isoform i.e. C219 as an IHC reagent may perform better in 
rodent than human tissues. Indeed Thiebaut et al, (1989) reported that, under the 
same conditions, C219 reacted less strongly with human liver compared to rodent 
liver. The second prediction that can be made based on table 3.1 is that C219 may be 
more effective at detecting the human class III isoform of P-gp compared to class I. 
Thiebaut et al, (1989) described C219 staining in human muscle tissue (a class III 
expressing tissue) as "strong localisation" which contrasts with his comments about 
C219 staining in the liver.
Georges et al (1990) went on to use a fifteen residue peptide spanning the 
C219 hexapeptide recognition sequence as a control reagent in IHC. Preabsorption of 
C219 with a 100 molar excess of the peptide completely obliterated all specific 
staining in tissues. They remarked that the use of the peptide in a competitive binding
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assay clearly resulted in enhanced specificity because it allowed them to identify 
non-epitope staining in tissues such as the seminal vesicles and colon. This epitope 
specific peptide therefore seemed an ideal approach to reduce misinterpretation in 
IHC.
A six aminoacid peptide (VQEALD) was synthesized for use in IHC. 
Unfortunately, in work carried out by Dr Nicol Keith, this peptide failed to block 
C219 in IHC or in Western immunoblots. Dr. Georges (personal communication) 
commented that this inability to block C219 could be due to the small hexapeptide 
failing to take up the correct conformation in solution (the original epitope mapping 
had used hexapeptides mounted on polypropylene pins).
Two longer peptides were generated; a ten residue peptide (VVQEALDKAR) 
and a fifteen residue peptide (VVQEALDKAREGRTC), described in section 2.1.8. 
The latter was identical to the peptide used in the immunohistochemistry reported in 
Georges et al, (1990). These two peptides were compared for effectiveness in 
blocking C219 reactivity in both IHC and Western immunoblot. Preabsorption of 
C219 with a 100 molar excess of the 15 residue peptide for 1 hour at room 
temperature prior to use in IHC completely obliterated specific activity. The MDR 
drug resistant cell line KBV-1 (see section 2.1.7) had no residual reactivity with C219 
preabsorbed with the fifteen residue peptide (figure 3.4a and b). The ten residue 
peptide was less successful at blocking C219 reactivity. Even at a 1000 molar excess 
some staining in KBV-1 cells would remain (figure 3.4c). Figure 3.5 shows two 
western blot of normal canine liver which were probed with C219 plus different 
concentrations of each peptide. The ten residue peptide failed to block C219 binding 
to liver P-gp at a 1000 molar excess whereas the 15 residue peptide was completely 
effective at the same concentration. The western in the lower panel shows smeared 
reactivity below lOOkD. This is presumed to be due to protein degradation.
The fifteen residue peptide was adopted for use in all further IHC using C219. 
Despite being completely effective at blocking in IHC at a 100 molar excess, the 
Western immunoblot suggested that a 1000 molar excess of peptide was needed. The 
15 residue peptide was routinely used at a 1000 molar excess in all subsequent IHC. 
The peptide solution deteriorated with storage at 4°C and was discarded and replaced 
by a fresh solution every two weeks.
Other measures were also adopted to improve the quality of staining. Sections 
were exposed to 3% rabbit serum for twenty minutes prior to the addition of primary 
antibody and the C219 concentration was reduced to 5ug/ml. Both of these factors 
helped to reduce background staining.
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Figure 3.4 KBV-1 Immunohistochemistry: comparison of blocking peptides
3.4a KBV-1 plus C219 (Top)
3.4b KBV-1 plus C219 preabsorbed with 15 residue peptide (100M excess) (Middle) 
3.4c KBV-1 plus C219 preabsorbed with 10 residue peptide (1000M excess) (Bottom) 
All are at xJO magnification.
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Figure 3.5 Western immunoblot: Canine liver plus C219 with titration of 
blocking peptide.
Equal quantities o f canine liver protein extract were loaded in each 
we 11.(Methodology in section 2.5 using a chemiluminescence detection system). 
Where indicated, C219 was preabsorbed for one hour at room temperature prior to 
use.
Upper Panel
Titration o f 10 residue peptide 
1. no peptide preabsorption  
2 .1 0 0  molar excess
3. 1000 M excess
4. 104 M excess
Lower Panel
Titration o f  15 residue peptide
1. no peptide preabsorption  
2 . 1000M excess 
3 . 100M excess 
4 . 10M excess
10aa peptide
------------------  Molar
0 100 103 104 excess
200
. kD
*  ♦  .
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15aa peptide
Molar
0  103 100 10 excess
200
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3.4 USE OF COMPETITIVE IMMUNOHISTOCHEMISTRY TECHNIQUE 
TO DETECT P-GP IN NORMAL CANINE TISSUES
3.4.1 RESULTS
The normal tissue distribution of P-gp isoforms is discussed in the 
introductory chapter. Both C219 and mdr isoform specific antibodies have been 
useful in the investigation of normal tissue P-gp distribution in other species.
A small study was performed of normal canine tissues using C219 with the 
twofold aims of determining the similarity of the dog to other species, but also as a 
means of gaining familiarity with the use of C219 in IHC and hence gain expertise in 
scoring a range of P-gp expression critical for the assessment of lymphomatous nodes 
discussed in chapter 5. Tissues from a normal adult male dog were collected shortly 
after euthanasia.
Most tissues were stained using the alkaline-phosphatase/fast red based 
system described in section 2.6.2. However, certain tissues, including the gastro­
intestinal tract, the CNS, adrenals and pancreas could not be assessed using the 
alkaline-phosphatase system because of endogenous alkaline phosphatase activity 
which resulted in a severe background problem. These tissues were stained using an 
avidin-biotin-peroxidase system provided as an "ABC” kit by Vector labs, detailed in 
section 2.6.3.
Figures 3.6-3.10 shows cardiac and skeletal muscle, adrenal and colon tissue 
stained with C219. TTie adrenal and colon were stained using an ABC-peroxidase 
system. Positive staining appears as a dark brown colour. Table 3.2 lists the normal 
tissues examined and indicates which tissues gave background problems such that 
they could not be adequately assessed by either the alkaline-phosphatase nor the ABC 
technique.
The most positive tissues were liver, muscle tissue and the adrenal. Lung, 
testis, bladder and ureter were not adequately assessed due to problems with the 
quality of the sections. Staining in Leydig cells was seen in some testis sections but 
was not reproducible. Pancreas and the CNS had background problems which were 
not overcome by switching to an ABC system nor by the inclusion of steps to block 
endogenous avidin/biotin binding or by endogenous peroxidase quenching.
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Figure 3.6 Cardiac muscle immunohistochemistry with C219
3.6a Cardiac muscle plus C219, x50 {Top)
3.6b As above except C219 preabsorbed with blocking peptide {Bottom).
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Figure 3.7 Skeletal muscle immunohistochemistry with C219, x20
Figure 3.8 Colon immunohistochemistry with C219 (ABC-peroxidasei, x40
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Figure 3.9 Adrenal immunohistochemistry with C219 (ABC-peroxidase 
technique)
3.9a Adrenal (x 4) Top picture 
3.9b Adrenal (x 10) Bottom picture.
The P-gp negative Z. glomerulosa is the outermost layer (at top o f  picture) with the 
P-gp positive Z.fasciculata underneath.
Table 3.2 P-gp in normal canine tissues
Tissue p-gp Comment
Liver + Hepatocyte canalicular surface
Pancreas UI Unacceptable background
Oesophagus -
Stomach -
Duodenum -
Jejunum -
Ileum -
Colon + surface and cytoplasmic 
staining of epithelial cells
Cardiac muscle + Striated staining not limited to 
cell surface.
Skeletal muscle + Striated staining in certain 
muscle fibres
Kidney + Collecting tubules positive 
Background in cortex
Ureter UI Poor tissue morphology
Bladder UI Poor tissue morphology
Prostate -
Testicle UI Staining in Leydig cells? 
Poor tissue morphology.
Lung UI Poor tissue morphology
Spleen + Minority dendritic cell 
population P-gp positive
Cerebrum UI Background stain in endothelia
Cerebellum UI Background stain in endothelia
Adrenal + Innermost zones of the cortex 
positive in the adult male
+ positive, - negative, UI, uninterpretable
3.4.2 DISCUSSION
In general the canine tissue distribution matched that of other species. Intense 
P-gp staining was found in skeletal and cardiac muscle, adrenal cortex and liver. Less 
intense staining was found in tissues like the kidney and colon. The staining of a 
dendritic-type cell population in the spleen is discussed further in chapter 5.
Liver P-gp was localized to the canalicular surface of the hepatocytes as 
expected from other species. Bradley et al, (1990) and Van der Valk et al,(1990) used
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isoform specific antibodies to show that the P-gp in hamster and human liver 
respectively is of the class I isoform.
The pattern of staining in canine skeletal and cardiac muscle was identical to 
that reported by Bradley et al (1990). Cardiac muscle fibres and a subset of skeletal 
muscle fibres showed intense staining with C219 in a coarse striated fashion which 
may be due to staining of internal membranes of muscle fibres. This staining of 
cardiac and skeletal muscle by C219 was originally thought to be a cross-reaction to a 
muscle protein (Thiebaut et al 1989) because it was in discordance to the results of 
MRK16 staining of muscle tissue. As information became available about the tissue 
distribution of the different mdr isoforms (Croop et al, 1989; Bradley et al, 1990) it 
became apparent that this intense staining was due to C219 detecting the class El 
isoform in muscle tissue. It was predicted from the epitope-mapping of C219 
(Georges et al, 1990) that C219 would be particularly effective at detecting class El 
versus Class I or II isoforms. This seems to be borne out by the intensity of staining 
in canine muscle tissue relative to liver.
Bradley et al, (1990) reported sex differences in the P-gp expression in the 
adrenal cortex of the adult male versus adult female. The male hamster expressed 
considerable class II P-gp in the adrenal cortex whereas the female did not. The 
adrenal shown in figure 3.6 is from a male dog and it has the same localisation as the 
hamster, the inner zona reticularis and the zona fasciculata stain strongly whereas the 
outermost zona glomerulosa is negative. The adrenals from a neutered bitch and an 
intact bitch (both of which had received immunosuppressive doses of corticosteroids 
prior to euthanasia) were examined and both had less intense staining with P-gp than 
the adult male. However, both nodes had marked adrenal cortical atrophy, 
presumably as a result of the steroid administration, and hence are not a valid 
comparison to the adult male. The adrenals from a normal adult female were not 
examined.
Minor differences between the dog results and published results in other 
species include the inability to detect P-gp in blood vessels in the CNS compared to 
rodent and humans (Cordon-Cardo et al, 1989, Bradley et al, 1990, Van der Valk et 
al, 1990). Unfortunately, in both the alkaline-phosphatase and the ABC stained CNS 
sections, there was staining of the blood vessels which could not be entirely abolished 
by the competitive peptide. It was therefore impossible to rule out some spurious 
staining at this site. Endothelial staining in the capillaries of the testes has been 
reported by the same groups as reported CNS endothelial staining (Cordon-Cardo et 
al, 1989, Bradley et al, 1990, Van der Valk et al, 1990). Again it was not possible to 
confirm this in dog testes primarily because of the poor quality of the sections and 
diffuse background problems in the interstitial spaces between the seminiferous
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tubules. Initial staining suggested that Leydig cells may be P-gp positive, but this was 
irreproducible. The Leydig cells and blood vessels are packed together into the small 
areas between the seminiferous tubules so unless morphology is good, it can be 
difficult to get adequate visualisation of this area.
P-gp in the upper gastro-intestinal tract (stomach and small intestine) of the 
dog could not be found, but these tissues were particularly problematic regards 
background. Other workers have failed to unequivocally detect P-gp in the gastro­
intestinal tract. Suguwara et al, (1988) could not detect P-gp in the GI tract of human 
samples using MRK16. Ichikawa et al, (1991) used a Western immunoblotting 
technique which could detect P-gp in the positive control cell line KB 8-5 (described 
in section 2.1.7) and detected only minimal P-gp in colon membrane preparations 
with C219 in comparison to liver and adrenal. Bradley et al, (1990) did not detect P- 
gp in hamster stomach but did locate P-gp in the small and large intestines. However 
they commented that "the caecum and colon consistently demonstrated the highest 
levels of P-gp, whereas samples from elsewhere in the intestinal tract had barely 
detectable levels of P-gp". Van der Valk et al, (1990) described the staining in human 
stomach tissue to be "partly positive". The emerging impression is that P-gp 
expression in the GI tract may not be as ubiquitous nor as strong as might be implied 
in some of the first papers studying mdr mRNA expression (Fojo et al, 1987b; 
Mukhopadhyay et al, 1988; Chin et al, 1989). The ubiquity of P-gp in the GI tract is 
repeatedly reported in subsequent review articles (Kaye, 1988; Gottesman and Pastan, 
1988; Van der Bliek and Borst, 1989), but this may be a simplification of the truth.
P-gp in the canine kidney was localised to the collecting tubules and not to 
the kidney cortex as might have been expected from previous work (Van der Valk et 
al, 1990). The kidney cortex gave faint staining in the glomeruli and the convoluted 
tubules but this staining could not be obliterated by the peptide so had to be 
dismissed as mainly background (data not shown). Other workers have also reported 
that the kidney cortex contained C219 staining that could not be abolished by peptide 
competition (Bradley et al, 1990) and concluded that the hamster kidney did not 
contain P-gp. They could offer no explanation for the Western results of Lieberman et 
al, (1989) who found P-gp in the isolated renal brush border membranes of the rat, 
dog and human also using C219.
This study has detected P-gp in canine kidney both by EHC and western 
immunoblot. In the western shown in figure 3.2, the signal from the kidney sample 
(which was from cortical tissue) was less intense than the signal from the liver 
sample. Yet according to the IHC results, the kidney cortex does not contain staining 
which can be abolished by competitive peptides and so the distinct and specific band 
on the Western is unexpected. It cannot be ruled out that the protein preparation
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isolated from kidney cortex used in figure 3.2 was inadvertently contaminated with 
medullary tissue. Nor is it impossible that the canine kidney cortex does contain P-gp 
but that genuine staining in the cortex is being masked by non-epitope binding of 
C219 to the glomeruli and convoluted tubules. In support of this arc the results of 
Lieberman et al, (1989) who used purified brush border membranes from human, rat 
and dog in their C219 Western immunoblots and obtained a band of the appropriate 
size in all their species. They remarked that they had to over-expose the immunoblots 
relative to the positive controls to get an adequate signal from the kidney tissue. The 
C219 probed western immunoblots produced by Ichikawa et aly (1991), like figure 
3.2, showed a less intense signal in (human) kidney samples compared to liver. IHC 
of kidney cortex using MRK16 has repeatedly detected P-gp in kidney tubules 
(Theibaut et al, 1987 and 1989; Sugawara et al, 1988; Van der Valk et al, 1990) 
although Van der Valk et al (1990) described the kidney tubule staining as being only 
"partly positive". From this amalgam of results, it is not unreasonable to speculate 
that there is P-gp in the normal kidney cortex but due to tissue-specific background 
problems it is difficult to distinguish "signal" from "noise" using C219. Yet again the 
emerging impression is that P-gp expression in the kidney, like the GI tract, may be 
more limited than was first appreciated by initial RNA analysis (Fojo et al, 1987b; 
Kakehi etal, 1988).
3.5 SUMMARY
Normal canine tissues were assessed for P-gp presence using the monoclonal 
antibody C219. Following problems with non-specific reactivity of the monoclonal, a 
competitive immunohistochemical technique was adopted as a control to show 
specific P-gp reactivity. This technique used a fifteen residue peptide containing the 
recognition sequence for C219 to competitively block C219 specific binding. The 
peptide was shown to block binding at a 100 molar excess on IHC and on Western 
immunoblots. However, to allow a safe margin of error, the peptide was routinely 
used at a 1000 molar excess. C219 was preabsorbed with a 1000 molar excess of 
peptide for 1 hour at room temperature prior to use in IHC.
Strong P-gp expression was found along the canalicular surface of 
hepatocytes, in the inner zones of the adrenal cortex of the male and in cardiac and 
skeletal muscle. Less intense staining was found in the kidney and colon. The P-gp 
distribution in the dog would therefore appear to be similar to the distribution in other 
species.
87
CHAPTER 4 
DETECTION OF CANINE MDR1 HOMOLOGUE
4.1 CONSERVED EXON PROBE DETECTS FOUR PUTATIVE MDR GENES 
IN THE DOG
4.2 HUMAN MDR1 GENE PROBE, MDR5A, HYBRIDISES TO CANINE 
HOMOLOGUE.
4.3 USE OF RNAse PROTECTION ASSAYS TO DETERMINE HOMOLOGY 
BETWEEN HUMAN MDR1 AND CANINE HOMOLOGUE.
4.4 DISCUSSION
4.5 SUMMARY
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4.1 CONSERVED EXON PROBE DETECTS FOUR PUTATIVE MDR GENES 
IN THE DOG
In the introductory chapter, the mdr gene family of rodents and man was 
described. Comparing the sequences available for the three hamster genes, Ng et al 
(1989) created a probe corresponding to the terminal exon (immediately adjacent to 
the 3' untranslated region) of pgp2 gene as a means of determining the total number 
of genes in the hamster mdr family. This exon probe, pEX172, has 98% sequence 
similarity to hamster pgpl and pgp3 genes, 94% and 95% with murine mdrlb and 
mdr2 genes and 92% and 91% homology with the human mdrl and mdr2 genes 
respectively. This 172 base pair fragment does not contain the recognition site of any 
of the common six base-pair cutting restriction enzymes nor does it cross-hybridise 
with the equivalent exon in the 5' homologous half of the molecule. It can therefore 
be used to detect individual members of the mdr gene family. The position of this 
probe relative to a prototype mdr gene is shown in figure 4.1.
Using this probe, Ng et al (1989) detected two bands in genomic digests of 
human and rhesus monkey DNA and three bands in the mouse and hamster genome. 
This corresponds to the number of known mdr genes in these species. The pEX172 
probe was obtained from Dr. Ling and used to investigate the number of potential 
members of the canine mdr gene family.
The results of a Southern blot probed with the pEX172 probe are shown in 
figure 4.2. The canine samples (in lanes 1-3 and 7-9) were digested with EcoRl, Hind 
III and Pvu II. Each digest produced four discrete bands upon hybridisation with 
pEX172. The EcoRl and Hind III digests of murine and human DNA samples gave 
three and two bands respectively. (In lanes 6 and 12, faint bands present on the 
original autoradiograph have been lost in the photographic reproduction of the gel).
The pattern obtained in the mouse and human samples matches that of Ng et 
al, (1989). The results from the hybridisation to the canine genome suggests that the 
dog may have four mdr genes. The conserved fragment pattern of mdr genes between 
the canine cell lines 3132 and normal canine genome suggest that the cell line has 
retained all of its mdr genes. Curiously, one fragment in each digest of 3132 DNA 
gives a more intense signal which could represent amplification of that gene. 
However, in the Hind III digest of normal DNA (lane 8), the same band as in 3132 is 
also more intense. This increase in intensity may be due to sequence differences 
between the canine genes which results in stronger hybridisation to one particular 
gene. The difference in band intensity in 3132 could not be satisfactorily repeated 
so was not investigated further.
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Figure 4.1 Position of mdr probes relative to human mdrl sequence
The base pair positions are calculated from the human mdrl sequence, EMBL 
accession code M14758.
The MDR5A was subcloned into the EcoRl site o f pGEM4 (Promega Biotec) as 
described in materials & methods section 2.1.9. The MDR5A-pGEM4 construct was 
linearised using BamHl (which cuts in the plasmid multiple cloning site) for 
riboprobe production used in Southern blots. Riboprobes for RNAase protection 
assays were linearised with Xmn I and transcribed using the Sp6 promoter. The Sp6 
promoter adds 10 base pairs onto the size o f the riboprobe products. The Xmn 
riboprobe total length is 279 base pairs.
The pEX172 probe is a per product using a hamster Pgp2 sequence as a template.
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Figure 4.2 Southern blot of canine genome probed with pEX172
Southern was run according to method in section 2.4.2 and hybridised using the non- 
formamide conditions (section 2.4.6). DNA sources were: 3132 (canine) cell line, 
NIH 3T3 mice, dog and human liver samples. SM = size markers
Lanes:
Digest 3132 Mouse Canine Human
EcoRl 1 4 7 10
HincUII 2 5 8 11
PvuII 3 6 9 12
2 3 4 5 6 7 8 9  10 11 12 S M
2 3 .7
9 .4 6
i  6 .6 7
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4.2 HUMAN MDR1 GENE PROBE, MDR5A, HYBRIDISES TO CANINE 
GENE
The ultimate aim of this study was to investigate the expression of P-gp in 
lymphoma tissue and to determine if this P-gp expression affected clinical 
performance. As discussed in the introduction, only the mdrla/lb  genes are 
associated with the multi-drug resistance phenotype; the expression of mdr2 genes 
does not have any proven relevance to clinical resistance. It would therefore be 
important to exclude the expression of mdrl when assessing mdr mRNA in 
lymphomatous nodes. This is especially important given that the 
immunohistochemical analysis of P-gp in canine tissues relies on the C219 
monoclonal which does not differentiate between the drug-resistance relevant and 
irrelevant isoforms.
A human mdrl specific probe, MDR5A, was investigated for suitability to 
detect the canine mdrl equivalent gene or genes. The location of the probe within the 
human mdrl gene and its restriction map are given in figure 4.1.
It is not known if the canine resembles the human in having only one mdrl 
gene, or has multiple mdrl genes like rodents. The results from section 4.1 suggesting 
that the dog may possess four mdr genes means that multiple mdrl genes are a 
distinct possibility.
From a comparison of rat, hamster, mouse and human mdr sequences 
(Silverman et al, 1991), human mdrl more closely resembles the rodent mdrla genes 
and in this respect one could expect the human MDR5A to cross-hybridise with the 
canine mdrla equivalent. However the overall homology between mdrla and mdr lb  
genes is high; murine mdrla is 82.2% and mdr lb  78.7% homologous to human mdrl. 
Published results using MDR5A in rodent tissues are lacking so there is no 
information to indicate if this probe does detect the rodent mrla  and mdrlb genes. It 
is quite possible that the MDR5A probe could cross-hybridise with both mdrl genes 
if they exist, in canine tissue.
Figure 4.3 shows a Southern blot of canine and murine genomic DNA 
hybridised with an MDR5A riboprobe produced after plasmid linearisation with 
BamHl. The filter was hybridised in the presence of formamide as described in 
section 2.4.4. EcoRl and Hind III digested canine DNA (lanes 1 and 2), give a single 
band of approximately 12kb and 9.5 kb respectively. PvuII digested canine DNA 
produces two bands about 14kb and 8 kb in size. The murine genomic digests in 
figure 4.3 gave two bands in all three digests.
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The dearth of information on the use of this probe in rodent tissue makes it 
impossible to determine if the two bands in each of the murine digests represent 
hybridisation to one or both of the murine m drl genes. However, the canine pattern 
suggests that under these conditions, only one canine gene is detected, presumed to 
be an m drl homologue.
Figure 4.3 Southern blot of canine genome probed with MDR5A
Hybridised under formamide conditions. Canine DNA obtained from  cell line 3132, 
mouse DNA from NIH 3T3 liver.
Lanes:
1. Canine, EcoRl digest
2. Canine, Hind III digest
3. Canine, Pvu II digest
4. Mouse, EcoRl digest
5. Mouse, Hind III digest
4. Mouse, Pvu II digest
7. Size markers
1 2 3 4  5 6  7
2 3 .7
mm-
9 .4 6  
6 .67
■■ - : * £ v
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The MDR5A probe was used to analyse mdrl homologue expression in 
normal canine tissue. RNA was extracted from normal adult male tissue as described 
in section 2.2.2 and analysed on Northern blots (methodology in section 2.4.2). The 
filter was probed with random primed full length MDR5A clone (described in 
sections 2.1.9 and 2.3.3) under non-formamide conditions. The filter was stripped and 
reprobed with 7S to adjust for RNA loading. The results are shown in figures 4.4. and 
table 4.1.
Table 4.1 Tissue expression of mdrl homologue(s) in the dog
Lane Tissue mdrl Lane Tissue mdrl
1 KB8-5 +++ 11 colon +
2 liver +++ 12 prostate -
3 testicle - 13 bladder -
4 skeletal muscle - 14 kidney ++
5 skin - 15 adrenal ++
6 cerebrum - 16 spleen +/-
7 cerebellum -  ■ 17 lymph node -
8 stomach - 18 oesophagus -
9 duodenum - 19 lung -
10 jejunum + 20 cardiac muscle
- negative; + positive; +++ strong positive; +/- marginal expression
Figure 4.4 shows that there is detection of transcripts of the same size as the 
human mdrl message in liver, kidney, and adrenal. Some expression is also seen in 
the caudal GI tract i.e. jejunum and colon and the spleen may also have a low level of 
expression. This tissue distribution of expression is in general agreement with RNA 
analysis of mdrl gene expression in humans (Fojo et al, 1987b) and mouse (Croop et 
al, 1989).
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4.3 USE OF RNAse PROTECTION ASSAYS TO DETERMINE HOMOLOGY 
BETWEEN HUMAN mdrl AND CANINE mdr TRANSCRIPTS FROM 
DIFFERENT TISSUES
Ultimately to determine the number and class of genes in the canine mdr 
family will require cloning and sequencing of all members of the family. An attempt 
was made to clone the canine mdrl homologue by screening a canine genomic library 
with the MDR5A probe. Unfortunately, this screening failed to produce any positive 
clones, possibly because the library was not fully representative and no further 
attempts were made.
The results of section 4.2 suggest that a canine mdrl homologue is detectable 
by the human mdrl probe MDR5A and that the tissue distribution of this gene (or 
genes) is similar to other species. In chapter 3, C219 monoclonal antibody detected P- 
gp in cardiac and skeletal muscle yet both of these tissues were negative for mdrl 
homologue expression (figure 4.4); this could represent expression of an mdr2 
homologue in muscle tissue which does not cross-hybridise to MDR5A. Without 
canine gene-specific probes it is difficult to prove that certain tissues have mdrl 
homologue expression and others have mdrl gene expression.
RNAse protection assays provide an indirect method of assessing the 
homology between RNA species when sequence information is not available. In this 
section, the aim was to determine the degree of homology between canine mdr 
species and human mdrl using RNAse protection assays (RPA). At the same time, 
the assay was investigated as to its’ suitability as a rapid semi-quantitative assay for 
quantitating mdrl from tumour samples, as used by Herweijer et al, (1990).
The RNAse protection assay protocol used in this study is given in section 
2.4.3. In summary, it consists of 20ug of total RNA hybridised overnight with Xmnl- 
linearised MDR5A riboprobe, subjected to RNAase A and T1 digestion and the 
products then run on a denaturing polyacyrylamide gel. The restriction map of the 
MDR5A plasmid is shown in figure 4.1. MDR5A riboprobes for use in the RNAse 
protection assays were produced from the Xmn-1 linearised plasmid for two reasons. 
Firstly, it was difficult to produce adequate amounts of full length riboprobes from 
longer MDR5A templates. Secondly, the shorter Xmn-1 linearised riboprobe does not 
extend into the "joining" region between the two halves of the mdr gene. This joining 
area is that part of the gene with the lowest homology both between isoforms and 
between species. It seemed likely that the diversity in this area would compromise 
detection of homologies on an RPA.
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Initially, effort was concentrated on optimizing the conditions of the assay. 
Figure 4.5 is an RPA of KBV-1 RNA hybridised with (Xmn-1 linearised) MDR5A 
and digested with a decreasing amount of RNAse enzymes. Lane 4 represents 
digestion with the full amount of enzyme detailed in the methods section. Lane 5 and 
6 have been digested with a half and a tenth of the total enzyme concentration used in 
lane 4. The lanes did not run completely straight and so it was not possible to 
determine if the KBV-1 protected band was in lane 5 or 6 or both. At the lowest 
concentration of enzyme (0.1), there was no residual probe left in the control lane 
(lane 8) nor was there a signal from the KB3-1 sample in lane 7. On this basis, a tenth 
of the RNAse A and RNAse T1 concentration given in the methods was adopted for 
the next assays.
Considering the degree of gene amplification and mdrl over-expression in the 
KBV-1 cell line, the signal seen on RPA was modest. If RPA were to be of use in a 
quantitative basis, it was important to ensure that the amount of probe added was not 
the limiting factor in the intensity of signal achieved. In figure 4.5, 500,000cpm of the 
MDR5A probe was hybridised to the test RNA. Figure 4.6 shows the results of 
hybridising KBV-1 with different counts of probe, ranging from 50,000 cpm to 
800,000cpm. There was no large increase in the signal intensity achieved in lane 1 
compared to lane 6 so it was decided to continue using 500,000cpm of the MDR5A 
probe per sample.
Herweijer et al, (1990) simultaneously hybridised tumour RNA with mdr 
riboprobes and y actin probes (as an RNA loading standard) to allow a 
semiquantitative assessment of mdr expression. The y actin probe used by Herweijer 
was obtained and figure 4.7 represents human and canine RNA run in conjunction 
with 50,000cpm of the y actin probe. The human RNA sample protects a 145bp 
fragment almost the same length as the actin riboprobe. This is in agreement with the 
results of Enoch et al, (1986). The canine RNA protected a fragment of 
approximately 85bp. Thus it appeared that the actin probe could be used as a standard 
for RNA loading in both human and canine samples.
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Figure 4.5 Titration of RNAse concentration with KBV-1 RNA in an RNAse
protection assay (RPA)
1. Size markers
2. Xmn 1 MDR5A (undigested)
3. empty
4. K B V -1:1 x total RNAse
5. KBV-1: 0.5 x total RNAse
6. KBV-1: 0.1 x total RNAse
7. KB3-1: 0.1 x total RNAse
8. MDR5A alone: 0.1 x total RNAse
1 2 3 4  5 6  7 8
m
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Figure 4.6 Optimisation of MDR5A probe counts in KBV-1 RPA
1. KBV-1 +800,OOOcpm
2. KBV-1 +600,OOOcpm
3. KBV-1 +400,OOOcpm
4. KBV-1 + 200,OOOcpm
5. KBV-1 + 100,OOOcpm
6. KBV-1 + 50 ,OOOcpm
7. No RNA + 800,OOOcpm
8. empty
9. Undigested MDR5A
1 2 3 4 5 6 7 8  9
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Figure 4.7 RNAse protection assay with y actin probe
1. Human RNA plus 50,OOOcpm of y actin riboprobe
2. Canine (liver) RNA plus 50,OOOcpm of y actin riboprobe
3. y actin riboprobe alone (undigested).
1 4 2 -
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The MDR5A and actin probes were used together in the RPA shown in figure 
4.8. Lane 6 is KBV-1 RNA hybridised with MDR5A alone whereas in lane 7 and 8, 
MDR5A and y actin were hybridised simultaneously to KBV-1 RNA and the drug 
sensitive parent KB3-1. Lane 9 represents normal dog liver RNA hybridised to 
MDR5A alone. Comparing lanes 7 and 8, the RNA loading of KBV-1 and KB3-1 
looks similar as judged by the intensity of the y  actin band but KBV-1 has a 
considerably more intense mdrl fragment. The detection of low-level mdrl 
expression in the parental cell line contrasts with the negative results of Northern 
blots (one of which is shown in figure 5.1). The detection of mdrl expression on RPA 
but not on Northern could merely represent the improved sensitivity of the RPA. 
However, the results in lane 9 (the canine liver RNA sample) were considered 
suspicious. Canine liver RNA would appear to have given complete protection to the 
entire length of the mdrl riboprobe, (implying that there is complete or very strong 
homology between the RNA species. This degree of protection was unexpected and, 
in conjunction with the obvious band in the KB3-1 lane, it was thought that this result 
could be an artefact due to incomplete digestion of the MDR5 A labelled riboprobe.
The control lane (lane 5) was identical to the other lanes regarding probe 
counts and hybridisation/digestion conditions but had no test RNA; all of the probe 
was digested in this control. However, the other lanes contain RNA which has been 
freeze-dried after a salt precipitation and resuspension step. The presence of these 
salts may alter the digestion efficiency of the RNAses. A second factor is the RNAse 
concentration; the RPA in figure 4.8 was digested with one tenth of the enzyme 
concentration detailed in the original protocol. Because of the concern over the 
completeness of the digestion, the enzyme concentration was restored to the original 
concentration for subsequent assays.
When digestions were carried out with the full concentration of enzyme, the 
269bp protected fragment seen in figure 4.8 with the canine liver RNA disappeared. 
Instead, a shorter fragment of llObp, plus ladder, was produced. This MDR5A 
ladder overlapped and obscured the y actin fragment, which made it unsuitable for 
simultaneous MDR5A and actin hybridisations. Figure 4.9 shows the results of an 
RPA using the full amount of enzyme with RNA from canine liver, kidney, and 
skeletal muscle. Kidney and skeletal muscle samples were hybridised with y actin in 
adjacent lanes to the MDR5A hybridisation. Lanes 6 and 10 show that canine liver 
and kidney RNA both protect an MDR5A fragment of llObp and give identical 
laddering. Lane 7 and 8 used the same quantity of skeletal muscle RNA in the 
hybridisations; the y actin hybridisation protects a band of the expected size whereas 
in the MDR5A lane, there is no protection of fragments. Comparing intensity of the y 
actin fragments of the muscle tissue versus the kidney tissue, it would appear that 
more RNA was loaded in the muscle lane. So the lack of protection in the muscle 
tissue is not likely to be due to insufficient starting quantities of muscle RNA.
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Figure 4.8 Combined use of MDR5A and actin probes with human RNA 
samples
1 Size markers
2 undigested actin probe
3 undigested MDR5A probe
4 empty
5 MDR5A + actin (no test RNA)
6 KBV-1 plus MDR5A
7 KBV-1 plus MDR5A + y actin
8 KB3-1 plus MDR5A + y actin
9 Canine liver RNA plus MDR5A
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Figure 4.9 Canine RNA hybridised with MDR5A and y actin probes
1. size markers
2. undigested MDR5A
3. MDR5A (no test RNA)
4. KB3.1 +M DR5A
5. KBV-1 +M DR5A
6. canine liver RNA + MDR5A
7. canine skeletal muscle + y actin
8. canine skeletal muscle + MDR5A
9. canine kidney RNA + y actin
10. canine kidney RNA + MDR5A
11. y actin (No test RNA)
12. undigested y actin
The conclusion from this piece of work was that liver and kidney contained an 
mdr RNA species which skeletal muscle does not The identical size and intensity of 
the protected fragments in the liver and kidney hybridisations suggest that the mdr 
mRNA in these two tissues is identical and given its’ partial homology to MDR5A, is 
likely to be an mdrl species.
The BamHl linearised MDR5A riboprobe (which is 1383bp compared to the 
Xmn-I riboprobe of 269bp) produced a single band in the EcoRl and Hind III 
digested canine DNA shown in figure 4.3. The conclusion from the RPA analysis that 
liver and kidney express an mdrl species is partially dependant on the short Xmn-l 
MDR5A riboprobe retaining the specificity of the longer probe. This was verified at 
the genomic level by Southern analysis. A southern of dog, human and mouse DNA 
was divided and one half hybridised with the BamHl MDR5A riboprobe, and the 
duplicate half with the Xmn-I digested MDR5A riboprobe. The results are shown in 
figure 4.10.
The hybridisations in figure 4.10 were performed in non-formamide buffer at 
65°C, whereas the southern in figure 4.3, was hybridised at 42°C in 50% formamide. 
The high temperature non-formamide system was adopted because it was found to be 
more sensitive and this is illustrated in figure 4.10. The three digests of canine DNA 
(lanes 1-3 ) in figure 4.10, each contain an additional faint band which was not 
apparent on the southern shown in figure 4.3. The complex and rather fuzzy bands in 
the human DNA digests (lanes 4-6) give similar results to other workers who use the 
MDR5A probe. MDR5A hybridisations to human DNA digested with PvuII, Hindlll 
and EcoRl are found in Ueda et al, (1987b), Shen et al,(1988) and Lai et al,(1989) 
respectively. Therefore, under the hybridisation conditions used in this system, the 
MDR5A probe retains its specificity for human mdrl and does not detect human 
mdr2.
Comparing the equivalent lanes in the two halves, the Xmn-l MDR5A 
hybridisation has lost bands relative to the BamHl MDR5A pattern. Given that the 
Xmn-I probe is considerably smaller, this is expected. The quality of this southern 
hybridisation is not good but there is certainly no compelling evidence that the 
shorter probe is detecting additional genes. There is a faint band of high molecular 
weight in lane B1 which is not present in lane 1 but in itself this was not considered 
to indicate that an mdr2 gene (or genes) was being detected. The Xmn-l MDR5A 
hybridised murine and human digests do not contain any new bands which 
corroborates the canine results and gives further credence to the assessment that the 
shorter Xm/i-i digested riboprobe retains mdrl specificity.
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Figure 4.10 Duplicate Southern blots hybridised with MDR5A and Xmn-l 
digested MDR5A.
Left hand panel (1-9) was hybridised with full length MDR5A riboprobe, right hand 
side (B1-B9) with Xmn-l linearised MDR5A riboprobe. Lanes 1-9 and B1-B9 are 
identical. DNA was from outbred dog liver, human clinical sample and murine (NIH 
3T3) liver. SM, size markers.
1 Canine: EcoRl digest 7 Murine: EcoRl digest
2 " Hind III digest 8 " Hind III digest
3 " Pvu II digest 9 " Pvu II digest
4 Human: EcoRl digest
5 " Hind III digest
6 " Pvu II digest
S M  1 2  3  4  5  6  7  8  9  B1 B2 b 3  b 4  b 5  b 6  b7 b 8  b 9
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As an assay, the RPA did not lend itself to semi-quantitative use in the dog; 
the size of the mdr and y  actin fragments were too similar in size to allow 
simultaneous hybridisation. Although the technique appeared to be very sensitive ie. 
could detect mdrl in the KB3-1 parental cell line, it did not differentiate between 
moderate and high expression. The signal from canine kidney was similar to KBV-1 
yet from Northern results it is obvious that KBV-1 has considerably more mdrl 
mRNA. It also required RNA of extremely high quality; some KBV-1 RNA which 
appeared perfect on an ethidium stained gel did not give protection in the assay. The 
inconsistency of the assay was judged to be too great for routine analysis of canine 
tumour RNA.
4.4 DISCUSSION
Section 4.1 used a highly conserved probe (pEX172) of exon 28 of the 
hamster pgp2 gene to determine the number of mdr genes in the dog. This probe 
detected the appropriate number of bands in human and mouse DNA. The equivalent 
exon of the rat mdr lb  gene has also been used for the same purpose in the rat and 
confirmed that the rat would appear to have three mdr genes like other rodents 
(Silverman et ah 1991). The pEX172 probe revealed that the dog may have four mdr 
genes, which would be more than any of the species examined so far. The designation 
of these four genes into mdrl Imdr2 (or more?) categories cannot be carried out 
without sequencing information.
Unpublished work, which was presented at an American Association of 
Cancer Research meeting in 1991, suggests that the mdr gene family in some 
mammals may be complex. Using the (pEX172) probe , Childs and Ling discovered 
that the pig had five potential mdr genes. Three genomic clones from the pig were 
isolated using pEX172 and the 3' untranslated region (UTR) of these clones was 
sequenced and analysed. The 3' UTR is known to be isoform specific and well 
conserved across species and may therefore be used to classify genes according to 
their isoform (Endicott, et ah 1987; Ng et ah 1989). This analysis revealed that the 
pig had one gene that was the equivalent of an mdrl but the other two, although very 
homologous to each other, did not correspond to any of the preexisting classes. The 
fourth and fifth porcine genes have not yet been characterised.
Based on this incomplete information on the pig mdr gene family, it would 
seem unsafe to make predictions about the class organisation of the canine mdr 
family. The pig information also poses questions as to the functional potential of this 
new class of mdr, it is difficult to envisage a class of genes with an essential function 
which is expressed in the pig but completely absent in humans and rodents. It may be 
that these new mdr genes are actually pseudogenes of no functional significance.
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The homology between the different isoforms, and between species, increases 
towards the 3' end of each half of the P-gp molecule. This corresponds to the 
conserved intracytoplasmic portions of the P-gp. Because of this, probes from these 
areas tend to cross-hybridise with other family members; the pEX172 probe in the 
conserved 3’ end of the carboxy-terminal half of the gene is an example of this 
phenomenon. MDR5A spans the middle third of the human mdrl molecule including 
the conserved nucleotide binding site but avoids problems of cross hybridisation to 
human mdr2 presumably by its incorporation of the divergent linker region and some 
of the external domains. However, other probes in the middle portion of the mdr 
molecule are not always gene specific. The probe, pCHPl, used by Riordan et al, 
(1985) detected approximately ten bands on southern blotting of EcoRl digested 
hamster DNA. Similarly Croop et al, (1989) derived the probe pcDR1.3 from mouse 
mdr lb  cDNA which includes the highly conserved nucleotide binding site. Croop 
commented (without actually showing Southern data) that this probe cross-hybridised 
extensively with murine mdrla and mdr2 genes.
In contrast to Riordan et al, (1985), the fragment pattern seen with MDR5A 
and EcoRl digested canine DNA is very simple: using a formamide hybridisation 
system, only a single fragment was detected and using a different hybridisation 
protocol, a second band of less than 5kb appeared. This suggests that MDR5A cross- 
hybridises with a single gene in the dog.
The results of the Northern analysis of canine tissue also supports the view 
that MDR5A is cross-hybridising with a single gene and its products. Firstly, the 
tissue distribution of the MDR5A cross-hybridising species is very similar to mdrl 
expressing tissues in other species. Secondly all of the transcripts from the different 
tissues were of the same size. In the human and mouse, mdrl and mdr2 transcripts are 
different sizes and can be differentiated on gel fractionation. In the human, the mdr2 
transcripts are approximately 400bp shorter than the mdrl transcripts (Van der Bliek 
et al, 1987). In the mouse the mdr2 transcripts are again shorter than mdrl mRNA. 
Using the pcDR1.3 probe mentioned above, Croop et al, (1989) detected transcripts 
ranging from 4.5-6kb in normal mouse tissues.
Multiple transcripts have never been seen in canine tissues using MDR5A. 
This in itself does not rule out that two genes (for example an mdrla and an mdr lb) 
are being detected. In the mouse, the mdrla gene produces transcripts of multiple 
sizes depending on the transcription initiation site and the polyadenylation signal 
used (Hsu et al, 1990). The size variation means that an mdrla transcript can overlap 
with an mdrlb transcript and appear as a single species. In the mouse, these two 
transcripts are differentiated using probes from the diverse linker region. (Hsu et al, 
1989).
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Table 4.2 Comparison of mdr gene sequences in the Xmn 1 MDR5A riboprobe 
region of the mdrl gene
Gene
Access
Code
(EMBL)
Nucleotide
Difference/
homology
Longest
unbroken
run
Longest 
run: lbp  
difference
Hamster mdrla M17897 20/92.6% 38 57
Mouse mdrla M33581 24/91.1% 38 57
Hamster mdrlb M17896 34/87.4% 38 57
Mouse mdrlb M14757 41/ 84.8% 20 38
Rat mdrlb M62425 42/ 84.4% 38 53
Human mdr2 M23234 59/78.1% 17 23
Mouse mdr2 J03398 65/75.9% 22 28
Rather than proposing the complex situation of mdrla and mdrlb transcripts 
masking each other, the simplest conclusion which fits the Southern and Northern 
data is that a single gene cross-hybridises with MDR5A. The RNAse protection 
assays illustrate the homology between the canine mdr mRNA and human mdrl. 
Table 4.2 details the exact number of nucleotide differences between mdr genes over 
the 269 bases covered by the Xmn-I MDR5A riboprobe. The percentage homology 
between the mdrla genes and human mdrl in this short region is greater than the 
homology over the entire gene. A comparison of rat, mouse, hamster and human mdr 
gene sequences is given in table 4.3, adapted from Silverman et aU (1991). The 
overall homology between mouse, mdrla and human mdrl is 82.2%, but in the 
riboprobe region rises to 91.1%.
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Table 4.3 Overall homology of mdr genes using coding and non-coding 
sequences (adapted from Silverman et al, 1991)
Gene % nucleotide homology 
Human mdrl Human mdr2
Hamster mdrla 83.5 64.2
Hamster mdrlb 75.7 47.7
Mouse mdrla 82.2 71.6
Mouse mdrlb 78.7 70.6
Mouse mdr2 71.1 86.1
Rat mdrlb 79.1 71.5
Human mdr2 74.9 100
When the sequence differences are shown in their actual positions (figure 
4.11), then it can be seen that most of the base pair changes are not contiguous; there 
are only a couple of locations in the mdrla which has two adjacent base pair changes. 
In comparison to mdrla, the murine mdr2 gene has nine sites with contiguous base 
pair changes. The RNAse enzymes digest areas of single-stranded RNA. It may be 
that single nucleotide differences which are well dispersed do not sufficiently disrupt 
the RNA-RNA duplex to be recognised and destroyed by the enzymes.
The differential in the frequency and dispersion of base pair substitutions 
probably accounts for the ability to detect protected bands in the canine liver RNA 
hybridisations but the absence of protection in the muscle RNA samples. From cross- 
species comparisons, muscle tissue would be expected to predominantly express the 
mdr2 gene; if the canine mdr2 gene resembles the mouse mdr2 gene then it would not 
seem likely that protected fragments of over 40 nucleotides would be generated. In 
contrast, the mdrla gene has long stretches where RNAses may not pick up single 
base differences; in the middle portion there is a distance of 127 bases with only 
single nucleotide changes. Both kidney and liver produced the same fragment ladder 
on RPA so it would seem logical that these two tissues express the same mdr gene. If 
there was a mixture of mdrla and mdrlb mRNA in one or both these tissues then one 
might expect the intensity of the fragments in the two tissues to be different. This is 
not the case, yet again suggesting MDR5A cross-hybridises to a single species.
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Figure 4.11 Nucleotide differences in Xmn-l MDR5A riboprobe region of the 
three murine mdr genes relative to human mdrl.
Sequence of the human mdrl gene is given in full with the nucleotide positions 
numbered according to the human mdrl cDNA EMBL accession number M14758 
(Chen et al, 1986). Mouse mdrla, mdrlb and mdr2 are aligned (in that order) 
beneath the human sequence. Identity is indicated by a dash. Adjacent base 
differences are in bold script.
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The overall conclusion remains that MDR5A cross-hybridises to a single 
gene, almost certainly an mdrl homologue. Whether this homologue is an mdrla or 
mdrlb equivalent cannot be determined, indeed it is not clear if the dog has more than 
one mdrl gene. In rodents, the mdrla/mdrlb gene expression in tissues has 
considerable overlap. However, the major difference between the expression of the 
two mdrl genes is that in both the hamster and the mouse, the mdrlb form 
predominates quite markedly in the adrenal cortex. In the canine, the adrenal mdr 
transcript was an identical size to the liver transcript which suggests that unlike the 
rodent, the same gene may predominate in both organs. This could suggest the dog is 
similar to humans and only has one mdrl gene.
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Even if dogs do possess two mdrl genes, human mdrl is more homologous 
to mdrla than mdrlb and so the expected cross-hybridisation would be to the mdrla 
gene. However the difference between mdrla and mdrlb is not great and when a rat 
cDNA library was screened with the human MDR5A probe, it was the rat mdrlb gene 
which was subsequently identified (Silverman et al. 1991). Given the complexity of 
the potential cross-hybridisation and differential tissue expression of the mdrl genes, 
it is not possible to rule out that dogs may have more than one mdrl gene but that 
under the stringent hybridisation conditions used in this study, only one gene is 
apparently detected at the genomic level.
4.5 SUMMARY
Using a conserved exon probe from the 3' end of the mdr gene, four fragments 
were produced on Southern blot (implying that the dog may have four members of the 
mdr gene family. The human mdrl specific MDR5A probe appears to only detect one 
of these genes at the genomic level. Northern analysis of mdr gene expression from 
canine tissue detects transcripts of a single size and the tissue distribution of this 
transcript expression is consistent with an mdrl gene distribution. The strong 
homology of the canine gene to the human mdrl gene is evident in the llObp 
fragment which is protected by canine liver and kidney RNA on RNAse protection 
assay. From comparison with mdr2 sequences in the human and mouse, it is highly 
unlikely that a canine mdr2 homologue could protect a fragment of this length. The 
gene detected by MDR5A would therefore appear to be a canine mdrl homologue.
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CHAPTER 5:
P-GP AND MDR mRNA DETECTION IN CANINE LYMPH
NODES
5.1 DOTBLOT QUANTITATION OF mdrl IN CELL LINES
5.2 IMMUNOHISTOCHEMICAL DETECTION OF P-GP: SENSITIVITY 
AND LIMITATIONS OF THE TECHNIQUE.
5.3 STUDIES WITH CANINE LYMPHOMA CELL LINES
5.3.1 IN VITRO CHEMOSENSnTVITY OF CANINE LYMPHOMA 
CELL LINES.
5.3.2 LACK OF P-GP EXPRESSION IN CANINE CELL LINES 
5.3.3. LACK OF P-GP EXPRESSION IN CANINE CELL LINES
FOLLOWING DRUG EXPOSURE.
5.4 DETECTION OF P-GP IN NORMAL, REACTIVE & LYMPHOMATOUS 
NODES
5.4.1 ACQUISITION OF CLINICAL SAMPLES
5.4.2 CHEMOTHERAPEUTIC TREATMENT OF MLSA
5.3.3 P-GP DETECTION IN A DENDRITIC CELL POPULATION 
AND ENDOTHELIUM OF LYMPH NODES
(i) P-gp in normal, reactive and lymphomatous nodes.
(ii) Characterisation of the P-gp positive dendritic cells.
(iii) Do the dendritic cells express m drl?
5.4.4 DETECTION OF P-GP AND MDR mRNA IN LYMPHOMA CELLS
5.5 SUMMARY
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5.1 BLOT QUANTITATION OF mdrl IN CELL LINES.
In the introduction, the problems of quantifying P-gp protein expression or 
mdrl mRNA were discussed. From that discussion, the importance of using well 
characterised and well-recognised cell lines as controls was emphasized.
For this work, cell lines from the KB cell series were used in a similar fashion 
to Goldstein et al, 1989. The cell lines are described in section 2.1.7. Table 5.1 
documents the relative resistance of these cell lines to doxorubicin and the estimated 
over-expression of mRNA as calculated in 3 papers.
Table 5.1. KB cell lines
KB3.1 KB8.5 KBV.l
Doxorubicin 
resistance * 1 3.2 420
mdrl overexpression
Shen et al, 1986c n.d.^ 33 320
Fojo et al, 1987b 1 40 >500
Kuwazuru et al, 1990a 1 15 n.d
1. The doxorubicin resistance is relative to KB3.1. 2. not done. 3.Shen et al could not detect any mdrl 
signal in KB3.1 so compared KB 8 5  to KB8 which has a relative resistance to doxorubicin o f  only 7.1
Very highly resistant cell lines, such as KBV-1, are difficult to use in 
techniques which rely on densitometric reading of autoradiographs. This is because 
the mdrl expression of KBV-1 is so great in comparison to the clinical samples that it 
is not possible to obtain exposures which have both the sample and KBV-1 in the 
linear portion of the response curve of the radiographic film. Mdrl gene amplification 
has occurred in KBV-1; the biological relevance of gene amplification in clinical 
resistance has never been documented. Thus, for both biological and technical 
reasons it is important to have a control with intermediate mdrlPgp expression.
KB8-5 meets these requirements. In contrast to KBV-1, the in vitro resistance 
of KB8-5 to MDR drugs is modest. The fold increase in mRNA is within what could 
be described as a realistic range, judging from previous work with human tumour and 
rodent tissue (Goldstein et al, 1989, Fairchild et al, 1987). The "fold increase" in 
mdrl mRNA present in KB 8-5 is commonly referred to but seldom measured. Most 
workers who use these cell lines do not obtain detectable mdrl hybridisation signal 
on a Northern with the sensitive parental cell line KB3-1. Shen et al, 1986c could not
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get any mdrl hybridisation with KB3.1 signal so expressed the KB8.5 value relative 
to another cell line with only very marginal drug resistance. Even the paper which is 
most quoted as having shown that KB8.5 has a 40 fold increase in mdrl mRNA (Fojo 
et al, 1987b) does not have any visible mdrl hybridisation to KB3.1 RNA in the 
figures shown. Thus when the derived cell line KB8.5 is described as having a 40 fold 
induction of mdrl mRNA relative to KB3-1, it has to be assumed that this refers to 
the background hybridisation that KB3-1 gives in dot-blot analysis. Those groups 
which use KB8.5 in their quantification system have not independently re-calibrated 
the KB lines for relative mdrl expression in their own particular system. Thus 
Goldstein et al (1989), Bourhis et al, (1989a and 1989b) arbitrarily assign a value of 
”30" to the KB8-5 signal based on Fojo et al (1987b) without mentioning what fold 
difference was actually achieved in their system. Kuwazuru et al, (1990a) re­
examined KB8-5 and reported mdrl expression approximately 15 fold greater than 
the parental KB3-1 by slot-blot analysis. There is, therefore, some leeway in the 
accepted relative mdrl overexpression of KB8.5 as judged by the current literature.
Figure 5.1 is a northern blot of the KB cell lines plus two canine lymphoma 
cell lines probed with MDR5A. These RNA sources are the panel of controls run on 
every dot-blot. Figure 5.1 illustrates the extremely strong signal obtained from KBV- 
1 in comparison to KB8-5; it is not possible to accurately quantitate this signal. No 
signal is seen with the canine cell lines.
Repeated dotblots of the same batch of RNA from the KB cell lines were 
performed (data not shown). Following hybridisation to MDR5A, the blots were 
reprobed with poly(d)T as a measure of poly(A) containing RNA. The mdr 
expression was obtained by dividing the MDR5A densitometric signal by the 
poly(d)T signal. The ratio of KB8-5 to KB3-1 in repeated experiments (n= 10) varied 
between 3.45 and 11.3, with a mean of 7.3 and a standard deviation of 2.43. The 
range obtained is probably a reflection of the imprecision of the technique rather than 
genuine variations in the mdrl content of KB 8-5.
The reason for this variation may be related to the weakness of the signal 
from KB3-1 . It was possible to reduce the KB8-5/KB3-1 ratio from 8.5 to 3.2 merely 
by using a longer autoradiographic exposure of the same filter. With this sort of 
technical artefact, it is particularly important to ensure that every clinical sample is 
assessed at least twice on separate dotblots to minimize artefactual errors.
Irrespective of the exact fold difference between the two cell lines, it is 
apparent that the range obtained here falls short of the 30-40 fold reported by Fojo et 
al, (1987b) and is closer to the figures reported by Shen et al (1986c) and Kuwazuru 
et al (1990a) shown in table 5.1. The variances may be largely due to technical 
differences in factors such as the sensitivity of the densitometry system used.
114
Figure 5.1 Northern blot hybridised with MDR5A
1. KBV-1
2. KB8-5
3. KB3-1
4. 3132 
5C L-1
1 2  3  4
mdr5a
The ratio of the KBV-1 to KB3-1 signal obtained from dot-blots was subject 
to an even greater degree of variation than the KB8-5 results. The ratio ranged from 
a mere 7.73 to 124.4 with a mean of 37 and a standard deviation of 34.9. This large 
variation is almost certainly related to the difficulties mentioned earlier i.e. it is 
virtually impossible to obtain an autoradiograph which has an adequate KB3-1 signal 
without allowing the KBV-1 signal to reach the saturation plateau of the radiograph 
film. Again, the fold differences were consistently less than what might have been 
anticipated from previous published work. However, unavoidable use of these over­
exposed KBV-1 radiographs could account for the low readings obtained in this 
study. The exposures were deliberately aimed to provide readable signals from KB3.1 
and KB8.5 and consequently KBV.l accuracy was jeopardized.
The control cell line RNA is of very good quality as determined by 
visualization on agarose gels and performance in RNAse protection assays. 
Unfortunately, the RNA obtained from clinical samples is of mixed quality and not 
infrequently partially degraded. The impossibility of obtaining consistently good 
quality RNA determined the need to use dotblots rather then Northern blots in the 
analysis of these samples.
The effect on m drl signal intensity of using partially degraded RNA in 
dotblots is seldom addressed. Marie et al (1991) reported (without showing data) that 
controlled degradation of mRNA using RNAase A did not alter the subsequent signal 
obtained after m drl hybridisation. This was performed using a sensitive parental cell 
line which had a negligible m drl signal under normal conditions. The effects of 
degradation on an m drl positive cell line was not examined. To determine the likely 
consequences of using degraded RNA in this system, 20ug of KB8-5 RNA was 
incubated with 0.25ng/ml, 2.5ng/ml and 25ng/ml of RNAse A (lanes 2-4 in figure
5.2) for 15 minutes at 37°C. The result of MDR5A hybridisation of the RNAsed 
KB8.5 samples is shown in figure 5.2. Lane 1 has not had RNAse added. Visually, 
there is no easily discernible difference between the lanes. However, the computer 
densitometer could detect a 2.4 fold increase in signal intensity in lane 4 (the lane 
which received the most RNAse) relative to the control lane 1, whereas there was a 
negligible variation in the poly(d)T signal. This suggests that under these conditions, 
dotblot assessment of partially degraded RNA would have the tendency to over­
estimate m drl content by about twofold.
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Figure 5.2 Effect of controlled RNA degradation on dot-blot hybridisation
All lanes contain KB8-5 RNA. Dotblot methodology is given in section 2.4.4. All 
dotblot hybridisations were in non-formamide conditions (2.4.6). Upper panel, 
MDR5A hybridisation. Lower panel, rehybridisation with poly(d)T. Amount o f RNAse 
A used is given below.
1.0
2. 0.25ng/ml
3. 25ng!m l
4. 25nglml
1 2  3 4
•  •  t  • mdr5a
1 2  3 4
■ polyd(T)
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5.2 IMMUNOHISTOCHEMICAL DETECTION OF P-GP: SENSITIVITY 
AND LIMITATIONS OF THE TECHNIQUE.
The same KB cell line series was used to determine the sensitivity of the 
alkaline phosphatase immunohistochemical technique described in section 2.6.2 and 
used in chapter 3. Figure 5.3 shows KB8-5, and KB3-1 stained with C219 (KBV-1 is 
shown in figure 3.4a).
KB3-1 does not have any staining whereas KB8-5 has discreet surface 
staining. Detection of P-gp in KB 8-5 appeared to be at the limits of the sensitivity of 
this immunohistochemical technique in that if multiple KB8-5 coated coverslips 
were stained in parallel, not all the coverslips would yield positive cells. Thus the 
cells shown in figure 5.3a were on one of the four out of six positive coverslips on 
that day. The sensitivity of the system is good, especially considering it is a relatively 
simple protocol. Chan et al (1988) reported a sensitive IHC technique which is 
considerably more complex than this one which could detect P-gp in an ovarian 
carcinoma cell line which was only 8 fold resistant to vincristine and was P-gp 
negative on a Western blot. Both Chan et al (1988) and Grogan et al (1990) 
concluded that carefully optimized IHC was more sensitive than western blotting and 
probably at least as sensitive as Northern blotting. Grogan et al (1990) investigated 
different fixation techniques to use with C219 and concluded that acetone fixation 
was the most sensitive. Acetone fixation was used throughout this study.
KBV-1 stains very intensely with C219 to the extent that it is not possible 
determine that the staining is limited to the cell membrane (figure 3.4a). Read-out 
systems based on the enzymatic production of a coloured substrate are not ideal for 
providing accurate localisation of the antigen. To help determine if the cytoplasmic 
component of the staining in KBV-1 was an artefact created by the combination of 
gross P-gp overexpression and an enzymatic read-out system, KBV-1 was stained 
with a gold bead system (see section 2.6.4) using identical primary antibody 
conditions to that used in the alkaline phosphatase based methodology. Figure 5.3c 
shows KBV-1 stained using Aurogold^m then counterstained with the cytoplasmic 
stain saffrenin (it proved difficult to visualise the gold beads against a blue 
haematoxylin background). This system shows slightly better localisation to the cell 
membrane suggesting that some of the apparently cytoplasmic staining in KBV-1 
using alkaline phosphatase may be a technical artefact. However, many of the cells 
still appeared to have a generalised scatter of gold beads across the cell. Further 
investigation of P-gp distribution in KBV-1 was not attempted but would benefit 
from confocal microscopy. The Aurogold system had problems with sensitivity and 
visualisation which made it unsuitable for use with clinical material.
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Figure 5.3 C219 IHC with the KB cell line series
5.3 a KB8-5 using alkaline phosphatase technique, x50 (Top) 
5.3b KB3.1 using alkaline phosphatase technique, xlOO (Middle) 
5.3c KBV-1 using Aurogold system, x50 (Bottom)
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5.3 STUDIES WITH CANINE LYMPHOMA CELL LINES
Several basic experiments were performed with the two canine lymphoma cell 
lines 3132 and CL-1. 3132, has surface Ig (Holmes, 1989) and is therefore a B cell 
whereas CL-1, has an immature T-cell phenotype, described in section 2.1.7. Dogs 
with T cells tumours perform poorly following chemotherapy compared to B cell 
tumours and thus examining these two cell lines provided a means of determining 
whether this difference in performance was related to the intrinsic chemosensitivity 
of the cell type or due to the presence P-gp in T cell tumours but not B cell tumours.
5.3.1 IN VITRO CHEMOSENSmVITY OF CANINE LYMPHOMA CELL LINES.
The in vitro chemosensitivity of canine lymphoma cells has not been studied, 
probably because of the difficulties of growing canine lymphoma cells in culture. The 
availability of the two canine cell lines allowed the in vitro chemosensitivity of these 
two lines to be established.
The in vitro chemosensitivity of these two canine lymphoma cell lines was 
determined by MTT assay (described in section 2.7.1). The chemosensitivity of 3132 
was also determined by a soft agar clonogenic assay (see section 2.7.2). CL-1 did not 
form colonies in soft agar or methocell. Conditioned media prepared from 3132 and 
CL-1 (section 2.7.4) was added to the methocell or soft agar at a 10-30% 
concentration in an attempt to encourage colony growth in CL-1. The conditioned 
media failed to encourage CL-1 colonies. The chemosensitivity of CL-1 was 
therefore only determined using the MTT assay.
Chemosensitivities were determined for doxorubicin and epirubicin in both 
cell lines; the cells were exposed to drug for 24 hours and then allowed to recover & 
grow for a further 3 days (which is approximately three doubling times for these cell 
lines). The resultant graphs are shown in figure 5.4a and 5.4b. These graphs were 
obtained by combining the results of two independent MTT assays. Each assay 
produces eight determinations for each drug concentration so the points in figure 
5.4a and 5.4b represent 16 independent observations.
Figures 5.4a and 5.4b show that the putative T cell line is not more resistant to 
doxorubicin or epirubicin than the B cell line. In fact, CL-1 may even be more 
sensitive than 3132. The D50 value ( being the drug concentration required to reduce 
the absorbence to 50% that of the control untreated cells) for the two drugs is given in 
Table 5.2. The standard errors on the results of the two independent experiments are 
sufficiently large that it is impossible to give an accurate D50. However it would be 
prudent to conclude there are no significant differences between the two cell lines nor 
is there any significant difference in the cytotoxicity of the two anthracyclines.
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Figure 5.4 Chemosensitivity of canine lymphoma lines.
5.4a Doxorubicin chemosensitivity by MTT assay (Top)
5.4b Epirubicin chemosensitivity by MTT assay (Bottom)
5.4c 3132 epirubicin chemosensitivity by clonogenic assay (over page)
Figures 4a and 4b; Graphs o f percentage viability as a function o f drug 
concentration for 3132 and CL-1. Mean values are shown plus error bars 
representing standard errors o f the mean (for 16 observations).
X = 3132 cell line Triangle = CL-1 cell line
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5.4c Epirubicin chemosensitivity of 3132 determined bv soft agar clonogenic 
assay.
Figure 5.4c: Graph o f percentage colony numbers compared to controls. Mean 
values are shown plus error bars representing the standard error o f the mean (for 10 
observations)
C olony nos. (% of control)
100  -
60
40
20
0.01 0.1 1 10
Drug Concentration (nM)
T able 5.2 D 5 0  values for canine cell lines.
Cell line Doxorubicin Epirubicin Method
3132 18nM 25nM MTT
Cl-1 9nM 14nM MTT
3132 not done 2nM soft
agar
The D5 0  of these cell lines are similar to other unselected cell lines. The D5 0  
of H69 (a small cell lung cancer cell line) to doxorubicin and epirubicin is 
approximately 30nM and less than lOnM respectively under similar conditions 
(Mirski et al, 1987). A2780 (an ovarian carcinoma line) has a D5 0  between 1 and 
5nM following a 24 hour exposure to drug (Luo, 1992). These cell lines with 
chemosensitivities in the same range as 3132 and Cl-1 do not express P-gp as 
determined by a variety of techniques (Luo, 1992; Plumb et al, 1990).
The difference between the 3132 D5 Q generated by the clonogenic assay 
(approximately 2nM) compared to the MTT assay (approximately 25nM) may be
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related to the difference in the length of the drug exposure. In the soft agar cloning 
assay, the drug was incorporated into the agar whereas the MTT assay used a 
discrete 24 drug hour exposure. The half life of doxorubicin in culture is about 15 
hours (Beijnen et al, 1986) and so there was longer exposure to the active drug in 
the clonogenic assay compared to the MTT assay. However, excluding the 
methodological differences, there may be genuine differences between the 
chemosensitivity of the clonogenic cells measured by the soft agar assay and the 
surviving, proliferating fraction measured by the MTT assay. Clonogenic assays can 
produce a D50 concentration that is half that of MTT assays* using identical drug 
exposure times, (Plumb et al, 1989).
5.3.2 LACK OF P-GP EXPRESSION IN CANINE CELL LINES.
Cl-1 and 3132 do not express mdr mRNA on Northern blots (figure 5.1) and 
give a dotblot signal which is less intense even than the sensitive parental cell line 
KB3-1 (figure 5.8). Neither cell line has P-gp as determined by western blotting 
(figure 3.2) or by immunocytochemistry with C219 (data not shown).
5.3.3 LACK OF P-GP EXPRESSION FOLLOWING DRUG EXPOSURE
The canine cell lines were also used to assess if P-gp expression could 
(temporarily) increase following exposure to epirubicin. Normal liver increases 
mdr transcription following surgically or chemically induced damage within a few 
hours, and levels remain elevated for up to 3 days (Fairchild et al, 1987). Under 
physiological conditions, the P-gp content in the female reproductive tract can alter 
during pregnancy (Bradley et al, 1990; Sugawara et al, 1988; Huang et al, 1989). 
Thus certain tissues have the capability of inducing P-gp in response to various 
stimuli.
It is unknown if normal or neoplastic lymphocytes can undergo fluctuations 
in their P-gp content in response to the acute effects of chemotherapy. If increases in 
P-gp do occur within a few days of receiving chemotherapy, then this could affect the 
interpretation of the results of the in vivo P-gp study where dogs may have received 
chemotherapy only a few days before a relapse sample was collected. To ascertain 
whether discernible fluctuations would occur, the mdrl expression in both CL-1 and 
3132 was measured for 5 days following drug exposure.
Cl-1 and 3132 were split in fresh media to give a cell concentration of 
lOfyml. Epirubicin was then added at either lOnM or InM (approximately D50 and 
D |q  respectively). Drug was removed after 24 hours and replaced with fresh media. 
RNA for analysis was collected at time O, 24hrs, 48hrs, 72hrs and at 5 days. The 
daily percentage viability of the cells was monitored. The lowest viabilities recorded
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were 38% and 43% for CL-1 and 3132 immediately upon termination of the lOnM 
drug exposure.
The RNA was dot-blotted and electrophoresed on a northern g e l. Following 
MDR5A hybridisation no mdrl mRNA was seen in any of the canine cell line 
samples in the five day period following drug exposure (figure 5.5).
The experiment was only performed once although the RNA recovered from 
the cell lines was Northern blotted four times to repeat the negative result. This result 
suggests that significant fluctuations in P-gp do not occur in either the T or B cell line 
following anthracycline exposure. By analogy, acute P-gp fluctuations in MLSA 
cells due to induction following chemotherapy may also be absent (or at least below 
the limits of detection).
Legend for figure 5.5
1.KB8.5 11. as above, 5 days
2. 3132, timeO 12. 3132 + lOnM epirubicin, 24hrs
3. Cl-1, time 0 13. as above, 48 hrs
4. 3132 + InM epirubicin, 24hrs 14. as above, 72 hrs
5. as above, 48 hrs 15. as above, 5 days
6. as above, 72 hrs 16. CL-1 + lOnM epirubicin, 24 hrs
7. as above, 5 days 17. as above, 48 hrs
8. CL-1 + InM epirubicin,24hrs 18. as above, 72 hrs
9. as above, 48 hrs 19. as above, 5 days
10. as above, 72 hrs 20. KB3-1
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5.4 DETECTION OF P-GP IN NORMAL, REACTIVE & LYMPHOMATOUS 
NODES
5.4.1 ACQUISITION OF CLINICAL SAMPLES
MLSA samples were obtained from clinical cases which were referred to 
Glasgow University Veterinary College between September 1988 and March 1992. A 
total of 62 cases were accrued in this time; the breakdown of these samples in terms 
of chemotherapy exposure is given in table 5-3.
Lymph nodes were examined both immunohistochemically (methodology in
2.6.2) and by dot-blot hybridisation (2.4.4) for the presence of P-gp and mdrl mRNA 
respectively. All of the 62 cases (with the exception of one relapse sample), were 
assessed by dotblot hybridisation whereas only 44 of the cases were also examined 
immunohistochemically. This shortfall in the immunohistochemistry is due to the fact 
that for the first year of the project, clinical samples were not consistently collected in 
a manner suitable for subsequent immunohistochemical work.
Table 5.3 GUVC MLSA Patient Sample Collection
Number Sample Type
29 Pre-chemotherapy only
9 Post-chemotherapy only
2 Unknown status
22 Pre-chemotherapy plus follow-up
post-chemotherapy
The majority of the pre-chemotherapy samples were obtained by excisional 
lymph node biopsy. Most of these dogs went on to receive chemotherapy described 
in the next section. The post-chemotherapy samples were obtained either from a 
second surgical biopsy or more commonly at time of euthanasia due to tumour 
progression. Twenty-eight of the thirty-one post-chemotherapy samples were obtained 
from dogs with clinically resistant disease; the other three dogs died in remission for 
reasons unrelated to tumour progression. These three samples are indicated in the text 
and tables as required.
A list of the sixty-two dogs plus their signalment is provided in table 5.4. 
Further clinical detail of the GUVC cases is given in chapter 7. MLSA samples were 
also received from other veterinary institutions. The clinical information on these 
cases is sparse and the treated dogs received different multi-drug protocols. In total, 
there were 17 pre-chemotherapy samples, 4 relapse samples and 3 unknowns from 
other veterinary institutes.
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Table 5.4 GUVC MLSA Case Signalment
Name Case # Signalment
JAW 108557 9yr M GSD
CRS 107311 2yr F Golden retriever
107 107235 Adult M Golden retriever
KMD 107190 7yr F Bull Terrier
MOK 108548 5yr FN Cross breed
LUJ 109456 9yr M Labrador
LET 109341 5yr FN Great Dane
ROB 109342 lOyr M Cross breed
MMG 109533 3yrF WHWT
SMM 109393 13yr M Labrador
PAM 110488 9yr M Border C Collie
BRM 109969 lOyr FN Labrador
BMC 109542 5yr FN Labrador
RMD 111055 9yr M Scottie
RIC 111692 5yr M CKCS
HOG 111352 8yr FN Golden Retriever
TOB 111864 13yr M CKCS
PES 111925 6yr M Collie
GOF 102612 12yr F Labrador
MIG 111979 5yr F CKCS
RMI 111961 5yr F Golden Retriever
BOA 112230 5yr MN Bull Mastiff
SAO 112305 9yr M Labrador
CHP 112379 5yr F Bull Mastiff
CIS 112955 5yr FN Cross breed
SAD 112908 3yr M Cocker Spaniel
LAQ 113168 1 lyr M Cross Breed
RMC 113310 7yr MN Cross Breed
n r 112539 yr FN Cross breed
SAC 113294 6yr M Golden Retriever
TM 113617 3yr FN Springer Spaniel
M, male; MN, male neuter; F, female; FN, female neuter; GSD, German Shepherd 
dog; CKCS Cavalier King Charles spaniel; WHWT, West Highland White terrier.
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Table 5.4 (continued) legend on previous page.
Name Case# Signalment
LOK 113070 6yr M GSD
MAK 113069 6yr M GSD
BRP 113419 1 lyr M Elkhound
BIP 113579 13yr MN Cross breed
TAB 112614 6yr F Airedale
ZAK 114133 5yrFGSD
CMD 114189 5yr FN Bull Mastiff
SAB 114195 8yr M Cross breed
BEM 114768 5yr MN Golden Retriever
KEH 114800 lOyr FN Old English Sheepdog
BEH 114887 4yr M Springer Spaniel
BRC 115029 8yr M Labrador
KEB 115069 5yr F Irish Setter
MMK 115227 8yr FN Bearded Collie
LEB 115251 9yr M Cross breed
TRC 115074 7yr M Old English Sheepdog
BOS 115498 5yr M Collie cross
SPC 115616 4yr M Cross breed
BMD 115824 4yr M Lhaso Apso
BEA 115827 6yr M Great Dane cross
SMD 115839 7yr FN Bull Mastiff
SAS 104529 4yr F Boxer
RMM 116793 3yr M Bull Mastiff
CIP 117240 1 lyr FN Cross breed
BOB 116202 6yr M Labrador
SAB 116826 9yr M Old English Sheepdog
HEH 117986 3yr M Tibetan Terrier
THH 109400 7yr M Dobermann
SAP N.A. 1 lyr FN Miniature Schnauzer
ZAS 116674 7yr FN Cocker Spaniel
DHS 115030 8yr MN Labrador
In addition to the lymphomatous nodes , six normal nodes from three dogs (a 
submandibular and popliteal node from each dog) plus samples from four dogs with 
non-neoplastic lymphadenopathy were also included in this study. The case numbers 
and the histopathologic diagnoses of the four lymphadenopathies is listed in table 5.5. 
These nodes were surgically biopsied as part of the routine investigation of chronic 
lymphadenopathy.
1 2 8
Table 5.5 Signalment of lymphadenopathy cases
Code Number Signalment
OLS
GEG
MUS
LAM
113813
111688
111953
112275
1.5yr M Bullmastiff 
Pyogranulomatous Lymphadenitis 
3yr F Border Collie 
Granulomatous lymphadenitis 
15yr FN English Springer 
Reactive Hypeiplasia 
2yr FN West Highland White 
Reactive hyperplasia
Abbreviations as for table 5.4
Chemotherapeutic Treatment of MLSA
The main aim of this project was to investigate the role of P-gp in contributing 
to acquired anthracycline resistance in a naturally occurring chemosensitive tumour. 
To serve this aim, MLSA cases were given a protocol dominated by the MDR-type 
anthracycline, epirubicin. The exact protocol is detailed in chapter 1, table 1.14.
Epirubicin was given in preference to doxorubicin because of its\reduced 
cardiotoxicity . It was anticipated from previous work with single agent doxorubicin 
(Postorino et al, 1989) that the majority of dogs would relapse with clinically 
resistant disease prior to reaching a dangerous cumulative dose.
A total of forty-nine dogs were treated with chemotherapy; the remaining 
thirteen dogs were euthanased at the owners request at the time of diagnosis. The 
majority of the forty-nine treated dogs received the epirubicin-based protocol. The 
epirubicin was provided free of charge and administered under the informed consent 
of the owners.
Two dogs (BMM and SMD) were not considered suitable for the epirubicin 
protocol because of pre-existant myelosuppression and cardiomyopathy respectively. 
These two dogs received a standard vincristine and cyclophosphamide and 
prednisolone (COP) protocol (Carter et al, 1987). Samples were obtained from 
another six dogs which received COP with or without cytosine arabinoside in 
addition to the COP. These dogs did not receive epirubicin merely because they were 
referred to GUVC after the withdrawal of the subsidised epirubicin protocol. Those 
dogs which did not receive the standard protocol are indicated where appropriate.
Forty-one dogs received the epirubicin/prednisolone protocol until time of 
first relapse. Once clinical relapse was apparent, the management of the dogs was not 
standardised. If owners elected to try further treatment, various options were used
129
which depended on the patient parameters and on clinician preference. Two main 
approaches were used. The first was increasing the epirubicin dose to 30mg/m^ or 
above plus the addition of oral cyclophosphamide (50mg/m^) every other day and 
using induction doses of prednisolone. The alternate approach involves substituting 
weekly vincristine (0.7 mg/m^) for the augmented epirubicin. If either of these failed 
to induce a response, L-asparaginase was used in a limited number of patients. 14/31 
of the relapse samples were obtained from the dogs following the failure of rescue 
therapy so it cannot be ruled out that these other drugs may have influenced the 
expression of P-gp in the lymphomatous nodes. However, for reasons discussed in 
chapter 7, it was felt that the contribution of the non-epirubicin cytotoxic drugs to the 
drug resistance profile of the tumour was minimal in comparison to the drug 
resistance mechanisms already present in the resistant tumours at the onset of relapse. 
The clinical performance of the protocol is discussed in chapter 7.
5.4.3 P-GP DETECTION IN A DENDRITIC CELL POPULATION AND 
ENDOTHELIUM OF LYMPH NODES
5.4.3 (i) P-gp in normal, reactive and lymphomatous nodes
The alkaline phosphatase based immunohistochemical technique outlined in
2.6.2 was used to stain all lymph nodes. Two sections from each block were stained 
in parallel; one with C219 and the other with C219 which had been preincubated with 
a 1000M excess of 15 amino acid blocking peptide for 1 hour at room temperature, as 
described in chapter 3.
In normal, reactive and lymphomatous nodes, C219 stained the luminal 
surface of blood vessel endothelium (Figure 5.6a). This endothelial staining was 
present in virtually all sections. In fact the Fast Red substrate helped in the detection 
of collapsed small blood vessels which may otherwise have avoided detection. 
Occasionally larger vessels would be included in the sections and in some of these 
vessels, P-gp appeared to be within the muscular layer of the vessel wall rather than 
on the endothelial surface (Figure 5.6b and c); P-gp has been reported in the 
cytoplasm of smooth muscle in other tissues (Van der Valk, 1990). Endothelial P-gp 
has been documented in other organs such as the CNS and testes (Theibaut et al, 
1989; Cordon-Cardo et al, 1989; Bradley et al, 1990). The physiological significance 
of P-gp in endothelium is unknown but is unlikely to be involved in the exchange of 
nutrients between tissue and blood because endothelial P-gp is not limited to 
capillaries but is also found in small arterioles and venules (Bradley et al, 1990) .
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Figure 5.6 P-gp in Blood vessels from lymphomatous nodes
(AP-IHC with C219)
5.6a Endothelial surface staining (x 40) Top 
5.6b Muscular layer staining.(x 20) Bottom 
5.6c Muscular layer staining.(x 50) Next page
4*
*
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5.6c Muscular layer staining in blood vessel. (x50)
Diffuse staining was also commonly seen in a dendritic type cell (figure 5.7a). 
These cells were found in the vast majority of lymph nodes examined (Table 5.6). 
These cells were not frequent in lymphomatous nodes; within an average high power 
field (x40) less than 5 cells would be identified (figure 5.7b). Two large 
lymphomatous nodes were dissected into separate blocks and each block examined 
individually; the distribution of these cells within each block was haphazard but 
there was no large variation between the blocks (data not shown).
Most lymphomatous nodes do not retain noticeable normal lymph node 
architecture so it was not possible to ascertain if these dendritic cells were associated 
with a particular area of the node. However, in the normal and reactive nodes, the 
distribution of these P-gp positive cells was more orderly. P-gp positive cells were 
identified in both the B cell follicular areas and in the T cell paracortical areas but 
only rarely in the lymph node medulla (figure 5.7b and c). Even in the follicles and 
paracortical areas, the positive dendritic cells were still a minority population 
compared to the lymphocytes. Figure 5.7c shows a positive cell within a follicle; the 
block is from case "GEG" which was diagnosed as a reactive process.
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Figure 5.7 P-gp in Dendritic cells
5.7a Normal node (xlO) Top
5.7b Reactive node "GEG" (x20) Bottom
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Figure 5.7 P-gp in Dendritic cells (continued)
5.7c Lymphomatous node "KEH" (x40) Top 
5.7d Lymphomatous node "SNB" (xlOO) Bottom
s l . r
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Interestingly, this "GEG" sample also shows C219 staining in the B cells of 
the reactive follicles, but not in the T cell areas. This result was repeated in this 
sample but was not seen in normal nodes. However normal nodes occasionally gave 
unrepeatable faint staining of B cells; the significance of this is discussed further in 
section 5.4 and chapter 8.
Two tumours were identified (BMD and KEB) which had an over- 
representation of the dendritic cells within the lymphomatous node; more than 10 
cells per high power field could be detected. These two cases will be discussed in 
more detail later.
Table 5.6 P-gp Staining in Lymph Node Dendritic cells
Lymph node Type Number of samples with
P-gp in stromal cells
Normal 6/6
Reactive 4/4
GUVC* Lymphomas 
NCSU-CVM^ Lymphomas
40/44
18/18
CSU-CVM^ Lymphomas 3/3
CUVC^ Lymphomas 2/3
1. Glasgow University Veterinary College
2. North Carolina State University College o f Veterinary Medicine
3. Colorado State University College of Veterinary Medicine
4. Cambridge University Veterinary College
The dendritic cells were intimately associated with the lymphocytes and 
appeared to extend processes between adjacent lymphocytes; occasionally the cells 
appeared multinucleate. The staining pattern was not obviously localisable to the cell 
membrane alone but appeared as a rather granular pattern within the cytoplasm 
(figure 5.7a). Section 5.1 discussed the role of the enzymatic substrate reaction in 
contributing to the cytoplasmic staining of KBV.l. However these stromal cells do 
not stain as intensely as the mdrl gene amplified cell line and so it may be that the 
cytoplasmic component may be a true representation of the P-gp localisation and not 
merely a technical artefact. The Aurogold"^ bead system was used to try to confirm 
the cellular localisation but unfortunately the technique was not sensitive enough for 
detection in the lymph node sections.
P-gp localisation at sites other than the cell membrane is a contentious issue 
(Battifora, 1991). P-gp localisation within the Golgi region of cells has been 
documented repeatedly using immunohistochemistry and has become accepted as a
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genuine phenomenon (Willingham et al, 1987; Chan et al, 1988; Grogan et al, 1990; 
Salmon et al, 1989 and 1991). The exact physiological role of the protein at this site 
is unknown but is presumed to function in some transport capacity.
P-gp has also been reported in the cell cytoplasm in numerous papers 
(Broxterman et al, 1989; Wishart et al, 1990; Weinstein et al, 1991). This is generally 
regarded with some scepticism because most background problems manifest 
themselves as cytoplasmic staining (Battifora, 1991) and in some papers, the controls 
run are not adequate to identify artefactual staining (Wishart et al 1990). Cytoplasmic 
staining has been reported in tumours using both C219 and the mdrl specific 
monoclonals MRK16 and JSB-1 (Weinstein et al, 1991; Wishart et al, 1990; Van der 
Valk et al, 1990). When multiple monoclonals to different epitopes on the same 
protein give the same cytoplasmic localisation and the controls appear to be adequate, 
it is difficult to dismiss the results as spurious merely because they do not "fit" the 
currently accepted view of P-gp physiology.
However, in defence of the sceptics, studies which used C219 without a
peptide competition block have to be reevaluated more thoroughly since the
revelation that certain batches of C219, and JSB-1, have in the past been 
contaminated with reagents which react with blood-group antigens (Finstad et al, 
1991). Epithelial tissues such as gastrointestinal tract and genitourinary tract can 
express blood group antigens and hence spurious staining with C219 in these tissues 
may have occurred due to contaminated C219 batches (Weinstein et al, 1990a). This 
problem with the quality control of C219 will not affect this canine work firstly 
because canines do not share blood group antigens with humans and secondly
because the use of a competitive peptide block technique would reveal spurious
reactivity.
Although the canine lymph nodes will not be affected by blood-group 
reactive species which may contaminate C219, lymph nodes present their own 
problems with quality control. Different cell types within normal lymph nodes 
express receptors for the Fc component of immunoglobulins and hence they have a 
propensity to bind Ig in a non-specific way. In particular, some of the 
macrophage/monocyte population can give problems in immunohistochemistry in this 
regard. This potential problem is normally avoided by exposing the sections to sera or 
purified immunoglobulin prior to applying the primary antibody so that all Fc 
receptors will already be occupied. In this study, 3% rabbit sera and 5% skimmed 
milk were both tried as the initial blocking solution , however general background 
was lowest when a mixture of 1.5% canine and 1.5% rabbit sera was used inferring 
that cell populations within the lymph nodes may possess Fc receptors which bind 
canine Ig in preference to rabbit Ig. The rabbit/canine sera mixture was therefore
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adopted as the block solution for all lymph node IHC. However, the stringency of the 
peptide competition as a control negates the risk of misinterpretation of C219 
binding through Fc receptors because this would be seen as background.
5.4.3 (ii) Characterisation of the P-gp positive dendritic cells
P-gp positivity has been reported in non-lymphocytic cells in human 
lymphomas. Miller et al, (1991) reported P-gp within Reed-Stemberg cells in 
Hodgkins lymphoma using JSB-1 and C219. Schlaifer et al (1990a and b) have also 
reported P-gp expression in a stromal cell population within lymphomatous nodes 
using both C219 and MRK16. Neither group examined normal lymph nodes but 
Schlaifer et al (1990b) used a CD68 monoclonal to identify certain 
macrophage/monocyte lineages (Kelly et al 1988) which they claimed were 
morphologically identical to the P-gp positive cell population, however dual staining 
was not performed. The authors remarked that the CD68 positive cells were more 
frequent than the P-gp positive cells and suggested that P-gp was only present in a 
subpopulation of the CD68 positive cells.
P-gp positivity is also reported in macrophage like cells in other tissues. Van 
der Valk et al (1990) used the mdrl specific MRK16 and described P-gp positive 
cells "that were difficult to characterize; they were usually large cells with ample 
cytoplasm and showed a coarsely granular staining with MRK16. On the basis of 
their morphologic characteristics and their distribution, they were considered to be 
macrophages." These putative macrophages were found in the lung, spleen, skin, 
breast and prostate. The same paper also reported that JSB-1 stained a few cells in 
the brain with a dendritic morphology and that this staining was granular.
Thus there is precedence for cytoplasmic P-gp in macrophage/monocyte type 
cells. The morphology of the P-gp positive non-tumour cells in the canine lymph 
nodes is not typical for a phagocytic type cell. Instead their dendritic morphology and 
their localisation in normal and reactive canine nodes would suggest that they may be 
accessory cells involved with antigen processing and presentation. In B cell areas, 
follicular dendritic cells (FDC) present antigen whereas in T cell areas interdigitating 
cells (DDC) have a similar function (Steinman, 1991; Heinan et al, 1988). The canine 
cells sometimes appeared to be bi- or multi-nucleate. FDC in other species have been 
reported to be multi-nucleate (Pallesen and Myrhe-Jensen, 1987; Gerdes et al, 1983).
Precise identification of FDC and IDC is not simple. In mice and humans 
they are usually identified based on the pattern of reaction with a panel of 
monoclonals against a variety of haemopoietic determinants, plus enzyme 
histochemistry. Certain monoclonals such as Tul, R4/23, To5 and Ki-M4 were once 
considered fairly FDC specific but as more information became available on the
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antigens recognised by these monoclonals, it has become apparent that they are not 
FDC specific. For instance Tul recognizes CD23 which is present on B cells as well 
as FDC (Pallesen, 1987) and To5 recognizes the C3b receptor (CD35) which 
although is present in FDC, is also present on other macrophages populations. The 
R4/23 antigen has not yet been characterized but the manufacturers state that R4/23 
reacts (weakly) with splenic and follicular B cells (Dako product sheet code no. 
M709). In a rare case of FDC sarcoma investigated by Pallesen and Myhre-Jensen 
(1987), the FDC tumour cells did express most of the expected markers but were 
negative for R4/23. This illustrates the importance of using multiple monoclonal 
antibodies to different antigens to identify this cell type.
Monoclonal antibodies against murine or human blood cell CD groups do not 
usually cross-react with canine cells (discussed by Holmes, 1989). It is therefore 
difficult to take advantage of the commercially available reagents. In an attempt to 
characterize the canine dendritic cell population further, lymph nodes were stained 
using the MAC387 monoclonal which identifies a "histiocytic" type of macrophage 
(Flavell et a l , 1987). MAC387 is one of the few commercially available monoclonals 
against macrophage or monocytes which cross-reacts with canine determinants. 
MAC387 did identify a cell population within lymph nodes but these cells were 
found predominantly in the medullary region and were more globular than the cells 
identified with C219 (data not shown). It was concluded that MAC 387 did not 
identify the same population as C219. However, MAC387 is not reported to react 
with FDC nor IDC (Dako Product Sheet Code No.M747). Thus from the outset, this 
monoclonal was not anticipated to react with the same population as C219.
As an alternative to species specific monoclonal reagents, FDC and IDC are 
reported to possess S-100, which is an acidic protein originally identified in neural 
tissue (Takahashi et al, 1984) and which is conserved between species. S-100 has two 
subunits, a  and p; FDC differentially react with a  subunit monoclonals and IDC with 
p subunit monoclonals (Takahashi et al, 1984; Tanaka, 1986). The use of a 
polyclonal anti-S-100 sera with activity against both subunits should identify both 
populations of cells. In fact, Fondevila et al (1989) used an S-100 polyclonal sera to 
identify putative FDC and IDC within formalin fixed canine lymph nodes. They 
documented S-100 positive cells in 13 out of 24 lymphomas examined, either 
scattered throughout the tumour or in follicles.
S-100 has not been universally successful in detecting canine FDC. Sandusky 
et al (1985) examined canine lymph nodes and reported that S-100 reactivity was 
restricted to IDC of the paracortex and the same group (Sandusky et aly 1987) failed 
to detect S-100 positive cells in fourteen lymphomas. Failure to detect accessory cells 
either in normal or B cell tumours may be due to the differential reactivity of the
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polyclonal sera. Tanaka (1986) suggested that bovine brain (the antigen source for the 
Dako polyclonal product) is dominated by the p subunit of S-100 and thus there is a 
propensity for some polyclonal products raised against bovine neural tissue to detect 
IDC in preference to FDC. In follicular forms of NHL, FDC are known to proliferate 
in conjunction with the neoplastic B cells, forming a defined meshwork. On the 
contrary, FDC are relatively rare in T cell NHL and are mainly restricted to 
peripheral T cell lymphomas such as angioimmunoblastic lymphadenopathies 
(Gerdes and Flad, 1992). Thus it is possible that a canine B cell tumour may possess 
numerous FDC but these would not necessarily be detected adequately by S-100 
polyclonal sera raised against bovine brain.
BMD and KEB, the two samples with numerous P-gp positive dendritic cells, 
are both putative B cell tumours (as determined by their lack of T cell gene 
rearrangement; see chapter 6) and so they would be expected to contain FDC. 
Histological reports on these two tumours classed BMD as a diffuse large cell tumour 
whereas KEB had a mixed follicular/diffuse pattern (histological classification kindly 
carried out by Sean Callanan of the Dept. Veterinary Pathology). Despite the 
potential problems with polyclonal S-100 regards the ability to detect FDC, these two 
tumours were examined using an S-100 polyclonal sera from Dako. This work was 
kindly performed by members of the Pathology Department at the Royal Infirmary 
under the guidance of Dr A. McNicol. The S-100 staining failed to identify any cells 
in frozen sections cut in series with the P-gp positive sections. Formalin fixed blocks 
and a sensitive ABC system were then tried. Figures 5.8a and 5.8b show dendritic 
cells stained for S-100, with identical morphology to the P-gp positive cells. These 
cells are distributed diffusely throughout the BMD sample. The S-100 stained cells 
are extremely common in this section, more than those identified on the frozen 
section (data not shown). Unfortunately, the S-100 staining was performed on a 
paraffin block and not on an adjacent frozen section to the C219 staining, so it was 
not possible to rule out that this disparity in frequency was merely the result of using 
different blocks. The KEB sample gave background problems and could not be 
interpreted.
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Figure 5.8 S-100 positive dendritic cells within lymphomatous node
The pre-chemotherapy sample from "BMD" was examined fo r  S-100 using a Dako 
anti S-100 polyclonal sera and an ABC-peroxidase system on paraffin fixed sections. 
This was performed by members o f the Department o f Pathology at the Royal 
Infirmary.
5.8a "BMD" (x40) {Top)
5.8b "BMD" (xlOO) {Bottom)
Without performing dual staining with S-100 and P-gp simultaneously, it is 
not possible to categorically state that the two monoclonals are identifying the same 
population or that P-gp is only present in a subset of S-100 positive cells. However 
the preponderance of both P-gp positive dendritic cells and S-100 positive dendritic 
cells within the same tumour is highly suggestive that they are the same population. 
Both C219 and the S-100 antibodies stain cytoplasmic components and so dual 
staining would be technically difficult. Unfortunately, due to time and resources 
constraints, it was not possible to extend this work to include S-100 staining of other 
tumours. It would have been very interesting to look at the distribution of the S-100 
cells in normal lymph nodes and in the T cell tumours.
5.4.4 (iii) Do the dendritic cells express m drll
C219 positivity does not prove that the canine dendritic cells possess mdrl. 
However, as discussed above, macrophage like-cells in human lymph nodes have 
been identified with mdrl specific monoclonal antibodies and hence from cross- 
species comparison, it is not unlikely that the dog cells also express the mdrl isoform. 
Unfortunately, the dotblot hybridisation results are not useful in confirming mdrl 
expression. Most lymph nodes (the majority of which contain P-gp positive dendritic 
cells and endothelium) give a signal below that of KB8.5 in a similar range to KB3.1. 
The relative paucity of the P-gp positive dendritic cells in comparison to the 
lymphocyte population in most of these tumours is such that, if the lymphoma cells 
were P-gp negative, it would be unlikely that the dendritic cell population would be 
able to produce an mdrl signal as high as KB8.5.
The two tumours with numerous dendritic cells (BMD and KEB) had positive 
tumour cells both before epirubicin and at relapse. Despite the frequency of the 
dendritic cells in these two tumours, lymphoma cells still greatly outnumbered the 
dendritic cells and made up the bulk of the tumour. The BMD samples gave a signal 
greater than KB8.5 both before and after chemotherapy but curiously the KEB 
samples gave a signal similar to the other lymphomatous nodes ie. negative.
Several interpretations can be made of the KEB result. The first would be that 
there was a technical problem with the dotblot hybridisation such that KEB yielded a 
false negative. The second (relapse) sample from KEB was collected over twelve 
hours after death and hence the RNA was very poor quality. From the controlled 
RNAase experiment (described in section 5.1), degraded RNA may be expected to 
yield a falsely increased signal. However, the degradation in this clinical sample may 
have gone beyond that of the experiment and be adversely affecting the hybridisation. 
However the repetition of the negative result in the first KEB sample in which the 
RNA quality was excellent would argue against this. The second reason to explain the
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negative hybridisation result could be that the dendritic cells did express mdrl but the 
tumour cells expressed an mdr2 homologue and the dendritic cell mdrl mRNA was 
still not sufficient to boost the entire tumour block to a "significant" signal on the 
hybridisation. The third could be that neither the stromal cells nor the tumour cells 
expressed mdrl.
The human work suggestjjhat accessory cells in lymph nodes do express 
mdrl and for this and other reasons discussed in the final chapter, the second 
alternative ( mdrl positive dendritic cells but mdr2 homologue positive tumour cells) 
is favoured.
5.4.4 DETECTION OF P-GP AND mdr mRNA IN LYMPHOMA CELLS
Sixty-two MLSA cases from GUVC were examined for mdrl mRNA 
expression using the dotblot hybridisation system described earlier in this chapter. 
Forty-four of these cases were also examined by IHC, either before and/or after 
chemotherapy. Both dotblots and IHC was repeated at least twice for each sample.
Positivity in the dotblots was defined as those samples with an mdrllpoly(d)T 
value equal or greater than the KB8.5 value. Samples had to score positive in both 
dotblots to be ranked as positive. Only one sample gave positive on one dotblot and a 
negative on the duplicate ("RMM" pre-chemotherapy sample); the IHC on the same 
sample was consistently negative and so this sample was classed as negative.
Goldstein et al (1989) classified tumour positivity into "low" or "high" 
according to whether the signal was between the values obtained with KB3-1 and 
KB8-5 or greater than KB8-5. On this basis, almost all the tumours would have been 
"low-positive" (illustrated in figure 5.10). This low-positive category was felt to be 
inappropriate for the canine lymphoma samples because the IHC had already 
revealed that the majority of these "low-positive" samples did not express P-gp in 
their tumour cells but did have P-gp in a dendritic cell population and endothelia. The 
problems of RNA degradation potentially increasing the mdrl signal also makes 
interpretation of "low" positives a dubious one.
Figure 5.9 illustrates two duplicate dotblots probed with MDR5A containing 
positive samples from cases BMD, BEH, RMM and CIS. In both dotblots it is 
possible to visually identify the positive samples. However, the degree of positivity 
(i.e. the sample MDR5A:poly(d)T value compared to the KB8-5) was not the same in 
the two dot-blots. For example, in the top panel, the BEH sample in lane 9 gave a 
signal 2.4 fold greater than KB8-5 but in the lower panel the same sample was only 
1.06 fold greater. In general, the clinical samples did not yield values much greater 
than KB8-5. If KB8-5 is given the same arbitrary value of "30" assigned by Goldstein 
et al, (1989) then the most positive sample was the BMD relapse sample which gave
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a value of 86 on one of the dotblots but only 44 on the other. Most of the positive 
samples gave values in the 30 - 50 unit range.
Figure 5.9 Duplicate dot-blots hybridised with MDR5A
Dotblots have identical samples loaded except lanes 18 and 19 are reversed in the 
lower panel.
"pre", pre chem otherapy;"p o st", post chemotherapy
1.KBV-1
2. empty
3. KB8.5
4. BMD pre
5. BMD post
6. CMD pre
7. CMD post
8. BEH pre
9. BEH post
10. KEB pre 
11 KEB post
12. LEB pre
13. KB3-1
14. 3132
15. mouse kidney
16. TIH pre
17. TLH post
18. RMM pre
19. RMM post
20. BRC pre
21. BRC post
22. CIS pre
23. CIS 1st post
24. CIS 2nd post
m d r5 a  DUPLICATES
13
12
24
•  •  •  
•  •  •
•  • 12
13 » •  #  24
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Marie et al (1991) examined the repeatability of dotblot readings. Duplicate 
dotblots of tumour samples were probed with mdr probes and they reported 
correlation coefficients of 0.927. This was calculated by a linear correlation test of 
the test values relative to the positive and negative controls. Despite considerable 
effort to standardise the dotblot procedure, correlation coefficients this high could not 
be achieved in this study.
The value of the MDR5A:poly(d)T ratio was transformed into ’'units” giving 
the KB8.5 signal a value of 30 and KB3.1 a value of 1. A correlation test (Pearsons) 
was performed on the "unit" values. For the samples illustrated in figure 5.9, the 
correlation coefficient was very good at 0.96. However when all the dotblots were 
analysed the correlation fell to only 0.77. The graphic representation of this 
correlation is illustrated in figure 5.10, which shows that the correlation is worst at 
the lower unit range.
Figure 5.10 Correlation between dotblot duplicates
The value of the MDR5A/poly(d)T ratio was converted into ”units" relative to KB8.5 
with an arbitrary value of 30.
90+ * *
Dotblotl-
* *
60+
* *
*
*
30+ * * *
- *2 
- * *2 * * *
- 233* *** * * 
-24488*** 2 *
0+ 86+ * 2*
0 10 20 30 40 50
—Dolblot2
The original Goldstein paper using KB8-5 on dotblots did not give the exact 
densitometric value for the four hundred tumour samples in their study. This group 
divided the tumours into high positive, low positive and negative based on the values 
from a single dotblot. They expressed no concern over the repeatability of their 
results; their blots were reprobed with y actin to standardise for RNA loading but 
remarked that generally loading was even and did not require standardization. The 
reader is then left uncertain as to whether all the densitometric-based results
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presented in the paper have actually been adjusted for loading using the actin probe. 
When remarking on the range of values obtained for certain tumour types (e.g colonic 
tumours gave values ranging from 0 to 90) they ruled out technical artefact as a 
possible source of error based solely on the fact that the test RNA was intact prior to 
blotting.
Unfortunately, despite the use of agarose gels and spectrophotometric 
measurements to quantitate RNA prior to blotting, in this study it was impossible to 
guarantee even loading of samples accurately enough to give comparable readings on 
the densitometer. Visually, samples would appear the same but the laser scanner 
could detect variability which affected the final value generated. The correlation 
coefficient of 0.77 between dotblot readings is an indicator of the technical artefacts 
which could not be removed from the methodology. Figure 5.10 plots the correlation 
between values on duplicate dotblots and illustrates the imperfect correlation, 
especially at lower spectrophotometric readings.
Because of the inherent problems with the dotblots, in effect, the IHC result 
was taken as the genuine representation of the presence of P-gp and the dotblot 
results were used to corroborate the likelihood of this P-gp being an mdrl species. 
This may result in some tumours with P-gp too low to detect by IHC and with a 
dotblot signal between the KB3.1 and KB8.5 being erroneously classed as negative. 
The second sample obtained from "CIS'1 may fall in this category. However, the 
danger of false negatives was felt to be minor compared to the problems that could be 
created in adopting the dotblot readings rather than the IHC as the more accurate 
measure of P-gp/mdrl. Figure 5.11 shows a Northern blot of the pre-chemotherapy 
and relapse samples of case "BEH" probed with MDR5A. By IHC, "BEH" was P-gp 
negative prior to treatment but positive at relapse. Figure 5.11 illustrates that despite 
the problems with dotblots, it is possible to confirm the result by Northern blotting in 
samples with good quality RNA.
Positivity in the IHC was determined over a minimum of two staining session 
in which the morphology and quality of the staining was considered suitable for 
interpretation. Staining quality was determined from normal canine liver sections 
which were stained in parallel with the lymphoma sections. Normal liver was found 
to provide a more dependable and gradeable reactivity to C219 than the KB8-5 cell 
line. The KB cell lines had to be grown on coverslips and at least four coverslips used 
per positive control to allow for problems with cell quality following storage and 
fixation. It was therefore an impractical and expensive control and was abandoned in 
favour of the normal liver sections. The liver sections had the added advantage of 
giving a more accurate representation of the background problems encountered in a 
tissue section which are not seen with cells grown on coverslips.
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Figure 5.11 MDR5A Northern blot with canine lymphoma samples
Left hand side; northern blot hybridised with MDR5A
Right hand side; ethidium bromide stained gel prior to blotting.
1.BEH post chemotherapy
2.BEH pre-chemotherapy
3.KB8.5
4.KB3.1
1 2  3 4
2 8 s '  #  «  
1 8 S  *
If a sample yielded divergent results in two runs, then it was stained a third 
time. Positivity in more than 5% of cells in a section is often used as the cut-off for 
positivity (Dalton et al 1989, Miller et al 1991). This was unnecessary in this study 
because all of the positive samples contained P-gp in over 80% of the cells i.e. 
virtually all the tumour cells in a given block would be positive. An example of a 
positive tumour sample, with virtually all the cells positive, is shown in figure 5.12 (c 
and d).
Other workers emphasize the importance of differentiating cell membrane 
staining from cytoplasmic staining; Chan et al (1990) and Miller et al (1991) both 
exclude cytoplasmic staining from their definition of positive. The previous section 
discussing the presence of P-gp in a dendritic cell population presented some of the 
evidence suggesting that P-gp may not be limited to the cell membrane. In the frozen 
sections prepared from canine lymphomatous nodes and illustrated in figure 5.12, it is 
not possible to differentiate cell membrane versus cytoplasmic staining of the 
lymphocytes. This is not just because of the poor morphological detail of frozen 
sections but also because lymphoma cells have a scanty rim of cytoplasm around a 
large nucleus and therefore membranous staining by an alkaline phosphatase based 
system appears virtually identical to cytoplasmic staining. In the dendritic cells it 
was easy to see that there was a cytoplasmic component to the staining because the
•» *
r* *4
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cells are larger than the lymphocytes and had abundant cytoplasm. Positivity in 
lymphoma cells was therefore by necessity defined as any Fast Red staining in the 
lymphoma membrane and/or cytoplasm which was repeatable in the competitive IHC 
assay on at least two occasions.
Two samples required staining more than twice due to difficulties in 
interpretation; these were SND (figure 5.12 b and c) and CIS (the first relapse 
sample). SND gave a positive result in 2/3 of the samples and was therefore classed 
as positive whereas CIS only stained faindy positive in 1/4 samples and was 
classified as negative. None of the positive samples had an intense P-gp expression. 
The difference between a negative and a positive tumour sample was often quite 
subtle (figure 5.12 a and d). Scoring systems based on the intensity of the staining 
have been adopted for classification of other tumour types (Verrelle et al, 1991). 
Despite the possible merits of this approach (Dalton and Grogan, 1991) the 
uniformity of staining in the lymphomas made it impossible to adopt a scoring 
system. The results are therefore given in the same way as the dotblot results as a 
simple plus or minus.
The results of the dotblots and IHC are given in Tables 5.7 (GUVC cases) and 
table 5.8 (non-GUVC cases). The two samples of unknown status were both negative 
on dotblot and are not shown in the tables. The samples from other veterinary 
institutes were not examined by dot-blot hybridisations.
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Figure 5.12 P-gp positive and negative Iymphomatous nodes.
5.12a "BEH" pre-chemotherapy: tumour cells P-gp negative (x40) 
5.12b "SNB" post-chemotherapy: tumour cells P-gp +/- (x20)
c -  :■ ■ V O
Figure 5.12 (continued)
5.12c "SNB" (repeat staining): tumour cells P-gp positive (x50) 
5.12d "JAW" Relapse : tumour cells P-gp positive (x40)
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Concentrating on the pre-treatment GUVC samples (upper and middle 
portions of table 5.7), P-gp expression in tumour cells at the time of diagnosis was a 
rare occurrence; only 1/33 (3%) pre-chemotherapy samples which were examined by 
IHC were positive on both IHC and dotblot. An additional one sample (KEB) was 
positive on IHC but negative on dotblot. Including the GUVC samples which were 
dotblotted but not examined by IHC, then only 1/51 (1.9%) samples expressed P-gp 
(of mdrl) origin at the time of diagnosis.
The cases from the other institutes yielded similar results; of the 17 pre- 
chemotherapy samples examined, only 3 were positive, equivalent to 17.6%. One of 
the positive samples from NCSU, (sample NC5 in table 5.8) was obtained from a dog 
which subsequently failed the multiple agent induction protocol.
In the post-chemotherapy samples, P-gp expression in the tumour cells was 
more common. A total of 31 GUVC post-chemotherapy cases were examined by 
IHC./0/31 of these samples were P-gp positive but mdrl expression could only be 
confirmed in 7 of these samples by dot-blot hybridisation. One dog (CIS) was 
sampled immediately on relapse and again at euthanasia less than 7 weeks later. The 
first relapse sample was positive by IHC on one out of four staining repetitions 
whereas the sample taken at euthanasia was repeatably positive by IHC. None of the 
four relapse samples from the other institutes were positive.
In table 5.7, three of the samples were not from dogs with clinically resistant 
disease. MMK and BEA both died during first remission from complications arising 
from the chemotherapy. BRC relapsed 44 weeks after induction and was given rescue 
therapy in the form of an increased dose of epirubicin and oral cyclophosphamide. 
The dog responded to this treatment but the owners requested euthanasia because of 
the side effects of the rescue therapy. The lymph nodes were atrophic with no 
histological evidence of tumour ten days after the epirubicin at the time of euthanasia.
If these dogs are excluded, then there were only 28 dogs with clinically 
resistant disease examined by IHC and dotblot. This means 7/28 (25%) dogs had 
evidence of mdrl expression at relapse.
The three cases which gave positive signals on EHC but were negative on 
dotblot shared some common features. All three dogs were unusual in having 
received chemotherapy within one week of sample collection. Normally, when 
tumour progression occurred in the face of continued chemotherapy, at each three 
weekly visit, owners would be offered the option of euthanasia for their pet. If it was 
felt that the clinical condition was so critical that the dog may actually die between 
treatments, then for humanitarian reasons, euthanasia was actively encouraged. Thus 
it was rare for dogs to be treated and then to represent for euthanasia or in a terminal 
condition shortly after chemotherapy.
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KEB was clinically resistant to treatment at time of death but was actually 
killed in a traffic accident only three days after treatment with an augmented dose of 
epirubicin (30mg/m^). There had been no detectable reduction in lymph node size at 
the time of death. TIH was under the care of the referring veterinary surgeon at the 
time of euthanasia and had received vincristine injection 5 days previous. (TIH was 
already completely unresponsive to epirubicin at time of death). BOB received 
vincristine four days before death at GUVC; he had been induced only twelve days 
previous but had not responded.
It is interesting to speculate that the positive IHC but negative dotblot results 
in these three dogs could represent short term induction of an mdr species which does 
not cross react with the MDR5A probe. Chapter 4 provides evidence that the dog 
may possess four mdr genes but only one of these may be recognized by MDR5A. 
All three dogs lacked p chain TCR gene rearrangements and are therefore putative B 
cells. Herweijer et al (1990) and Nooter et al (1990) presented evidence that B cell 
malignancies, but not T cell malignancies, express the human mdr3 gene. This 
provides a precedence for the expression of a non-mdrl gene in a B cell tumour.
Figure 5.7b showed a reactive follicle from case "GEG" which apparently 
had P-gp expression in the reactive follicles: despite this expression in the follicular 
area, this node gave a low signal on dotblot (less than "10" units on duplicate blots) 
and was classed as mdrl negative. This could represent the expression of the canine 
equivalent of the human mdr3 gene in these stimulated B cells. It is also possible that 
the three B cell tumours with positive P-gp on IHC but no mdrl on dotblot are 
expressing mdr3, perhaps related to the chronologic proximity to drug exposure.
However, an alternative explanation for the three dogs results can be offered. 
Due to the unexpected deaths of all three dogs, all of the samples were collected over 
4 hours after death and consequently the RNA quality was not optimal. It was 
impossible to run adequate Northerns to confirm the negativity of these samples. It 
cannot be excluded that these three samples may be false negatives due to the RNA 
degradation.
Legend for Table 5.7 (on next page)
+, positive; -, negative; nd, not done.
, post-chemotherapy samples from dogs in remission
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Table 5.7 P-gp and m drl detection in lymphoma cells
Name Pre chemotherapy 
IHC Dotblot
Post-chemotherapy 
IHC Dotblot
1. CRS nd _
2. MOK nd .
3. LET nd -
4. ROB nd -
5. MMG nd -
6. SMM nd -
7. PAM nd -
8. BRM nd .
9. RMP nd -
10. RIC nd -
11. TOB - -
12. GOF nd -
13. MIG - -
14. SAO nd -
15. DHS . .
16. CHP nd -
17. SAD nd .
18. TTT nd -
19. SAC . -
20. MAK -
21. BIP - .
22. BEM .
23. KEH .
24. LEB
25. TRC . .
26. CIP . .
27. HEH .
28. KMD nd .
29. BRP - -
30. JAW nd + +
31. HOG nd . . -
32. PES . -
33. RMI . . . -
34. BOA - - *
35. CIS . . . •
(2nd relapse) + +
36. LAQ - - . -
37. RMC _ -
38. TIH . + -
39. ZAK . . -
40. CMD . _ -
41. BEH* . - + +
42. BRC . . . -
43. KEB * + . + .
44. MMK . . -
45. BOS . . . -
46. SPC . . nd
47. BMI1 + + + +
48. BEA - . . -
49. SMD . _
50. SAS - . . -
51. RMM - - + +
52. SNB + +
53. BMC _ -
54. LOK _
55. TAB - -
56. BOB + .
57. SAB + +
58. THH - -
59. SAP . -
60. ZAS - -
Total 2/33 1/51 10/32 7/31
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Table 5.8 P-gp in lymphoma cells (IHC only) in non-GUVC cases
Name Pre-chemotherapy Name Pre-chemotherapy
NCI _ NC9 _
NC2 - NC10 +
NC3 - NC11 -
NC4 - NC12 -
NC5 + NC13 -
NC6 - NC14 -
NC7 - NC15 -
NC8 - NC16 -
CU1 +
%Post chemotherapy
NC17 _ NC18 _
CU2 - CU3 -
Protocols consisted of multiple agent protocols containing MDR and non MDR 
drugs. NC, North Carolina State University; CU Cambridge University
The results presented here are broadly in agreement with the published work 
with human NHL. The largest study of NHL (Miller et al, 1991) found expression at 
time of diagnosis in only 1 out of 39 tumours (2.5%) by IHC. In table 1.12, the 
overall incidence of P-gp at time of diagnosis was less than 10%. In the GUVC 
canine samples examined by IHC at diagnosis, only 1/31 samples contained P-gp 
positive tumour cells and of the foreign cases, 3/17 were P-gp positive which is an 
overall incidence of 4/48 (8.3%). Thus the dog seems to mirror human NHL with a 
low incidence of P-gp at time of presentation.
In clinically resistant NHL, the incidence of P-gp is higher. Miller found 5/9 
tumours (55%) were P-gp positive. However, Schlaifer et al, (1990) failed to detect 
P-gp positive tumour cells in fifteen resistant tumours. It is difficult to say whether 
this discrepancy between the Miller and Schlaifer results is due to differences in the 
sensitivity of the EHC or merely natural biological variation due to the small number 
of samples studied. All of the relapse patients in both studies were clinically resistant 
to combination chemotherapy protocols containing vincristine and doxorubicin plus 
other non-MDR drugs; the variety of chemotherapy protocols used prior to sample 
collection excludes the ability to determine the effect of protocol on subsequent P-gp 
expression in human NHL. The compilation of P-gp expression results in human 
NHL (table 1.12) gives an overall frequency of P-gp in relapse samples of about 50%.
The frequency of P-gp in these drug resistant dogs is somewhat lower than 
humans at 25%. It would therefore appear that in canine lymphomas, the acquisition
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of P-gp is not a major cause of treatment failure but it may contribute to the drug 
resistance of approximately one quarter of the tumours.
5.5 SUMMARY
Lymphomatous nodes from dogs before treatment and at time of clinical 
resistance to epirubicin were examined for P-gp expression using an 
immunohistochemical technique and dotblot hybridisation for mdrl mRNA.
The IHC was a sensitive technique based on its ability to stain the KB8-5 cell 
line. The mdrl mRNA signal from KB8-5 was used as the cut-off for positivity in the 
dotblot technique. Two canine cell lines (a B cell line and a putative T cell line) were 
negative for P-gp on both IHC and dotblot. Neither cell line showed evidence of mdrl 
induction following short term exposure to epirubicin.
The IHC revealed that normal, reactive and lymphomatous nodes contained a 
dendritic cell population which gave a granular cytoplasmic staining with the C219 
monoclonal. The morphology and localisation of these cells within normal and 
reactive nodes suggested that these cells may be antigen presenting cells. One sample 
which contained numerous dendritic cells also contained numerous S-100 positive 
cells which supports the hypothesis that the P-gp positive dendritic cells may have 
some form of antigen presentation function.
P-gp in lymphoma cells was rare at time of diagnosis: only one out of thirty- 
three samples (3%) examined by both dot-blot and IHC were positive. Of the 
seventeen pre-chemotherapy samples from dogs referred to other veterinary colleges, 
only three were positive on IHC (17.6%). The frequency of P-gp in the tumours from 
clinically resistant dogs was greater: seven out of the twenty-eight (25%) clinically 
resistant tumours studied by IHC were also positive on dot-blot. Four of these seven 
dogs were known to have converted from P-gp negative to P-gp positive during the 
course of their disease.
Three B cell tumours were positive on IHC but negative on dot-blot. A 
reactive node was identified which showed C219 staining in B cell areas but was 
negative on dotblot. It is not clear if this represents a subpopulation of B cells which 
express an mdr species not recognised by the MDR5A probe (perhaps as a result of 
drug induction or stimulation) or if it is an artefact resulting from the use of degraded 
RNA in the dotblot hybridisation.
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It has been feasible to positively identify canine B cell lymphomas for over a 
decade using anti-immunoglobulin reagents (see section 1.2.3). Unfortunately, it has 
not been so easy to positively identify phenotypic T cells because of the paucity of 
suitable monoclonal antibodies and because of unexpected (and perhaps spurious) 
reactivity of some of these putative T cell antibodies with Ig expressing cells.
It is accepted that overall, in canine lymphomas, phenotypic T cells perform 
poorly compared to B cell tumours (Greenlee et al, 1990) and one possible 
explanation for this could be that T cell tumours constitutively express, or acquire P- 
gp. In an effort to positively identify the T cell tumours within the lymphoma series, 
genotyping was attempted.
Four T cell genes exist; a, p, y and 8. Because of the hierarchical 
rearrangement of the TCR genes, a  and p genes are less likely to be rearranged in B 
cells neoplasms. The a  locus is particularly large and without the use of multiple J 
region probes is not easily screened for rearrangements. Consequently, the P chain 
was selected as the most suitable indicator gene for T cell genotyping.
6.1 DETECTION OF A TCR GENE REARRANGEMENT IN A CANINE 
CELL LINE
Genotyping canine MLSA samples was performed by Southern hybridisation 
analysis using a feline TCR p constant region probe described in section 2.1.9. 
Figure 6.1 shows the TCR P locus with the position of the feline probe.
Figure 6.1 TCR p chain locus showing position of feline probe
°B1 J B2 dB1 J B2
m m
< -2 .5  kb
felmefeline
probe
The four constant region exons are shown as filled areas.
The canine TCR p locus is not mapped and consequently prior to starting this 
study there was no information on the most useful digests to use in the assessment of 
TCR gene rearrangements. Fortunately, the acquisition of a putative T cell line (Cl-1) 
from Dr. Tsujimoto allowed initial experiments to be carried out comparing the 
restriction fragment patterns of ten different restriction enzymes obtained from 
normal dog germline, 3132 (a canine B cell lymphoma line) and CL-1. Results are
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shown in figures 6.2 and 6.3. In each digest (except Pvu  II) CL-1 has a different 
pattern from normal dog and 3132.
Figure 6.2 Determining suitable restriction enzymes for TCR p chain locus in 
canine.
Three canine samples were digested with five restriction enzymes.
Each triplicate is: 1. canine liver 2. 3132 3. CL-1
Lanes 1-3 EcoRl 
Lanes 4-6 Hind III 
Lanes 7-9 BamHl 
Lanes 10-12 Pvu II 
Lanes 13-15 K p n l
*  Q  +  *
2 3 4 5 6  7 8  9  10 11 12 13 14 15
36 - 
21 -  
14 -
10.6 -
6.2
4.7
3.6
2.6 *
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Figure 6.3 Determining suitable restriction enzymes for TCR (3 chain in canine.
Two canine samples were digested with five restriction enzymes. 
Each triplicate is: 1. canine liver 2. CL-1 3. empty
Lanes 1-2 Sstl 
Lanes 4-5 Bgl II 
Lanes 7-8 Xho I
Lanes 10-11 S m a l 
Lanes 13-14 X b a l
I 2 3 4 5 6 7 8 9  10 11 12 13 14
21 -
10.6 -
6 .2 -
4 . 7 -
2 .6 -
There is almost complete homology between the two (3 constant regions in the 
mouse and humans but relatively poor conservation of the intron sequences. The 
feline probe used in this study is from a virally transduced TCR (3 chain which lacks 
intron sequences (see section 2.1.9). Therefore the expectation would be that this 
390bp probe would detect both constant regions in the dog.
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In figures 6.2 and 6.3,7/10 of the enzymes detect two fragments in the normal 
germline sample and 3132. The simplest interpretation of this finding would be that 
one of these fragments represents Cgj and the other Cg2- hi each of these seven 
digests CL-1 lacks one of the germline bands. In T cell neoplasias in humans it is not 
uncommon that both alleles have undergone rearrangement and for Cg2 to he used 
(Rabbits et al. 1985). Hence the deletion of one or both C gi regions is expected 
(Minden et al, 1985). Taking this fact into account, the most obvious explanation of 
the complete loss of germline bands in CL-1 would be that these deleted bands 
represent the deleted CBj regions.
The EcoRl digest shown in figure 6.2 and the Xhol digest from figure 6.3 
both yield a single large fragment which would be large enough to span both CB 
regions. (In the feline, EcoRl also generates a single large fragment on hybridisation 
with this probe because there is no EcoRl site between the two Cg regions; Neil et 
al, 1988). EcoRl digested Cl-1 produces two new fragments not evident in the 
germline tissue. To retain consistency with the previous observation that both C g i 
alleles are probably deleted in CL-1, these two new EcoRl fragments could represent 
the clonotypic rearrangement of each allele to Cg2- On this basis, one would also 
expect the Xhol digest to yield two new fragments but only one is visible. Careful 
examination of lane 8 in figure 6.3 suggests there may be hybridisation to very large 
DNA species which is not resolved by routine agarose gels. It may be that the second 
Xhol fragment is lost in these high molecular weight species. There was difficulty 
digesting canine DNA to completion using Xhol and for this quality control reason, 
Xhol digests were not used routinely in the analysis of the canine samples.
The last enzyme which has not been discussed is Pvu II which generates a 
fragment of less than lkb. This is small enough to be contained completely within the 
constant region which would explain why CL-1 has the same fragment size as 3132. 
The strong homology between the two Cg regions means that restriction enzyme sites 
within exons are likely to be identical in the two regions. Hence the Pvu II fragment 
could represent the superimposition of the two Cg fragments. This digest is 
uniformative.
In figure 6.2 four lanes are marked with stars. These are above the normal 
germline DNA and 3132 lanes digested with Hindlll and BamHl. In these two 
digests, there is discordance between the patterns obtained from the two DNA 
sources. It would seem unlikely that 3132 should have a TCR p gene rearrangement 
that would only show up in two out of ten digests. The more likely explanation would 
be that this discordance is because of RFLP's in the dog population. In support of this 
a personal communication from Prof F Quimby (Cornell University) revealed that his 
group had discovered seven different canine RFLP’s with a BamHl digest and a
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murine constant region probe. When normal dogs expressing different RFLP patterns 
were mated, the DNA of the offspring showed clear inheritance of the RFLP's. 
Further work in support of the RFLP nature of the Hind HI digest pattern is discussed 
later in this chapter.
Phenotyping information on CL-1 (detailed in section 2.1.7) suggested CL-1 
was a pre-T cell and figures 6.2 and 6.3 confirm that Cl-1 has a T cell genotype. A 
mature T cell would express a surface TCR heterodimer; 1.3kb TCR (3 mRNA would 
be detectable in these cells. Partial rearrangements, characterized by D-J joining 
without variable region joining, can result in the production of truncated mRNA of 
lkb. However Northern analysis of CL-1 does not detect any TCR P message (fig 
6.4). This is consistent with CL-1 displaying an immature T cell phenotype. The lack 
of TCR mRNA could mean that both alleles have aberrant rearranged in a manner 
that does not permit mRNA production. Confirmation of this would require cloning 
and sequencing of the two alleles which was beyond the remit of this thesis.
Figure 6.4 Northern blot of putative canine T cell line hybridised with feline 
TCRg probe.
Ethidium stained gel prior to blotting is shown on right.
1. 3132 2. Cl-1 3. 3201 (feline T cell line)
1 2  3
origin-
28S-
18S
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6.2 MAPPING THE CANINE TCR LOCUS
From the information obtained from figures 6.2 and 6.3, EcoRl, Kpnl, Xbal 
and Hind III digests were selected for use in the clinical samples. Mapping of the 
restriction fragment sites of these four enzymes was carried out using double digests 
(figure 6.5). Working on the assumption that the fragment deleted in CL-1 represents 
the upstream CBj region it is possible to orientate the Hind III, Kpnl and Xbal 
fragments as shown in figure 6.6. The exact positions of these fragments relative to 
each other and to the TCR locus is not known and hence figure 6.6 is an 
approximation based on the available information. Lanes 5 & 6 of figure 6.5 illustrate 
that the Hind III and Kpnl digests are unchanged by digestion with EcoRl revealing 
that the Hind III and Kpnl restriction sites are contained within the large EcoRl 
fragment. The larger (C32) Xbal fragment disappears on digestion with EcoRl (lane 
8) but a fragment approximately 2kb shorter is generated. This allows one to 
conclude that the 3' Xbal site is downstream to the 3' EcoRl site. The XbalfHindlll 
double digest (lane 10) yields the normal Hind III pattern placing each Hind III site 
internal to the Xbal sites. The Kpnl/HindHI digest (lane 7) produces fragments 
shorter than Hind III alone. The constraints imposed by keeping the Kpnl fragments 
within the span of the Ecorl fragment produces the relative position shown in figure 
6.3. The KpnI/Xbal double digest (lane 9) leaves the C32 Kprd fragment unchanged 
but the C31 fragment is reduced below the length of the normal Xbal fragment, this 
places the 3' Kprd site upstream of the 3Xbal site.
Figure 6.6 uses the murine P chain locus as its template. The general 
homology between the murine and human locus in this region validates the use of the 
murine locus as a model for the canine locus (Toyonaga et al, 1985 and Gascoigne et 
al, 1984). The canine locus is likely to resemble the human & murine loci in terms of 
the approximate position and extent of its J regions i.e. the J regions are likely to be 
approximately 2.5kb upstream of the C regions and span 1.5 - 2kb. If this is indeed 
the case then several predictions can be made regards the use of these digests in 
detecting gene rearrangements in the MLS A samples.
Predictipn?;-
EcoRl: fragment spans both J regions and should therefore pick up clonotypic 
rearrangements to both C31 and C32.
Xbal: the C31 fragment does not extend into J31 and hence will be uniformative of 
C31 rearrangements. The C32 fragment is likely to span all of J32 and should pick 
up most C3 2  rearrangements.
Kpnl: the C31 fragment extends into J31 and should detect C31 rearrangements. 
The C32 fragment is likely to extend into the 3' end of J32 but may not span all of
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Jg2» this will depend on the exact extent of the J region in the dog. This detail cannot 
be fully determined without cloning and sequencing in the region.
H ind  Id : neither of the fragments extend into J regions and therefore it is unlikely 
that clonotypic fragments will be generated. However the C g j fragment, like the 
Cg i fragments of the Kpnl and Xbal digests can be monitored for loss o f intensity 
due to loss of one C gj allele, or, as in the case of CL-1, for deletion o f both alleles.
Figure 6.5 Mapping canine TCRg locus using double restriction enzyme digests.
This, and all subsequent figures in this chapter are Southern blots o f canine DNA 
hybridised with the feline TCR (3 constant region probe using methodology detailed in
2.4.1 and 2.4.6. All lanes in this figure contain 3132 DNA.
1. Xba I 6. Kpn I plus EcoRl
2. Hind III 7. Hind III plus Kpn I
3. K p n l  8. X b a l plus EcoRl
4. EcoRl 9. Xba I plus Kpn I
5. Hind III plus EcoRl 10. Xba I plus Hind III
1 2 3 4 5 6 7 8 9  10
36 - 
21 -
14 -
10.fr
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Figure 6.6 Approximate map of the canine TCR p gene
CB1
7 kb-
feline
probefelineprobe
Hind III 5 kbHindlll 2.8 kb
Xba 4.5 kb Xba 12kb
Kpn 6.5 kbK p n  11 kb
EcoRl 22 kb
6.3 DETECTION OF TCR GENE REARRANGEMENTS IN CLINICAL 
SAMPLES
6.3.1 HIND IE RESTRICTION FRAGMENT LENGTH POLYMORPHISM IN THE 
DOG.
The frequency of RFLP for the four chosen digests in the outbred dog 
population was unknown. Wherever possible, tumour samples were run in parallel 
with germline tissue samples from the dog. For those tumour samples which are 
matched with normal DNA from the same dog, RFLP's are easily identified and 
misinterpretation is avoided. However approximately half of the MLSA samples 
analysed could not be matched to germline tissue and in this group, RFLP's could 
present an interpretative dilemma.
To establish the likelihood of RFLP's being a problem in any of the four 
digests, PBL DNA was collected from 18 normal dogs. The results of the EcoRl and 
Hind ID digests are shown in figure 6.7. In the eighteen dogs, no RFLP were detected 
in EcoRl, Kpnl or Xbal digested DNA. In addition to these 18 dogs, germline tissue 
from a further 26 dogs (23 of them MLSA patients) was analysed for RFLP’s. None 
were found, suggesting that RFLP's at the EcoRl, Kpnl and Xbal loci are relatively 
rare.
However, in the Hind in digested DNA, two out of the eighteen dogs (lanes 
14 & 18) have an extra band immediately below the upper band as indicated by an
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arrow. This is in an equivalent position to the band in the Hind III digested germline 
sample in fig 6.2. The germline sample in Fig 6.2 was obtained from a Boxer dog 
whereas the dogs represented in lanes 14 & 18 of figure 6.7 were cross-bred dogs of 
indeterminable origin.
During the course of analysing the clinical samples it became apparent that 
the 2 band pattern produced by Hind III digestion of Boxer dog DNA was found in 
other boxers and also in another brachycephalic breed, the Bull Mastiff. Figure 6.10 
illustrates this pattern in the Boxer dog "SAS" and lane 7 of figure 6.12 shows the 
same in the Bull Mastiff "BOA". The 3 band pattern shown by the cross-bred dogs 
was found in 3 other cross-breds (two are shown in figure 6.12) plus two Lhasa 
Apso’s. Lhasa Apso's are extremely short-nosed and are likely to share common 
ancestry to the other brachycephalic breeds. So although inheritance of these 
restriction fragment patterns has not been formally proven, the occurrence in distinct 
breed types is strongly suggestive of heritability. The clinical cases in which Hind in  
RFLP's were found is listed in table 6.1. The Boxer and Bull Mastiffs completely lack 
the 2.8kb Hind III germline fragment and this could be because they are homozygote 
for this RFLP. The crossbred dogs retain the normal pattern but have the "extra" 
RFLP band. Thus these dogs are likely to be heterozygotes.
Table 6.1 Breed Disposition of Hind n i  RFLP
Homozygous * Heterozygous^
Name Breed Name Breed
SAS Boxer 
SPW Boxer 
CMD Bull Mastiff 
BOA Bull Mastiff 
RMD Bull Mastiff 
SMD Bull Mastiff
HEH Lhasa Apso 
BMD Lhasa Apso 
BIP Collie X 
CIS Mongrel 
PES Collie X 
SAP M.Schnauzer
1. Homozygosity is based on the complete absence of the lower (2.8kb) Hind III 
band.
2. Heterozygosity is based on the retention o f the 2.8kb Hind III band.
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6.3.2 TCR GENE REARRANGEMENTS IN MLSA
The remainder of this section describes in detail selected cases which exhibit 
TCR gene rearrangements. In the majority of these cases the EcoRl, Kpnl and Hind 
IE digests are shown but the Xbal digest is only shown in figure 6.14. Unfortunately, 
despite the initial results with Xbal shown in figure 6.3 (lanes 13 and 14), this 
restriction enzyme did not always yield the same pattern in the same sample. In 
particular it was not uncommon to have two or three bands in the 4 - 6 kb range rather 
than the single band seen in 6.3. For example, the normal DNA run in lane 13 of 
figure 6.3 is the same DNA that was used in lane 1 of the mapping southern in figure 
6.5, yet the latter has an extra fragment at about 5.5kb. In any particular batch of Xbal 
digested samples, all samples digested on the same day would produce identical 
pattern of fragments of 6kb and less. Some of these bands may have been created 
through partial digests; certain enzyme aliquots were particularly problematic in this 
regard. Other workers have also reported difficulty with partial digests using Xbal 
enzyme (Nicol Keith, personal communication; Bremner, 1990). The variation in the 
exact position and relative intensity of these lower bands made it difficult to judge 
which one was the equivalent of the 4.5kb Cg j band illustrated in the schematic map 
of the locus (figure 6.6). It was therefore impossible to use it as an accurate measure 
of C31 loss in the tumours. Fortunately the equivalent information regards the 
presence of one or two copies of the Cg \ region could be obtained from the Hind III 
and Kpnl digests. The larger, 12kb Xbal band remained constant throughout the 
digests but occasionally other bands of higher molecular weight would also be seen. 
The benefit of retaining the Xbal digests in the analysis was that this 12kb fragment, 
which corresponds to the Cg2 region, is estimated to span the entire Jg 2 region and 
should therefore detect most rearrangements involving this region. This proved to be 
the case; all samples which were judged likely to have a Cg2 rearrangement based on 
the other digests did have new bands in the Xbal digest. An example of this is shown 
in figure 6.14.
Figure 6.8 shows the results of genotyping two cases, DHS and ZAK . There 
is loss of the lower (2.8kb) Hind ID band, loss of the upper (llkb) Kpnl band plus 
loss of the single germline EcoRl band and the appearance of two new bands. The 
interpretation of this is therefore the same as for CL-1. The absent Hind ID and Kpnl 
bands represents the deletion of both C gj alleles. The unique rearrangement of both 
alleles, presumed to be to CB2, is represented by the two new EcoRl fragments.
The EcoRl fragments, both germline and rearranged, are large. The germline 
EcoRl fragment comigrates with the 23.7kb marker and it has not been possible to 
get an accurate measurement of its size using conventional gels. Attempts to
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accurately size this fragment on field inversion gel electrophoresis (kindly performed 
by Ms J Rose) failed. The EcoRl rearranged bands are generally above 12kb. This 
makes it difficult to compare between gels to assess whether or not these new bands 
are indeed clonotypic, as would be predicted from the mapping model in the previous 
section. To ascertain if the rearranged EcoRl fragments are unique to an individual 
tumour, three samples, Cl-1, ZAK and LOK were digested with EcoRl and run on a 
low percentage gel (0.6%) for 18 hours. The results are shown in figure 6.9 and 
confirm that the fragments appear to be unique.
Figure 6.8 TCR (3 gene rearrangements: samples "DHS" and "ZAK"
Left hand panel is DHS. Right hand panel is ZAK. Restriction enzymes are indicated 
in photograph. Germline and tumour samples are run in adjacent lanes; tumour 
sample is marked with a "T”.
Hind Pvu Kpn EcoRl Hind Pvu Kpn EcoRl
Figure 6.9 Canine samples digested with EcoRl and separated on low penentage 
gel show unique fragments.
1. canine germline
2. CL-1
3. ZAK
4.LO K GL, germline.
The band at 9.4kb was present in all samples and is presumed to represent cross hybridsation to 
sequences outwith the rearranging TCR P gene.
SM
(kb)
1 2  3 4
2 3 .7- -G.L,
►
► ►
►
*
9 .4 6 -
6 .6 7 -
Figure 6.10 shows the rearrangements in the tumours "SAS" and ’LOK". 
"SAS" has decreased intensity of the germline bands representing the C g j rtgion in 
all three digests. However there still remains a shadow of a band in the EccRl and 
Hind digests which has been interpreted as contamination with normal lymplocytes. 
This interpretation is subjective in nature but is taken based on prior experbnce of 
other cases plus examination of longer autoradiograph exposures of the same liter.
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Figure 6.10 TCR p gene rearrangements: samples "LOK" and "SAS"
Left panel: LOK. Right panel: SAS. Restriction enzymes as indicated in pho.ograph. 
Germline and tumour samples run in adjacent lanes, tumour sample marked with " T".
E c o R l
T
2 3 . 7 -
4 . 2 6 -
Kpn Hind E c o R l
T
Kpn Hind
«?
m
< 1
I
<
%
M  * *
H M -
*
m
"LOK" presents a different pattern. The loss o f the germline fragment in the 
EcoRl digest infers both alleles have attempted rearrangements. However 
examination of the Hind and Kpnl digests to see if there are any deletions of the C g 
regions presents a quandary. There is equivocally reduced intensity o f the lower 
(CBj) Hind III fragment but this is not matched by reduced intensity of the upper 
Kpnl band. In a similar fashion there is a more obvious reduced intensity of the lower 
(CB2 ) fragment of the Kpnl digest in comparison with the upper band yet there is no 
evidence of CB2  deletion in the Hind ID digest. In the Kpnl digest there is a new 
band, marked with an arrow. The approximate map of the canine locus (figure 6.6), 
predicts that both Kpnl fragments may span all or part of the Jg regions and 
therefore could generate new rearranged fragments. This new Kpnl fragment in the 
"LOK" sample could represent a rearrangement to Jg 2  This would explain why the 
intensity of the CB2  germline band is reduced in the Kpnl digest but not the Hind 
digest. Rearranged Kpnl bands have not been seen in other samples but this could be 
because the other cases have used 5' Jg 2  sequences which were outwith the span of 
the Kpnl fragment. Neither the exact location and extent of the canine Jg ;2  region nor 
the exact position of the Kpnl restriction site is known. Placing the 3' erud of the J g 2  
region 2.5kb from C g 2  (equivalent to the mouse locus) would allo-w the Kpnl 
fragment to span the 3’ end of the region and make the explanation o f  the "LOK" 
Kpnl pattern a viable hypothesis.
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The Hind in digest of "LOK" was hybridized with the full length V-D-J-C 
probe and in addition to the expected bands there is a faint band about 14kb in the 
normal sample but a doublet in the tumour sample (indicated by an arrow and a 
question mark). This may represent hybridisation to a rearranging V or J region of 
the canine loci. However the paucity of information on the use of the full length 
probe in canine Hind m  digested samples precludes any firm conclusions.
In the cases discussed so far, the EcoRl digests have consistently shown 
complete loss of the germline fragment plus appearance of two new bands 
interpreted as rearrangements of both alleles. Figure 6.11 shows 7 samples digested 
with EcoRl. Two of them (lanes 3 and 6) maintain the germline pattern . A further 
two (lanes 1 and 4) retain the germline band and have a single new band of equal 
intensity inferring only one allele has attempted rearrangement. However lanes 2, 5 
and 7 do not follow the previously described patterns. Lane 2 (RMI) has lost the 
germline band suggesting both alleles have rearranged yet only one new fragment has 
been created. Complete deletion of C gj is evident in the Hind III digest (figure 6.12, 
lane 2) and Kpnl digests (data not shown), confirming that both alleles have 
rearranged. So why is there only one new EcoRl band? It could be that one allele has 
undergone extensive rearrangements leading to deletion of the entire region including 
both Cg regions. This could explain why, despite what was sufficient loading of 
DNA on the gel (shown in figure 6.13), RMI gives a weaker Hind III signal compared 
to the neighbouring lanes.
Lanes 5 and 7 (SAP and SPW) of fig 6.11 are also problematic due to the 
retention of a faint germline band and the solitary new band. The intensity of the 
germline band does not seem sufficient to represent the remaining allele in the 
tumour cells and it could therefore represent normal tissue contamination. In the case 
of lane 7 "SPW" this is particularly likely because this is actually a cutaneous 
lymphoma case and it is difficult to completely remove normal skin and adnexa from 
these malignant growths. If both alleles have rearranged then one would expect two 
new EcoRl fragments. The other "SPW" digests do not suggest that complete 
deletion of one entire allele has occurred so there remains the question of where the 
missing EcoRl fragment has gone. In lane 7, two large fragments are marked with an 
arrow and a question mark. One of these fragments is above the germline fragment. 
For reasons of its very large size (more than 22kb) the intensity of this band may be 
poor and hence it could be the missing allele. The interpretation of the "SAP" 
rearrangements remains a contentious decision. The other three digests could not 
confirm rearrangements of both alleles. It is therefore classed as uninterpretable in the 
final assessment of p chain rearrangements in the tumour samples.
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Figure 6.11 EcoRl digested lymphoma samples
1. LMG* 4. BRP 7. SPW*
2. RMI 5. SAP ^
3. BRM 6. RMM cutaneous lymphomas
1 2 3 4 5 6 7
Figure 6.13 Ethidium bromide stained gel of figure 6.12 (next page) 
Lane 2 (RMI) is adequately loaded compared to adjacent lanes
2
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The RFLP pattern in lane 7 of fig. 6.12 (of the bull mastiff BOA) is unusual in 
that the upper (Cg2) band is less intense than the lower band. This could represent 
loss of one Cg2 region. Unfortunately this is difficult to confirm this with the other 
restriction digests (fig 6.14). The Kpnl digest is overloaded. However, there does 
appear to be loss of the 4.5kb band in the Xba digest (open arrow) which is suggestive 
of C gi loss. From the EcoRl digest it would seem that whatever rearrangement has 
occurred, one allele remains in germline configuration. In the Xba I  digest, and 
probably the Kpn digest as well, there is a new fragment in the tumour sample not 
present in the normal tissue (filled arrow). The C gi Xbal fragment is not predicted to 
enter the junctional region and therefore the Xbal fragment is more likely to represent 
a J32 rearrangement. However, the new Kpnl fragment could represent either a Jg 1 
or a Jg2 rearrangement (see diagram in fig 6.6). In fact, theoretically, both D g j-Jg i 
and D g2-Jg2 rearrangements can be detected on the same allele provided the 
downstream rearrangement has not proceeded to complete V-D-J joining with loss of 
the intervening sequences. In conclusion, "BOA" has rearranged one allele, probably 
to Dg2~Jg2- There is no unequivocal evidence of C gj loss so this would infer that 
the Jg2 rearrangement is perhaps non-functional, in which case "BOA" may not be a 
phenotypic T cell. However, because of the ambiguity of the Xba /, Kpn I  and Hind 
III digest results, it is not possible to rule out a functional rearrangement to C gi
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Figure 6.14 TCR (3 gene rearrangement: sample BOA.
Restriction enzymes as indicated in photograph. Germline and tumour samples run in 
adjacent lanes, tumour sample marked with "T”.
Open arrow: missing fragment in tumour.
Filled arrow: new fragment in tumour.
EcoRl
Mi
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6.4 DISCUSSION
The compiled results of the southern analysis of 45 cases of MLSA are given 
in table 6.2. In total 10/45 cases had evidence of TCR P chain rearrangements. With 
the available data it is not possible to state if these rearrangements are functional. 
There are no monoclonal antibodies available against the canine TCR complex hence 
it is not possible to look at protein production. Northern analysis for evidence of 
mRNA production is technically possible but could still present interpretative 
problems if there was a significant non-tumour T cell population present in the 
sample block. However Northern analysis was not carried out primarily because of 
time constraints and the availability of adequate quality of RNA in the relevant 
samples.
Table 6.2 TCR P chain rearrangements in MLSA
Germline Matched Samples Unmatched samples
Germline Rearranged Germline Rearranged
LEB SAS TRC RMI
TM BEM SAB SAD
BEH DHS BRM BOA
BRC ZAK TOB LOK
SMD SAC BRP
MMK TAB SAP
BEA HOG
KEH JAW
MAK RMC
BMD BIP
CMD LAQ
BOS CIS
BOB PES
KEB ZAS
CIP MIG
SPC ttt
RMM
THH
HEH
Total 19 Total 4 Total 16 Total 6
The results of the individual digests in the rearranged samples are presented in 
table 6.3. This table illustrates that even in the samples where germline tissue was not 
available, rearrangements were seen in more than one digest. This reduces the 
likelihood of RFLP's being responsible for the non-germline pattern. Five out of the 
ten cases have rearranged both alleles. As discussed in the introduction,
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rearrangement of both alleles in a B cell tumour has not been documented and thus 
even without proof of functional P chain rearrangements, it is highly likely that these 
five samples are genuine T cells.
Table 63  TCR Rearrangement Pattern in Putative T cells
Name Restriction Digest Interpretation
EcoRl Kpn Xba Hind III N o.of alleles 
rearranged1
CB1 7 
deleted^
SAS R L UI L 2 both
BEM R UI nd DI 1 one
RMI R L R L 2 both
SAD R DI R DI 1 one
BOA R R* R DI 1* none
SAP R nd R G 1* none
BRP R UI R DI 1 one
ZAK R L R L 2 both
DHS R L R L 2 both
LOK R R R G/DI* 2 UI
Totals 5/10 2/10 3
1. Rearrangement of both alleles is based on the loss of the germline band in the 
EcoRl digest.
2. Loss ofCBi  region is based on the relative intensity of the bands in the Hind III 
and Kpn digest.
3.2/10 samples retain both copies of Cgj .
R - rearranged, L- rearranged with complete loss of one band 
DI - decreased intensity of one band relative to the other 
y i  - uninterpretable G - germline 
interpretative problem discussed in text.
The majority of the remaining samples, despite having rearrangement on only 
one allele are also likely to be T cells because, as is shown in table 1.3, the incidence 
of p chain rearrangements in mature B cell malignancies such as NHL is low (6.9%). 
If the canine lymphoid malignancies are similar to human malignancies then one 
might expect that, at most, one of the five cases with a single allele rearrangement to 
be a misidentified B cell.
If there is a bigenotypic B cell tumour within this group of dogs with only 
single allele rearrangements, then two cases can be suggested as likely candidates. 
The first is "BOA", whose pattern could be interpreted as an incomplete 
rearrangement on one allele. The second candidate is ’’SAP". This sample was 
obtained from a referring veterinary surgeon at a late date and did not have a 
matching germline sample. It was not screened with all four enzymes, Kpnl was 
omitted. There was no loss of Cg i evident on the Hind III digest. Neither the EcoRl
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(figure 6.11) nor the Xbal digest (data not shown) produced patterns similar to other 
rearrangements. Clinically, this dog had a longer remission and survival than any 
other dog with a T-cell genotype and was not sick at presentation (see chapter 7) 
which would be consistent with this case being of B cell phenotype.
Confirmation of genotype in these two suspect tumours (and indeed all the 
tumours) could be achieved by screening concurrently for immunoglobulin gene 
rearrangements, preferably both heavy and light chain rearrangements. As discussd in 
section 1.1.4, light chain rearrangements would be the most definitive evidence of B- 
cell genotype. A human heavy chain junctional region probe, pHJi (Erikson et al, 
1982), murine kappa constant region probe, pHBC]£, (Lewis et al, 1982) and a 
murine heavy chain junctional probe, J l l ,  (Marcu et al, 1980) were all used for this 
purpose. Unfortunately, none of them hybridised adequately to canine DNA and so 
this part of the work could not be completed.
6.5 SUMMARY
TCR p chain rearrangements were detected in 10/45 MLSA samples using 
multiple enzyme digests and a feline constant region probe. The percentage of 
tumours with TCR rearrangements (22%) is in agreement with the phenotyping data 
produced by Greenlee et al (1990).
Five, or possibly six, of the tumours had evidence of rearranging both alleles 
and are therefore highly likely to be phenotypic T cell. Two samples, "BOA" and 
"SAP" did not show evidence of deletion of either C gj regions and had atypical 
rearrangement patterns. One or both may be bigenotypic B cell tumours but due to 
technical problems this could not be confirmed with the use of Ig gene probes.
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7.1 INTRODUCTION
The introductory chapter remarked upon the problems with study size and 
design which has resulted in very few published papers where the significance of P- 
gp is scrutinized by multivariate analysis. In one of the few longitudinal studies 
where P-gp status is analysed in conjunction with other patient and tumour 
characteristics, Chan et al. (1990) determined that P-gp was associated with poor 
prognosis independently of other variables. In haematologic malignancies, this has 
not yet been demonstrated. In the largest NHL study to date (Miller et al, 1991) P-gp 
was only found in one patient at diagnosis which renders subset analysis of P-gp as a 
prognostic variable futile. The incidence of P-gp at relapse (5/9) was statistically 
different but there was no information available on the tumour or patient 
characteristics of these nine patients.
In the present study, the numbers of cases is greater than the Miller (1991) 
study; 62 dogs were analysed for P-gp expression either at diagnosis and /or after 
receiving treatment. 49 of these dogs received chemotherapy, the remaining 13 were 
euthanased at diagnosis. For the majority of the treated dogs, remission duration and 
survival times are available and were entered in a database in conjunction with the P- 
gp status and genotyping information available from this study. Other potentially 
important prognostic factors entered in the database included stage and "B" 
symptoms, hypercalcaemia, and administration of oral steroids prior to chemotherapy 
induction.
Histopathological classification of canine MLSA has not been particularly 
successful as a prognostic tool (see section 1.2) but more recent papers using Kiel and 
Working Formulation schemes identified certain high grade tumour types as having a 
slightly better prognosis than other grades (Greenlee et al, 1990; Hahn et al. 1992). 
Hahn et al, (1992) identified immunoblastic tumours as having better first remission 
duration than other tumour types but overall survival was unaffected and there was no 
difference in performance between intermediate and high grade tumours. (Using the 
NCI Working Formulation there was only one low grade tumour in Hahn's survey 
which represented 3% of the population). Despite the poor correlation between 
histopathology and performance in canine MLSA, it had been hoped to obtain 
histopathological classification of the cases involved in this study. Unfortunately, this 
proved to be technically difficult; based on the Kiel classification, differentiating 
cleaved and non-cleaved populations was not straightforward. Forty-nine of the sixty- 
two cases in this study were classified but when ten of these tumours were 
reexamined, the pathologist reclassified all of them to a different subtype. This degree 
of discordance was felt to be unacceptable so the available histopathological 
information was excluded from this statistical analysis.
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The database was used to identify important prognostic factors in this group 
of dogs using univariate and multivariate analysis. Table 7.1 shows the information 
recorded for each of the dogs. The method of defining the entries is described in 
section 7.2.
7.2 DEFINITIONS OF PATIENT PARAMETERS 
Time to Treatment Failure
Time to treatment failure (Ti b) is the period of complete remission until time 
of relapse or death from any cause. Complete remission was defined as the absence of 
clinical signs of disease and where appropriate, resolution of leukaemia. Duration 
was calculated from date of induction until the first entry in the medical record 
indicating the dog had one or more enlarged lymph nodes detected either clinically or 
radiographically. Times were calculated to the nearest whole week. For the purpose 
of the database, dogs were divided into complete versus no response. A partial 
response category was not created because lymph node sizes on a weekly basis were 
not accurately measured hence the margin of error between partial and no response 
would be too subjective. Those dogs with a TTF of 0 therefore represents a mixture 
of partial and no responses.
Survival
Survival times (SURV) were calculated from date of induction until date of 
death, again adjusted to the nearest whole week. Not all dogs died at GUVC; date of 
death was found from the referring veterinary surgeon or owner where necessary. 
Natural death versus euthanasia were not differentiated nor was death from causes 
other than tumour progression.
Table 7.1a Patient and tumour data (untreated cases)
Abbreviations: M, male; F, female; MN, male neuter; FN, female neuter; Y, yes; n, 
no; uk, unknown; nd, not done.
Case Sex Stage A /B Hyper Steroid Geno
Signs calcaemia pre-tx type
PAM M IV B n n nd
MIG F IV B n n B
LEB M IV A n n B
SMM M III A n n nd
BEM M N IV B Y n T
HEH M IV B n n B
DHS M N IV B n n T
TOB M III A n n B
CRS F III A n n nd
M M G F IV B n n nd
SAC M IV B n n B
TIT FN IV B n n B
107 M uk uk uk uk nd
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Table 7.1b Patient and tumour data (treated cases)
CASE TTF SLTRV SEX Stage A / B Hyper Steroid JS Epi Geno PGP
signs calcaemia pre-tx Case Chemo type
JAW 31 36 44 III B n n n y B pos
KMD 17 22 F uk uk uk uk n y nd nd
MOK 18 27 FN III A n n n y nd nd
LUJ uk 4 M IV B n n n y nd nd
LET uk 8 FN III A n n n y nd nd
ROB 16 uk M III A n n n y nd nd
BRM 44 44 FN III B n n n y B nd
BMC 16 19 FN IV B n n n y nd neg
RMD 8 8 M III A n n n y nd nd
RIC 80 82 M III A n n n y nd nd
HOG 0 18 FN III A n Y n y B neg
PES 0 8 • M III A □ Y n y B neg
GOF 28 uk F III B n Y n y nd nd
RMI 0 9 F III B Y a n y T neg
BOA 12 29 MN III A a Y □ y T neg
SAO uk 33 M III A n n n y nd nd
CHP 21 25 F IV A n c n y nd nd
CIS 11 18 FN III A n n n y B pos
SAD 0 5 M IV B n n u y T nd
LAQ 16 21 M m A n a n y B neg
RMC 8 9 MN m B n Y n y B neg
TIH 18 25 FN hi A u n n y B pos
LOK 8 11 M IV B Y n □ y T neg
MAK 44 66 M m A n n Y y B nd
BRP uk 8 M m B □ a n y T nd
BIP 7 13 MN IV B a n n y B rid
TAB 24 26 F in A n n n y B neg--1
ZAK 7 21 F in A n n n y T neg
CMD 23 35 FN hi A n n Y y B neg
SNB uk 2 M IV B n n n y nd pos
KEH 52 94 FN m A n n Y y B nd
BEH 13 20 M IV B n n Y y B pos
BRC 44 48 M m A n n Y y B ■neg
KEB 0 11 F hi A a Y Y y B neg
MMK 30 30 FN hi A n n Y y B neg
TRC 1 1 M IV A n u Y y B nd
BOS 50 60 M m A n n Y y B neg
SPC 54 64 M hi A n n Y y B neg
BMD 16 17 M IV B a n Y N B pos
BEA 59 59 M ni A n a Y y B neg
SMD 35 50 FN hi A n n Y N B neg
SAS 14 21 F m B Y n Y y T neg
RMM 0 6 M hi A a Y n N B pos
CIP 18 21 FN hi A n Y n N B nd
BOB 0 2 M IV B n n n N B neg
SAB 0 10 M IV A n n n N B pos
THH 8 9 M hi A n n n N B neg
SAP 33 37 FN uk uk uk uk n N T neg
ZAS 28 29 FN uk uk Y uk n N B neg
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Censored information
Some dogs were lost to follow-up or died while in remission; one dog 
remained alive at the time of analysis. To allow for these cases, all TTF and survival 
data was censored according to whether or not the dog relapsed or was alive or dead 
at time of analysis. In order to simplify the table, this censored information is not 
shown in table 7.1 but pertains only to a few dogs which are listed below:- 
Death during first remission:- RMD, BEA, MMK.
Lost to follow-up in first remission:- GOF, ROB.
Alive in second remission at time of analysis: KEH.
Genotyping and P-glycoprotein status
Genotyping was obtained from the 45 cases which were analysed for TCR (3 
chain rearrangements. Dogs which had detectable TCR rearrangements were defined 
as T cell tumours and those without were classed as B cell tumours.
Those dogs which were P-gp positive on both IHC and dotblot were recorded 
as positive in the database. P-gp status (assessed by both IHC and dotblot) was 
available on 33 pre-chemotherapy samples but because only one dog expressed P-gp 
at diagnosis, the pre-chemotherapy values did not yield statistically useful results
(data not shown). Therefore in table 7.1, the P-gp status is referring to samples taken
after treatment.
Hypercalceamia
A calcium concentration above 3mM at any stage of treatment was defined as 
hypercalcaemic.
Stage
Staging was according to the scheme outlined by Squires et al, 1973) which 
has only four stages. Stage III permits splenomegaly whereas stage IV represents 
involvement of any other organ including bone-marrow (table 7.2). Animals were 
retrospectively staged according to the information in the medical records.
Staging was primarily based on the results of survey radiographs, blood cell 
counts and serum biochemistry parameters including calcium and liver enzyme 
concentration. Bone marrow biopsies were not routinely performed. In the absence of 
radiographic signs of organ metastasis or leukaemic blasts in the peripheral blood, 
dogs were classed as stage ID.
Differentiation between "A" and "B" signs was according to clinical signs at 
presentation, medical history from the owner, and serum biochemistry results.
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Table 7.2 Clinical Staging of Canine Lymphoma
Stage Description
I Involvement limited to one lymph node or group of 
nodes in one anatomic region
II Multiple lymph node involvement limited to one side 
of diaphragm
in Generalised involvement but limited to lymphoid 
tissue, i.e nodes, spleen, tonsils, thymus
IV Involvement of non-lymphoid tissue, including viscera, 
bone marrow, central nervous system etc
Clinical signs
A slight systemic signs (mild anorexia, lethargy, fever)
B severe systemic signs; weight loss, vomiting, diarrhoea, 
abnormal clinical chemistries.
Pre-treatment
This category was created to identify those dogs which had received 
corticosteroids preceding referral. Most dogs had received some corticosteroids in the 
weeks preceding referral but only those dogs with evidence of more than ten days of 
oral steroids or repeated injections of corticosteroids were classed as "pre-treated". It 
was not possible to define exact steroid doses from the information available.
Chemotherapy protocol and Clinical management
As mentioned in chapter 5, there were some dogs which did not receive the 
standard epirubicin protocol, either because of clinical contraindications or because 
the entry onto the epirubicin protocol had ceased. These dogs which received 
vincristine plus cyclophospamide instead of epirubicin are identified in the database 
under the column headed "Epi Chemo".
Also recorded are those cases which were managed personally by the author 
(table heading "JS Case") versus those which were managed by other clinicians at 
GUVC.
Missing values
Information on stage and calcaemic status etc. were obtained from the medical 
record. Some records were incomplete or missing (ZAS, KMD) or did not exist 
because the cases were from outwith GUVC (107 and SAP).
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The age and breed of the dogs is available in chapter 5. Age and breed were 
analysed as potential prognostic factors (see below) but were not found to be 
significant and so this information is not shown in table 7.1.
7.3 STATISTICAL ANALYSIS
Statistical analysis of the data was performed under the guidance and 
supervision of Mr. J Paul of the Cancer Research Campaign Clinical Trials office at 
the Beatson Oncology Centre, Glasgow. Analysis used the computer packages Sysstat 
(Inc) Evanston, Illinois and Minitab Data Analysis Software (Version 7.1).
TTF and survival curves were created using the Kaplan-Meier method 
(Kaplan, 1958). The influence of prognostic factors on TTF and survival duration was 
determined using logrank test. Factors showing an association with death or short 
TTF by logrank analysis were selected for inclusion in the multivariate analysis. 
Multivariate analysis used Cox’s Proportional Hazards model (Cox, 1972). A step-up 
procedure was performed where one variable was added at a time until no new 
variable was statistically significant.
The distribution of prognostic factors between different groups of dogs was 
compared using Fisher's Exact test.
7.4 POPULATION CHARACTERISTICS
The distribution of the dogs according to stage and symptoms is shown in 
table 7.4. No dogs presented with disease localised to one side of the diaphragm. As 
would be expected, the incidence of "B" signs in stage IV dogs was higher than in 
stage III dogs, and more dogs with advanced disease and severe clinical signs were 
euthanased at diagnosis.
Table 7.3 Stage at diagnosis of canine lymphoma patients
STAGE TREATED TOTAL
IDA 27 30
IBB 7 7
IVA 3 4
IVB 9 17
Unclassified 3 4
There were 38% more males than females in the study. Exact numbers were 
as follows: 33 males, 3 male neuters, 11 females and 15 female neuters . The mean
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age of the 62 dogs was 6.9 years, the median was 6 years of age. Patient age was 
calculated on a whole year basis; parts of years were discounted.
In the 62 dogs, 6 breeds represented 3 or more of the MLSA cases. These 
were Old English Sheepdog (3 cases), Cavalier King Charles Spaniel (3 cases), 
German Shepherd Dog (4 cases), Bull Mastiff (5 cases), Golden Retriever (6 cases) 
and Labrador Retriever (9 cases).
7.5 OVERALL CLINICAL PERFORMANCE
The mean and median TTF and survivals for all the treated dogs versus those 
dogs which showed a complete response is shown in table 7.4. The complete response 
rate was 82% (36/44). This response rate excludes those dogs with insufficient 
information in the medical records to determine response. Numbers are in weeks.
Table 7.4 Clinical Performance of MLSA dogs
All
Cases
Complete
Responders
Mean TTF 19.5 24
Median TTF 16 18
Range 0-80 1-80
Mean Survival 25 30.8
Median Survival 21 25
Range 1-94 1-94
7.6 UNIVARIATE ANALYSIS OF PROGNOSTIC FACTORS
The treated dogs were stratified according to the factors listed in table 7.5 and 
analysed for differences in remission and survival times by log rank test The 
resultant "p" values are shown in table 7.5.
From the univariate analysis, two factors are identified as affecting both 
remission and survival. Stage IV and management by the GUVC service (as apposed 
to a single clinician) are associated with shorter disease free survival and survival 
overall. T cell tumours and steroid pretreated tumours are both less likely to achieve a 
long first remission. P-gp positive tumours (predominantly detected at relapse) was 
associated with shorter survival but not with short remission. Treatment with the 
alternate vincristine/cyclophosphamide protocol had no apparent influence on 
survival.
Sex did not affect remission times or survival times either when neuters were 
categorised together with entire animals or separately (data not shown for the four
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individual categories). The effect of age on clinical performance was calculated by 
dividing the population into a young and old group. Three different ages were 
selected as the cut-off point; 5, 7 and 9. Stratification at any of the three ages did not 
reveal any effect of age on performance.
Table 7.5 Univariate analysis of prognostic variables
Factor Remission Survival
Hypercalcaemia/
non-hypercalcaemic
0.265 0.424
Stage IV/ 
stage III
0.002 0.00005
"A" signs/ 
"B" signs 0.086 0.004
Steroid pretreatment/ 
no prolonged steroids
0.008 0.068
P-gp positive/ 
P-gp negative
0.171 0.044
T cell genotype/ 
no TCR rearrangement
0.037 0.132
Single clinician (JS)/ 
Multiple clinicians
0.013 0.004
Epirubicin protocol/ 
COP protocol
0.218 0.347
Male or neuter/ 
female or neuter 0.862 0.532
Age see text.
Those numbers in bold are below the p=0.05 level of significance.
7.7 MULTIVARIATE ANALYSIS OF PROGNOSTIC FACTORS.
Those factors which were identified as influencing TTF or survival in the 
univariate analysis were included in the multivariate analysis. The results of a two- 
factor analysis of performance are shown in table 7.6. The table gives the hazard
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functions for each of the variables. The risk ratio represents the increased risk of 
treatment failure (or death) that one particular factor adds to the pre-existant risk; 
values greater than two are considered significant.
Table 7.6 Two factor multivariate analysis.
Factor combination Risk ratio 
Remission Survival
Stage IV 1.941 2.703
"B” signs 0.722 1.380
Stage IV 1.126 2.188
P-gp positive 0.528 0.597
Stage IV 3.197 4.189
Steroid pre treatment 3.179 2.869
Stage IV 2.092 3.377
T cell genotype 2.068 1.702
Stage IV 2.319 3.428
Single clinician (JS) -2.160 -2.518
Numbers in bold are above the designated significance level.
From the two-factor analysis, it is apparent that stage and pretreatment have 
the most profound influence on subsequent TTF and survival. The analysis was then 
"stepped-up" to include a third factor to determine if this would have any influence 
on clinical performance over and above stage and pretreatment status.
Table 7.7 illustrates that no other variable has a statistically significant effect 
on TTF after stage and pretreatment status are taken into account. Survival is further 
influenced by clinician even after allowing for stage and steroid administration; 
management predominantly by a single clinician (JS) had a positive effect on 
performance as indicated by the negative risk values. Stage IV and prior treatment 
with corticosteroids would therefore appear identify a poor prognostic group. The 
Kaplan-Meier curves for TTF durations in the good prognostic group (stage in and 
not steroid treated) versus the poor prognostic group is shown in figure 7.1; the 
difference between the two groups is readily apparent.
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Table 7.7 Three factor multivariate analysis
Factor Combination Risk ratio 
Remission Survival
Stage IV 2.876 3.235
Steroid pretreatment 3.045 3.044
"B" signs -0.004 1.677
Stage IV 1.972 2.712
Steroid pretreatment 3.295 3.028
P-glycoprotein 0.551 0.836
Stage IV 2.962 3.859
Steroid pretreatment 3.127 2.588
T cell genotype 1.729 0.977
Stage IV 2.940 3.830
Steroid pretreatment 2.517 2.281
Clinician-in-charge -1.425 -2.066
Numbers in bold are above the designated significance level.
Figure 7.1 Kaplan-Meier curves of TTF in good and poor prognostic groups.
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7.8 COMPARISON OF P-GP POSITIVE VERSUS -NEGATIVE 
LYMPHOMAS
The low incidence of P-gp at time of diagnosis (only 1/33 positive by IHC) 
means that it is not possible to perform any meaningful statistics to determine the 
prognostic significance of P-gp at time of diagnosis. The incidence of P-gp positive 
tumours was higher in the treated tumours (7/31). If P-gp is assessed in drug-resistant 
tumours (excluding the dogs who died in remission) then 7/28 samples were P-gp 
positive, which is a statistically significant difference in frequency compared to the 
pre-chemotherapy group (p=0.0113). However, by multivariate analysis, the 
acquisition of P-gp did not seem to have any statistically significant effect on 
remission and survival over and above the effects of stage and steroid pre-treatment.
To investigate the apparent clinical insignificance of P-gp in treated tumours, 
the distribution of other prognostic attributes in the P-gp negative and positive 
tumours was examined by Fisher's Exact test.
Table 7.8 Prognostic factors in P-gp positive drug-treated lymphomas
(missing values not shown)
Factor P-gp +ve P-gp -ve "P" value
Stage HI 3 19
Stage IV 4 3 0.038
Steroid pretreatment 6 17
No pretreatment 1 5 1.00
"A" signs 3 16
"B" signs 4 6 0.193
T cell genotype 0 6
B cell genotype 6 17 0.295
Male 6 11
Female 1 13 0.094
Epirubicin protocol 4 19
COP protocol 3 5 0.335
Single clinician 2 9
Multiple clinicians 5 15 1.00
Numbers in bold are below the 0.05 level o f significance
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Table 7.8 shows that P-gp positivity is associated with stage IV tumours but is 
not associated with a particular drug protocol. The association of P-gp expression 
with advanced stage was also apparent in the non-GUVC samples (table 7.9).
Table 7.9 Clinical stage, sex and P-gp status of non-GUVC cases
Stage HI Stage IV Stage V Male Female
P-gp positive 0 1 2 3 0
P-gp negative 7 9 2 8 10
Curiously, males also have a higher incidence of positive tumours (after treatment) 
than females but this is not statistically significant (p=0.094). All three P-gp positive 
dogs from other institutes were also males.
7.9 COMPARISON OF STEROID PRETREATED GROUP VERSUS 
UNTREATED GROUP
Table 7.8 detailing the distribution of prognostic factors in the P-gp positive 
and negative groups shows that pre-treatment with corticosteroids is not associated 
with a greater incidence of P-gp following chemotherapy. The adverse effect that pre- 
treatment with corticosteroids has on the clinical performance of canine lymphomas 
would appear to be independent of stage judging from the multivariate analysis. 
Table 7.10 emphasizes that dogs which have received prolonged corticosteroid 
pretreatment do not present in a more advanced stage, in fact the exact opposite is 
true; pretreated dogs are more likely to be stage III.
Table 7.10 Clinical presentation of steroid treated dogs
(missing values are not shown)
Factor No Steroid Mp" value
pretreatment pretreatment
Stage HI 29 8
Stage IV 21 0 0.041
"A" signs 28 6
"B" signs 22 2 0.449
Numbers in bold represent values below the 0.05 level o f significance
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7.10 CLINICAL PRESENTATION OF T-CELL GENOTYPE
Univariate analysis showed that T-cell genotype lymphomas had a poorer 
complete remission time than dogs lacking TCR gene rearrangements. Even after 
stage was taken into consideration, T-cell genotype had an influence on remission. 
The clinical information from the T cell tumour dogs was analysed in parallel with 
the putative B cell tumours to identify any differences in the prognostic factors 
present at diagnosis in the two populations. The information from the untreated dogs, 
which included two of T cell genotype, was included in this comparison. The 
frequency of attributes in the T cell versus the B cell lymphomas were compared 
using the Fisher Exact test.
Table 7.11 T cell versus B cell presentation
(missing values are not shown)
Factor T cell B cell "p" value
group group
"A" signs 2 23
"B" signs 7 12 0.027
Stage HI 5 23
Stage IV 4 12 0.702
Hypercalcaemic 5 35
Normocalcaemic 4 1 0.004
Steroid pretreatment 8 1
No pretreatment 1 6 1.00
Numbers in bold are below the 0.05 significance level.
From table 7.11 it is apparent that hypercalcaemia is very strongly associated 
with TCR gene rearrangements and that dogs with T cell tumours do not necessarily 
present with advanced stage of disease, but they are often systemically ill at time of 
diagnosis.
7.11 DISCUSSION
This population of MLSA cases showed the expected distribution of stage, 
age and sex. Compared to humans, most dogs present with more advanced disease 
and this is reflected in the complete lack of dogs with stage I or II. The mean age of
6.9 years is comparable with other studies (Calvert and Leifert, 1981; Teske et al. 
1990). A large epidemiological study of lymphoma incidence in the dog detected a 
20% greater incidence in males versus females (Schneider et al, 1983) whereas this
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study had 38% more males than females. However, given the small sample size, this 
variation is not unexpected. Other small studies have had populations with a large 
preponderance of males (Calvert and Leifer, 1981; Carter et al, 1987) or females 
(Gray et al, 1984). Of the breeds which were most common in the series, Labrador 
Retriever and Golden Retriever were the most common. However, given the 
prevalence of this breed in the general population, without performing detailed 
epidemiological analysis of the referral population, it is not possible to assume that 
these dogs have a higher incidence rate. However, even without further 
epidemiological data, five Bull Mastiffs with MLSA would appear to be a greater 
incidence than other breeds and the extremely high incidence of MLSA in certain 
Bull Mastiff families has been previously reported (Onions, 1984). The mean TTF 
and survivals of the Bull Mastiffs or the retriever breeds were not statistically 
different from the other breeds (data not shown) but numbers were insufficient for 
detailed subset analysis.
The overall clinical performance of canine lymphoma patients in this study 
was poor in comparison with published results with some multidrug protocols (Cotter 
et al, 1986; Greenlee et al, 1990). However, the comparison between studies at 
different institutions is difficult for various reasons; staging and data calculations are 
not standardised and some studies do not necessarily contain equivalent populations. 
For instance, some published studies do not contain any dogs with advanced stage 
disease (Gray et al, 1984; Weller et al, 1980) and most do not record the history of 
steroid intake prior to induction. Price et al, (1991) did record steroid intake prior to 
chemotherapy and found that this did reduce remission duration. In the present study, 
20/49 dogs (41%) were either stage IV or had received considerable amounts of 
corticosteroids prior to referral which has decreased the overall efficacy of the 
protocol.
Despite the somewhat disappointing overall TTF and survival figures, the 
results do suggest that epirubicin is considerably less cardiotoxic than doxorubicin 
when both are given by rapid infusion. In this study, two of the epirubicin treated 
dogs (BRM and BEA) died of epirubicin induced cardiomyopathy at cumulative 
doses of over 500mg/m^ and 550mg/m^ respectively. In the single agent 
doxorubicin trial of Postorino et al, (1989) which also used a three weekly schedule, 
3/37 dogs (8%) died of cardiomyopathy at cumulative doses of only 156, 172 and 
271mg/m^. It would therefore appear that it is possible to give a greater cumulative 
dose of epirubicin before cardiac damage is dose limiting. The two cardiomyopathic 
deaths represents 5% of the epirubicin treated dogs and with retrospect it should have 
been possible to have avoided these fatalities with more frequent monitoring of
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cardiac function. One of the dogs, BEA, was phenotypically like a Great Dane and 
was perhaps at increased risk of cardiomyopathy (Postorino et al 1989). From this 
study, it would appear prudent to perform echocardiograms on treated dogs at each 
cumulative 50mg/^ dose from 350mg/m^ onwards.
By univariate analysis, quite a few factors were identified as being associated 
with adverse prognosis. Stage IV and multiple clinicians adversely affected both TTF 
and survival whereas pretreatment with steroids and the T cell genotype appeared to 
only affect attainment of a good remission. The presence of P-gp after drug treatment 
appeared to affect overall survival but not necessarily affect TTF.
As discussed in the introductory chapter, staging in both human and canine 
lymphomas has not been universally useful in identifying a poor prognostic group. 
The three studies which were cited as failing to show a difference between TTF and 
stage all used a five stage system (Carter et al, 1987; MacEwan et al. 1987; Greenlee 
et al, 1990) whereas the two studies which did detect a better prognosis for stage III 
dogs used the simpler four stage system described earlier in this chapter (Squires et al 
1973; Cotter et al. 1983). The difference between stage III and stage IV in the four 
stage system differentiates tumours which are still contained within the 
lymphoreticular system (i.e. including spleen) from those which have disseminated to 
other organs. The five stage system attempts to differentiate those dogs with splenic 
and/or hepatic involvement from those with other organ involvement. This does not 
necessarily make biological sense and judging from the results of statistical analysis 
is not particularly useful.
A second pertinent point to be made about the ability of staging to predict 
clinical performance in this study was that it was performed almost exclusively 
without the use of bone marrow biopsies. Severe neutropenia or anaemia 
automatically classed a dog as stage IV without the need for a bone marrow aspirate 
to confirm tumour cells in the bone marrow. Because of variations in tumour 
dissemination within bone marrow, aspirates are less sensitive than core biopsies in 
detecting tumour spread (Raskin and Krehbiel, 1989). Therefore, unless every case is 
going to be given a core biopsy, it would seem more sensible to base staging on 
peripheral blood counts than on aspirates performed in only a few dogs. Inevitably, it 
is the peripheral blood counts that determine the treatment given and not the aspirate 
results. The inaccuracies created in differentiating between stage IV and stage V dogs 
when not all have had bone marrow core biopsies has been remarked on by other 
workers (Price et al, 1991) and they avoided this interpretative problem by analysing 
stage IV and Stage V dogs as a single group in comparison to stage III. By doing this, 
they determined that stage IV/V dogs performed worse than stage III dogs. This lends
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further support to the view that attempting to differentiate the magnitude of tumour 
spread outwith the lymphoreticular system is not merited as a prognostic exercise.
The influence of clinician on clinical performance is not entirely unexpected. 
The use of epirubicin as a chemotherapeutic agent for canine lymphoma had not been 
explored at GUVC prior to this study and management of cases by the author did not 
occur until the second and third years of the study. This meant that in effect, many of 
the cases managed by the department in the first year of the study were historical 
controls for the cases managed by the author in subsequent years, once there was 
greater experience with the protocol. The problems created by using historical 
controls in human NHL is discussed elsewhere (Armitage and Cheson, 1988). Figure
7.2 illustrates the difference in performance of the protocol in the first eighteen 
months versus the second half of the study. The cases in figure 7.2 are all stage III 
tumours which lacked TCR gene rearrangements and from dogs which had not been 
pretreated with steroids. The upper panel was managed by GUVC and the lower 
panel by the author.
Management by the author was associated with prolonged survival over and 
above the effects of stage but this is profoundly influenced by the attitude of the 
owners to rescue therapy once their dog had relapsed and probably reflects owner 
commitment more than biological differences in the tumours.
The effect of P-gp on survival but not remission could be construed as 
evidence that once a tumour relapses with P-gp positive disease, the animal quickly 
succumbs to tumour progression due to drug resistance. Unfortunately, due to 
deficiencies in study design, this cannot be stated categorically. For ethical reasons, it 
was not always possible to obtain tumour biopsies immediately relapse was clinically 
apparent. Instead, 14 of the 31 post chemotherapy samples were obtained at 
euthanasia from dogs which had received, and failed rescue therapy. The time from 
relapse to death is usually less than 8 weeks and in that time, complete remissions 
were rare. Only one dog (BRC), which was included in the post-treatment values 
obtained a complete remission following salvage therapy. This dog was still in 
complete remission at time of sample collection and was P-gp negative. All other 
dogs retained residual tumour between onset of relapse and administration of 
intensified chemotherapy. It is therefore likely, but cannot be proven that P-gp existed 
at the onset of relapse even before rescue therapy was given.
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Figure 7.2 Clinical Performance of the Epirubicin treatment protocol
All cases represent dogs which were stage III at presentation, lacked TCR gene 
rearrangements and had no history o f prolonged steroid administration before 
referral.
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The rescue therapy offered to the epirubicin treated dogs could not be 
standardised because it was dependant on the clinical condition of the dog, the 
availability of drugs and the wishes of the owner. Generally dogs were switched from 
the epirubicin protocol to a vincristine and cyclophosphamide containing protocol, 
but a few remained on epirubicin with the addition of oral cyclophosphamide and 
asparaginase. The frequency of tumours with P-gp expression was not statistically
different in those dogs receiving the epirubucin protocol versus a COP based protocol 
from time of induction. Also, the distribution of P-gp positivity in follow-up samples 
collected before or after rescue therapy was virtually equal (4/17 versus 3/14) and is 
illustrated in table 7.12. It would therefore seem unlikely that the exact type of drugs 
used in the salvage protocols would considerably alter the P-gp status in those dogs 
which had failed epirubicin treatment after several months.
Table 7.12 P-gp expression in post chemotherapy samples
No prior rescue therapy 
P-gp -ve P-gp +ve
Prior Rescue therapy 
P-gp -ve P-gp +ve
PES RMI 
BOA LAQ 
RMC LOK 
TAB ZAK 
BEA MMK 
THH ZAS 
BOB
BMD RMM 
SAB SNB
BMC HOG 
CMD BRC 
KEB BOS 
SPC SMD 
SAS SAP 
TM
JAW CIS 
BEH
Cases in italics were in remission at time of sampling.
It has been suggested that underdosing with chemotherapeutic agents may 
hasten the onset of clinical drug resistance (Sobrero and Bertino, 1986). Five of the 
dogs could be identified as chronically receiving epirubicin doses which were below 
the recommended 25mg/m^» and i n s t e a d  w ere in the 18-23mg/m^ range. This 
underdosing was either inadvertent (LAQ, BOA, BRP) or because of gastro-intestinal 
dose-limiting side effects (MAK and BOS). The mean TTF and survival of these dogs 
was a respectable 30.5 and 36.8 weeks respectively and of the three dogs followed up 
while in clinical relapse (LAQ, BOA and BOS) none were P-gp positive. Therefore 
within this small group there was no evidence that a small reduction in dose favoured 
the selection of P-gp expressing tumour cells or impaired clinical outcome. Hahn et al 
(1992) has shown that 3 cycles of doxorubicin with no further chemotherapy is 
equally efficacious as chronic COP; this may indicate that chronic maintenance with 
epirubicin in these dogs is irrelevant to their ultimate clinical performance.
Pretreatment with corticosteroids adversely affected performance but this did 
not appear to be due to P-gp expression in steroid treated tumours. None of the eight 
dogs which received considerable amounts of steroids were P-gp positive at diagnosis 
and only one of the six pre-treated dog (RMM) examined at relapse expressed P-gp.
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In conclusion, prior treatment with corticosteroids does adversely affect prognosis but 
this is not through rapid acquisition of P-gp.
The acquisition of P-gp was associated with tumours which presented in stage 
IV and hence, in multivariate analysis, P-gp was not a prognostic factor over and 
above stage. P-gp was also more common in male than female dogs. From the 
distribution of prognostic factors in the P-gp positive versus negative relapse 
tumours, stage would appear to be the largest influence on subsequent P-gp 
expression more than MDR drug dose (either in the epirubicin protocol or in the COP 
protocol) or steroid pretreatment. The potential significance of these findings arc 
discussed in the final chapter.
One of the aims of this thesis was to determine if the poor prognosis of T cell 
tumours was due to the rapid expression of P-gp. This does not appear to be the case. 
None of the T cell tumours examined either at diagnosis or at relapse expressed P-gp. 
Although only B cell tumours expressed P-gp, the difference in frequency of P-gp 
expression in the genotyped tumours was not statistically different.
The analysis of presentation of T cell genotype dogs versus those dogs lacking 
TCR gene rearrangements is in agreement with the findings of Greenlee et al, (1990) 
who found a strong correlation of T cell phenotype with hypercalcaemia. Greenlee et 
al. (1990) also found that T cell phenotype correlated with a shorter remission and 
survival and secondly that clinical illness was associated with poor survival. The poor 
prognosis of T cell genotype on outcome is less apparent in this study probably 
because there were very few treated T cell lymphomas. This is illustrated in the 
Kaplan-Meier TTF and survival curves of T cell versus B cell tumours shown in 
figure 7.3. These curves were plotted out until only five dogs remained evaluable. 
Eight T cell tumours received treatment but only seven T cell lymphomas could be 
assessed for TTF because of inadequate information in the medical record. The 
remission curve illustrates that there are too few evaluable cases to determine a 
statistical difference between the curves.
It is not possible to fully account for the poor TTF of T cell tumours from the 
factors analysed in this study. The dogs did not present in an advanced stage of 
disease but did commonly present with severe systemic signs. By univariate analysis, 
severe systemic signs influenced overall survival but not TTF and so it would not be 
possible to predict poor TTF in the T cell tumours merely from the presence of "B" 
symptoms. This tendency for T cell tumour dogs to present with less tumour bulk but 
severe illness has been noted by other authors (Appelbaum et al, 1984) and may 
make a valid, simple method for identification of potential T cell tumours, even in the 
absence of hypercalcaemia.
197
Figure 7.3 Kaplan-Meier curves of the clinical performance of 
genotypic T cell versus B cell lymphoma
7.3a Disease free remission curve (top)
7.3b Survival curve (bottom)
B cell tumours were defined as those lacking TCR p chain 
rearrangements.
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7.12 SUMMARY
Advanced stage and corticosteroid pretreatment were found to be the most 
important prognostic factors influencing performance in canine MLSA as determined 
by multivariate analysis. T cell genotype was also associated with a short disease free 
period and dogs which presented with systemic signs of disease had a shorter overall 
survival.
The expression of P-gp at relapse was more prevalent in dogs which presented 
with advanced disease (p=0.038) and hence P-gp as a prognostic factor was not 
independent of stage. The frequency of P-gp expression at relapse was significantly 
different from pre-treatment samples (p=0.0113) but this expression was not overtly 
influenced by the drug protocol administered.
Hypercalcaemia and systemic signs were associated with the T cell genotype. 
The adverse prognosis associated with T cell phenotype and steroid pretreatment was 
not mediated by P-gp.
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CHAPTER 8 
FINAL DISCUSSION
8.1 DOES P-GP PREDICT RESPONSE TO CHEMOTHERAPY, AND IF SO, 
DOES THIS STUDY USE A RELIABLE WAY TO DETECT IT?
8.2 P-GP IN A LYMPHOID TISSUE DENDRITIC CELL POPULATION: 
A MODEL FOR P-GP FUNCTION
8.3 IS MDR DRUG TREATMENT CRITICAL FOR P-GP ACQUISITION 
IN LYMPHOMAS?
8.4 CANINE MLSA AS A MODEL FOR NHL: CLINICAL CONCLUSIONS
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8.1 DOES P-GP PREDICT RESPONSE TO CHEMOTHERAPY, AND IF SO, 
DOES THIS STUDY USE A RELIABLE WAY TO DETECT IT?
Since 'P-gp/mdrl was first characterised there has been controversy over the 
ideal means of detecting its presence in clinical samples (Dalton and Grogan, 1991). 
It is generally accepted that it is important to exclude non-mdrl isoforms when 
attempting to assess P-gp mediated drug resistance. This is particularly crucial when 
working in an unknown biological system such as the dog. The human mdrl specific 
probe MDR5A, under the hybridisation conditions used in this study appeared to 
detect a single RNA species which is presumed to represent the canine mdrl 
homologue. The tissue pattern of expression of the form detected agreed with the 
pattern observed for mdrl in other species. It had been hoped to rule out any 
remaining ambiguity in the mdr mRNA measurement by using a canine specific 
probe obtained by screening a genomic library with the MDR5A probe. 
Unfortunately, a mdrl homologue was not detected in the canine library screened and 
so no canine specific mdrl probes were obtained. . .
With retrospect it may have been simpler to take advantage of the sequencing 
information available to select species conserved primers on either side of the 
divergent tinker region of the mdr and use these to amplify mdr species present in 
canine liver or kidney RNA by reverse transcriptase and per. This would 
automatically select that area of the mdr gene most likely to be isoform specific.
The monoclonal antibody used in this study was not isoform specific and this 
represents the most serious technical deficiency of this study. Most of the lymphoma 
samples which were C219 positive were also positive for mdrl based on dotblots 
analysis. However, three dogs had evidence of P-gp in their lymphoma cells but were 
negative on MDR5A dotblots hybridisation. No mdrl specific monoclonal antibody 
was available for use in these samples to attempt to confirm mdrl P-gp expression. 
The opposite could not be proven either i.e the definite expression of an MDR2 
isoform. A human MDR2 probe was acquired from Herweijer's group in the 
Netherlands but it did not cross-hybridise with canine sequences either on Southern 
or Northern hybridisations so could not help in the investigation of these samples. 
There are no MDR2 specific monoclonals in the human. In the hamster, detection of 
the mdrl homologue is based on the differential reactivity with C219 but not with the 
antibodies against the mdrlalmdrlb isoforms.
Although not available at the time, the hamster mdrl specific monoclonal 
antibody C494 also reacts with human mdrl isoform (Chan et al, 1988) and perhaps 
could cross-react with canine mdrl. This monoclonal is not commercially available 
but probably could be obtained from the originator (Dr. Victor Ling). If the three 
lymphomas and other canine lymphoma samples were to be re-investigated it would
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be worthwhile testing C494 and some of the other monoclonal antibodies which are 
now commercially available for reactivity in the dog. In this way it may be possible 
to build up a panel of reagents suitable for use in canine tissue in an analogous 
manner to Grogan et al (1990).
In the introductory chapter it was suggested that preoccupation with 
improving sensitivity of mRNA detection techniques has at times clouded the fact 
that heterogeneity of expression of P-gp within normal contaminants and within 
tumour cells may invalidate some of the results obtained with bulk techniques. The 
advantage of an IHC technique over slot-blot analysis is well illustrated by this study. 
The dotblots analysis was shown to be quantitatively difficult to reproduce and prone 
to artefactual errors created by the densitometric based readout system. After 
optimisation of the methodology, the IHC was reproducible and more importantly, 
revealed P-gp expression in non-neoplastic cell types. In this way, measuring P-gp by 
IHC rather than mdrl mRNA by dotblots analysis allows direct visualisation of P-gp 
in the tumour cell population as apposed to non-tumour elements, and provides a 
method of determining the extent of P-gp expression within the tumour mass.
Until relatively recently, it has been assumed that the major control of P-gp 
expression in both tumour and normal tissue was at the transcriptional level and 
therefore the mdrl mRNA content of a tumour would accurately mirror the P-gp 
content. Some of the work discussed below casts doubts on the validity of this 
assumption. Regardless of the contribution of post-transcriptional control in 
determining the final P-gp content of a cell, direct detection of the mdr gene protein 
product in IHC bypasses the inaccuracies that could be created by these mechanisms.
The assumption that transcriptional control is of paramount importance in 
controlling P-gp concentration was based primarily on early cell line work. The drug 
selected cell lines which were used in the initial discovery of mdrlP-gp contained 
multiple copies of the mdrl gene but it rapidly became apparent that gene 
amplification did not occur in human tumours (Chabner and Fojo, 1989; Weinstein et 
al, 1990) and so alternative reasons had to be sought for the increased P-gp in some 
of these tumour samples. Drug resistant cell lines which did not contain mdrl 
amplification showed a correlation between mdrl mRNA content and cellular 
resistance to MDR drugs (Shen et al, 1986a). The simplest conclusion at that time 
was that transcriptional control was the major factor influencing tumour P-gp 
expression. This conclusion may still be valid for tumours which arise in tissues 
which do not normally express P-gp in that some event must take place which 
switches on mdrl mRNA transcription. However, in tissues which already have a 
basal expression of P-gp (such as liver or adrenal cortex), post-transcriptional control
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mechanisms may also be relevant and may account for transient increases in P-gp in 
certain in vivo and in vitro situations.
Marino et al (1990) performed nuclear run-on assays on nuclei isolated from 
the livers of rats 4-72 hours after partial hepatectomy. Despite documenting a twenty 
fold increase in mdr mRNA, there was little or no increase in mdr gene transcription 
in the nuclear run-on analyses. They remarked that the 3' non-coding region of the 
mdrl mRNA shares instability sequences which are common to other unstable 
mRNA's and suggested that message stabilisation could account for some of the rise 
in mdr mRNA in these liver nuclei.
In vitro studies of the drug resistant cell lines derived from the macrophage 
cell line J774.2 have also produced evidence for post-transcriptional control of P-gp 
expression. Yang et al (1990) and Hsu et al,(1990) have shown that there may be 
post-transcriptional control of the rhrla isoform which is related to the transcriptional 
initiation site. It was found that those cells with the mRNA which was initiated at the 
downstream site expressed more protein than cell lines with initiation from the 
upstream site.
The relative importance of transcriptional versus post-transcriptional control 
in tumours is undetermined. With a lack of experimental information on this point, it 
would seem prudent to verify actual P-gp expression in a tumour, especially when the 
mRNA content is modest. Another advantage of P-gp rather than mdrl mRNA 
measurement lies in the relative instability of the mdrl mRNA compared to the 
protein. The half life of P-gp has been estimated at between 16 and 24 hours (Cohen 
et al 1990; Mickley et al. 1989) or possibly even longer in some chronically drug 
selected lines (Richert et al, 1988; Yoshimura et al, 1989) whereas the half life of 
mdrl mRNA (which contains instability sequences) may be less than 3 hours in some 
transient responses (Mickley et al. 1989; Chin et al, 1990b). However, the half-life of 
mdrl mRNA may vary according to the mechanism by which it is induced and 
possibly the cell type. Mdrl induced by heat shock in human carcinoma cells has a 
longer apparent half-life than doxorubicin induced mdrl in rodent cells (Chin et al, 
1990a). Mdrl induction by MDR drugs is not a universal phenomenon. Chin et al, 
(1990a) failed to show any induction of mdrl in a panel of human cell lines following 
challenge with a variety of MDR drugs. The two canine cell lines, Cl-1 and 3132, 
were similar to the human cells in their absence of mdrl induction following 
epirubicin exposure.
The rate of degradation of P-gp and mdrl mRNA in tumour cells following 
the death of the host is likely to be even greater than in normal tissue but it could still 
be anticipated that P-gp may be retained intact for a longer period post mortem than 
mdrl mRNA. The in vitro experiments of Chin et al, (1990a) showed that the
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sustained rise in mdrl mRNA following doxorubicin induction in rodent cells 
required new protein synthesis, perhaps a stabilising protein. The authors postulated 
that in the absence of a de novo synthesised stabilising protein, the mdrl mRNA is 
rapidly degraded. It is not unreasonable to suggest that mdrl mRNA degradation post 
mortem (perhaps in the absence of this stabilising protein) may be precipitous in 
comparison with more stable RNA species such as ribosomal RNA. Ribosomal RNA 
is in effect used as a marker for RNA quality on gel electrophoresis and may give a 
false impression of mdrl RNA quality. A rapid fall in mdrl mRNA could account for 
the lack of mdrl in the P-gp positive lymphoma samples discussed in chapter 5.
From this discussion, it would appear that P-gp protein detection is preferable 
to mRNA detection for the reasons outlined above. However, even measuring mdrl 
P-gp by IHC does not guarantee that an active pump is being detected. As long ago as 
1989, it was apparent that colon carcinoma cell lines which showed a transient 25 
fold increase in mdrl mRNA and a similar increase in protein following treatment 
with differentiating agents did not show an MDR phenotype nor did they have 
decreased drug accumulation (Mickley et al, 1989). Similarly, neuroblastoma cell 
lines which were induced to express P-gp with retinoic acid did not necessarily show 
any change in vincaalkaloid accumulation (Bates et al, 1989). The authors postulated 
that this paradox could be due to reduced phosphorylation of P-gp at critical residues 
in these sodium butyrate exposed cell lines.
There is now a growing body of data which shows that P-gp is indeed 
phosphorylated in vitro (Ma et al, 1991; Ganapathi et al, 1991) and that 
phosphorylation is associated with the active form of the protein (Fine et al, 1988; 
Chambers, 1990a). This phosphorylation can be through protein kinase C activity 
(Chambers et al 1990b) but transfection of mutant protein kinase A can also alter 
cellular sensitivity and hence may be implicated in P-gp phosphorylation. Hait and 
Aftab (1992) present a working hypothesis on how chemotherapeutic drugs induce an 
MDR phenotype in P-gp positive cells without altering the actual amounts of P-gp in 
the membrane. This model predicts that amphipathic drugs, such as doxorubicin, can 
increase the breakdown of phosphatidylinositol (to diacylglycerol and inositol 
triphosphate) through the activation of phospholipase C. The increased local 
concentration of diacylglycerol (DAG) leads to the translocation of PKC to the 
membrane where it phosphorylates P-gp. This then improves P-gp drug efflux hence 
the initial stimulator of the cascade (doxorubicin) in the membrane is removed. 
Following DAG metabolism, P-gp can then be dephosphorylated by phosphatases. 
Much of this is still speculative and the evidence is still somewhat contradictory 
regards the importance of PKC relative to other kinases (Hait and DeRosa, 1991).
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The mechanism by which P-gp phosphorylation increases efflux is completely 
unknown.
This model has implications for the interpretation of mdrl/P-gp studies in 
normal tissue and tumour. The mere presence of surface P-gp does not equate with a 
functional drug efflux pump and hence the degree of drug resistance may not exactly 
match the P-gp protein concentration. Also, the resistance to amphipathic drugs could 
feasibly be increased without necessarily increasing mdrl mRNA or protein 
concentration.
The pertinence of the phosphorylation studies to this project are that despite 
the fact that P-gp was primarily detected in MDR drug resistant tumours, it is not 
possible to firmly conclude that the P-gp is functional in these samples. However, 
given that most lymphomas were P-gp negative prior to treatment and drug exposure 
precedes the appearance of P-gp, it is likely that the P-gp is functional as an efflux 
pump. Proving this was not attempted and would not be easy.
It is as yet extremely difficult to prove that P-gp is functioning as an efflux 
pump in clinical material. Other workers have attempted to show P-gp function by 
performing drug accumulation studies on leukaemic cells and determining that 
accumulation can be abrogated by treatment with MDR modulating agents 
(Rothenberg et al, 1989; Dalton et al, 1989; Salmon et al. 1991; Solary et al, 1991). 
However even this is not ideal because modulating agents may have effects on 
cellular drug accumulation and distribution even in the absence of a functional mdrl 
encoded P-gp. For example, Herweijer et al, (1990) and Nooter et al, (1990) showed 
that the drug accumulation in mdr3 expressing leukaemic samples could be increased 
by cyclosporin treatment. This is in contrast to mdr3 expressing transfectant cell lines 
which do not have any demonstrable drug efflux activity (Schinkel et al, 1991). There 
are other examples of MDR drug resistant cell lines and patient tumour cells which 
can be modulated by MDR modulators even in the absence of P-gp and without 
altering the total intracellular accumulation (Larsson and Nygren, 1990; Kavallaris et 
al, 1990; Nygren et a l , 1991; Solary et al, 1991). Thus, because of the pleotropic 
effects of modulating agents (discussed by Twentyman, 1992), decreased drug 
sensitivity or drug accumulation in the presence of a modulator drug does not 
construe P-gp mediated resistance.
The use of in vitro chemosensitivity can be equally confusing; because of the 
presence of other resistance mechanisms, an MDR phenotype does not necessarily 
prove that the in vitro resistance is via a P-gp efflux mechanism (Salmon et al, 1989; 
Marie etal, 1991; Shen etal, 1991).
So unfortunately, there is no easy way of proving in vivo resistance in a P-gp 
positive tumour is actually P-gp mediated. Although the amelioration of resistance
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with modulators cannot be taken as proof of P-gp mediated resistance, it may 
eventually be possible to use monoclonal antibodies against critical residues to more 
specifically block P-gp activity. The perturbations of drug and ATP binding induced 
by the C219/C494/C32 series of monoclonals (Georges et al, 1991) indicates that this 
is probably feasible although these particular monoclonal antibodies require cell 
permeabilisation to work optimally and hence may not be suitable for drug 
accumulation studies.
In summary, at present the optimal method of detecting P-gp mediated 
resistance remains immunohistochemistry using mdrl specific antibodies. This does 
not prove P-gp functionality and the likelihood of P-gp mediated efflux has to be 
judged on the basis of the nature and source of the cell expressing the P-gp.
Using paired samples from lymphomatous nodes before treatment and at 
relapse, it was possible to document acquisition of P-gp in relapse tumours in four 
dogs and in another three drug resistant lymphomas with unknown pre-treatment P-gp 
status. It would seem likely that the P-gp acquired by these lymphomas may well 
contribute to their clinical drug resistance spectrum. Only one dog had documented 
P-gp of mdrl isoform before treatment. This dog responded to a COP protocol 
containing MDR and non-MDR drugs but relapsed with drug refractory disease 
within four months. The three dogs with P-gp, which may not have been mdrl 
isoform, were also drug-refractory to MDR and non-MDR drugs. So it would seem 
that P-gp in canine lymphomas is predictive of poor response to chemotherapy but 
this is usually at the relapse stage when all lymphomas, from clinical experience, are 
only marginally drug responsive. Given that the dogs in relapse (both P-gp positive 
and -negative) failed MDR and non-MDR drug salvage protocols it is unlikely that P- 
gp is the only resistance factor in these lymphomas.
8.2 P-GP IN A LYMPHOID TISSUE DENDRITIC CELL POPULATION: A 
MODEL FOR P-GP FUNCTION
The presence of P-gp in a dendritic cell population in both normal and 
pathologic nodes does not easily fit with current ideas on mdrl efflux of noxious 
hydrophobic substances (Gottesman and Pastan, 1988): these cells are not part of an 
excretory epithelial surface. In chapter 5 it was not proven that the canine 
dendritiform cells expressed mdrl but similar cells have been documented in human 
nodes using mdrl specific antibodies (Miler et al, 1991; Schlaifer et al, 1990a and 
1990b). The localisation of the dendritic cells within normal and reactive canine 
nodes and their morphologic similarities to the S-100 staining cells in one tumour 
sample supports the view that these dendritic cells may be part of the antigen 
presenting cell (APC) population of the lymph node. Why would an APC require an
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efflux pump? In this section, the presence of P-gp in a potential APC will be 
discussed in terms of possible functions of a P-gp in this cell type.
The presence of P-gp in this dendritic cell population of lymph nodes is 
unlikely to have major effects on the drug resistance profile of the lymphoma. It is 
theoretically possible for a sub-population of resistant cells to enable otherwise 
sensitive cells to survive drug exposure through cell-cell communication which 
allows potential resistance factors such as glutathione or drug to move between the 
resistant and sensitive cells (Frankfurt et al, 1991). However, the majority of drug 
resistant tumours did not contain many P-gp positive dendritic cells and so it would 
not seem feasible for the dendritic cells to effectively salvage the vast lymphoma cell 
population. Even in the two examples with numerous dendritic cells, it is not clear 
whether large moieties such as epirubicin could be transferred from a sensitive P-gp 
negative lymphoma cell through a structure such as a gap junction to a P-gp positive 
dendritic cell for efflux to the extracellular space. Lymphoid cells are not a cell type 
which are normally associated with the formation of gap junctions (Pitts et al, 1988). 
Overall, cooperativity between adjacent P-gp positive dendritic cells and P- 
glycoprotein negative lymphoma cells to lower the cytotoxic drug concentration in 
both populations does not seem likely. The presence of numerous dendritic cells in 
the two tumour samples (BMD and KEB) is more likely to represent the co­
proliferation of FDC with B lineage lymphoma cells of germinal centre origin 
(Gerdes and Flad, 1992).
The purpose of this discussion of P-gp in the putative APC of normal and 
lymphomatous nodes is not directed at explaining P-gp mediated drug resistance in 
lymphoma but to use this as a model for exploring the complex biology of P-gp. By 
doing this it will become apparent that there may be common themes underlying the '  
induced and drug selected expression of P-gp in neoplastic cells and normal lymphoid 
cells.
The dendritic cells of the lymph node are specialised cells which present 
antigens which initiate several immune responses including sensitisation of MHC- 
restricted T cells and the formation of T-dependant antibody responses. Dendritic 
cells are motile and can efficiently cluster and activate T cells. Distinct populations 
are recognised in lymph nodes and are often called interdigitating cells (IDC), in the 
T cell areas and follicular dendritic cells (FDC) in the germinal centres. The biology 
of these cells has been reviewed recently (Steinman, 1991).
Both of these cell types may express P-gp. Schlaifer et al (1990b) reported 
that the CD68 monoclonal KP-1 (from Dako) stained a cell population 
morphologically identical to the P-gp positive population. KP-1 is reported to 
recognise IDC in preference to FDC (Dako product sheet) but this distinction is
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unlikely to be absolute. The association of numerous P-gp positive dendritic cells 
with canine B cell tumours would suggest that FDC are P-gp positive. So for the 
purposes of this discussion, IDC and FDC will be considered together as APC. As 
discussed in chapter 5, Schlaifer et al, (1990a and b) and Miller et al, (1991) both 
identified P-gp positive non-lymphoid cells in lymphoma samples with mdrl specific 
monoclonal antibodies and so it would appear that APC may contain the mdrl 
isoform of P-gp. However isoform type was not proven in the dog and so it should 
not be completely excluded that other isoforms could be expressed in these dendritic 
cells.
The pathways of antigen processing is an area of intense interest at present. In 
brief, antigen processing can be divided into two pathways according to whether 
antigen is presented in association with class II (major histocompatibilty ) molecules 
or class I molecules. Peptides derived from intracellular antigens are generally 
presented on the APC surface in conjunction with class I molecules whereas antigenic 
fragments from exogenous antigens are presented with Class II molecules. Some of 
the most recent developments in the molecular models of antigen processing are 
discussed by Monaco (1992).
In class II presentation, antigens are acquired through an endocytotic process 
and are gradually degraded by proteases in the endosomal compartments into small 
peptides which eventually associate with class II molecules (figure 8.1 and reviewed 
by Brodsky and Guagliardi, 1991). The effective processing of antigen requires an 
increasingly acidic endosome environment and can be abrogated by drugs (such as 
chloroquine and ammonium chloride) which raise the pH of intracellular 
compartments. Macrophages and B cells can also present antigen acquired through 
endocytosis via the class II pathway.
Class I presentation is intimately involved with pathways of degradation of 
endogenous proteins in both cytosol and lysosomal compartments. Class I molecules 
are assembled and bind class I peptides in lumenal compartments; this would suggest 
that a mechanism of translocation is required to transport peptides across the 
endoplasmic reticulum or some pre-Golgi compartment. Recently, a group of genes, 
renamed the tap genes, (old and new nomenclature is given in Monaco, 1992) have 
been characterised which are members of the same ABC family as P-gp and the yeast 
peptide transporter STE 6. Transfection of these tap genes into mutant murine cells 
which are defective in peptide transport can restore antigen presentation function. It 
has therefore been proposed that the Tap proteins act as ATP dependant peptide 
transporters feeding antigenic fragments to the class I pathway.
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Figure 8.1 Antigen Presentation Pathways (from Brodsky and Guagliardi, 1991)
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The tap proteins, as members of the ABC superfamily, share homology to P- 
gp. It can be anticipated that homology will be greatest at or around the ATP-binding 
sites. C219 reacts with an epitope close to the ATP binding site of P-gp which is 
highly conserved between P-gp isoforms and between different species. There was 
therefore some concern that C219 could be cross-reacting with a tap gene product in 
these dendritic cells. However, in a manual sequence search performed by the author, 
the tap proteins do not contain the V-x-x-x-x-D motif considered obligatory for C219 
recognition (Georges et al, 1990), but more importantly MRK16 can also recognise 
the P-gp species in human APC so it is unlikely that the C219 reactivity is a cross- 
reaction with tap proteins.
Since peptide transport appears to be crucial for antigen presentation, and P- 
gp is a transporter for many moieties, it could be speculated that P-gp could 
contribute to this APC peptide transport capacity. The site of this transport is likely to 
be in either the endoplasmic reticulum or an early Golgi compartment, both of which 
are compatible with known P-gp intracellular distribution (Willingham et al, 1987).
P-gp would appear capable of peptide transport; MDR cells are often cross-resistant 
to the peptide antibiotics gramicidin D and valinomycin. In certain cell lines the 
relative resistance to these peptides greatly exceeds resistance to other MDR drugs 
(Mirski et al, 1987). For instance, the colchicine resistant cell line CHrC5 is 180 fold 
resistant to colchicine but 5000 fold resistant to gramicidin D perhaps suggestive that 
these peptides are a closer approximation of the natural substrate of the P-gp pump 
(Gerlach et al, 1986b). The fundamental nature of this peptide transporting ability of 
P-gp is illustrated by the fact that expression of human mdrl in yeast will still confer 
resistance to the peptide antibiotic valinomycin (Kuchler and Thomer, 1992). 
However, although P-gp may be capable of effluxing these highly hydrophobic 
peptides, it is probably not feasible that P-gp could be a universal peptide transporter 
for other more hydrophilic peptides. Certainly, the mdrl P-gp was incapable of 
transporting the 12 amino acid lipopeptide yeast mating factor when expressed on the 
yeast surface (Kuchler and Thomer, 1992).
So an alternative role for P-gp in APC could be postulated. In this study, the 
P-gp in the dendritic cells appeared as a coarse granular stain throughout the 
cytoplasm and not confined to a Golgi-like distribution pattern. As described in figure 
8.1, Class II presentation involves protein degradation within acidic compartments 
and an alternate transport system is also postulated for some cytosolic class I peptides 
which involves translocating peptides directly into a pre-lysosomal compartment. It is 
not inconceivable that the granular staining pattern in the canine APC (and in human 
phagocytic cells) could represent localisation in endosomal/lysosomal structures. P- 
gp expressing Ehrlich ascites cells show an increased rate of endocytosis (Sehested et 
al, 1987) suggesting there may be a connection between the MDR phenotype and 
endocytosis is some cell lines.
Endosomes become increasingly acidic as they develop into late 
endosomes/lysosome compartments. The MDR drug daunomycin has been shown to 
localise in organelles in the Golgi region and in lysosomes in drug resistant cells 
(Willingham et al 1986). Keizer et al, (1989) noted that drug sensitive cells retained 
drug in the nucleus whereas MDR cell lines distributed drug elsewhere (exact 
localisation was not possible with their system) and that this redistribution could be 
blocked by raising the extracellular pH. The pH required to return drug distribution to 
the nuclear pattern of the parental cell line increased in parallel with the P-gp content 
of the cell lines. This connection between drug distribution, pH and P-gp has not been 
explained. Could P-gp be involved, either directly or indirectly with acidification of 
internal organelles? Gervasoni et al, (1991) stated "the possibility that a molecule 
similar to the P-gp may act as an ion channel to acidify and trap drug within the 
vesicles is now being investigated". Since Gervasoni made this statement, there is
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evidence that mdrl may act as a volume regulated chloride channel (Valverde et al, 
1992), but the link between this and pH gradients in organelles remains obscure.
There are some intriguing associations between P-gp like molecules and 
acidic vacuoles in other biological systems. In malarial parasites, the ABC 
superfamily transporter protein encoded by the pfmdrl gene has been localised to the 
acidic digestive vacuole of the parasite. This internal compartment is the site of 
chloroquine accumulation in the parasite and resistant strains of P.falciparum 
accumulate less drug in this compartment. The product of the pfmdr gene appears to 
contribute to the reduced intra-vacuolar accumulation of drug (reviewed by Ginsburg 
and Krugliak, 1992). This accumulation deficiency can be partially corrected by 
MDR drugs such as vinblastine and daunomycin and by modulators such as 
verapamil and so it seemed reasonable to postulate that this accumulation deficit was 
due to the pfmdr product pumping chloroquine out of the food vacuole.
Just like the complexities of mdrl efflux and drug accumulation studies in 
cancer cells, the association of chloroquine efflux and drug concentration in the food 
vacuole is not straightforward and cannot be explained solely on the basis of a pfmdr 
chloroquine pump. In fact the hypothesis that point mutations in the pfmdr protein 
and pfmdr gene amplification lead to chloroquine resistance in malaria have now 
been discredited (Krogstad et al, 1992). Instead, complex changes in the kinetics of 
influx and efflux into the vacuole suggest that alterations in H+ pumping and H+ leak 
from the vacuole may contribute to the localisation of the drug. As yet, there is no 
clear understanding of the normal function of the pfmdr product in the digestive 
vacuole or its role in ion or proton fluxes.
It is obvious from analogies to Plasmodia that it is important to address the 
question of P-gp localisation and how this contributes to maintenance of acidic 
organelle compartments in cells. This is not just of relevance to antigen presenting 
cells and plasmodia but is also of major importance in drug resistance. The 
introductory chapter discussed some of the evidence suggesting that part of the MDR 
phenotype may be due to effectively separating the MDR drugs from their targets 
through re-distribution into alternate cellular compartments. Some of the MDR drugs, 
such as doxorubicin, are weak bases with a tendency to accumulate in acidic cellular 
compartments (discussed in review article by Van der Bliek and Borst, 1989). The 
role of P-gp in facilitating this compartmentalisation has to be studied further.
The antigen presenting cells, or perhaps phagocytic macrophages, may 
represent a convenient model for these investigations. However the presence of the 
tap gene products will have to be taken into account when assessing experimental 
results in APC. For instance, cyclosporin A, which is a P-gp modulator, is known to 
inhibit antigen presentation in vitro through an unknown mechanism (Dupuy et al,
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1991). This mechanism could conceivably involve blocking of P-gp or the tap 
proteins action. More specific methods of addressing physiological and pathological 
P-gp function are obviously needed; antisense oligonucleotides and function 
perturbing antibodies are two potentially useful approaches which would have greater 
specificity than modulator drugs.
In the canine dendritic cells, P-gp staining was granular rather than diffuse 
and hence the above discussion focussed on organelle localisation that could give this 
granular appearance. However cytoplasmic localisation of P-gp in cancer cells has 
been interpreted in a very different way by other workers.
For example, Weinstein et al (1991) have observed a relationship between 
expression of P-gp in solitary invading cells at the leading edge of colonic tumours 
and metastasis of these heterogeneously P-gp expressing tumours to the regional 
lymph nodes. They postulate that the solitary P-gp positive cells may have an 
increased potential for dissemination. Part of their hypothesis is based on preliminary 
observations that P-gp may be concentrated on the cell surface at adhesion plaques 
and that P-gp hyperexpressing cells have enhanced cell locomotion (Weinstein et al, 
1989). The authors do not speculate as to the function of P-gp at these sites. Dendritic 
APC are also highly motile cells; in the living state they can extend and retract 
lamellipodia from the cell body as if "sampling" the surrounding lymphocyte 
population (Inaba et al, 1992).
However, despite the elapse of three years since the meeting abstract was 
published which showed P-gp at adhesion plaques, these findings have not yet been 
published in a refereed journal. Although Weinstein's hypothesis is biologically 
interesting in terms of tumour progression events, there are problems in their 
argument. In the P-gp positive cells present at the leading edge of the colonic 
carcinomas, the P-gp in these cells was not proven to be associated with the cell 
surface or with adhesion plaques. In the authors own words "in P-gp positive invasive 
carcinoma cells, granular and diffuse cytoplasmic staining was common. Plasma 
membrane staining was difficult to demonstrate in paraffin sections." It is unfortunate 
that despite using paraffin sections rather than frozen sections these authors were still 
unable to show convincing membrane staining. This places their hypothesis about P- 
gp localisation around adhesion plaques in some doubt. In an earlier review article by 
the same group (Weinstein et al, 1990b), the P-gp positive cells at the invasion front 
of the colonic carcinomas was not linked to potential metastatic potential but instead 
likened to the morphologic alterations that can occur in bacteria when placed in 
impoverished circumstances. The authors postulated that this cytoplasmic mdrl 
expression could be a survival strategy for the cancer cells in a hostile environment.
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This latter hypothesis, suggesting a connection between P-gp and 
environmental stress certainly has more experimental support than the connection 
with cell motility. Figure 8.2 is taken from an article describing agents which can 
induce transcription of the hsp70 (heat shock protein) family (Morimoto, 1991). 
Many of the heat shock family inducers have also been shown to increase mdrl gene 
expression either in vitro or in vivo; these are listed in the legend of figure 8.2.
Figure 8.2 Factors which increase mdrl mRNA
1. e n v i r o n m e n t a l  s t r e s s
A M I N O  A C I D  
A N A L O G U E S
T R A N S I T I O N  
H E A V Y  M E T A L S
S H O C i n h i b i t o r s  o f  e n e r g y
M E T A B O L I S M
2.  P A T H O P H Y S I O L O G I C A L  S T A T E  i
F E V E R
H Y P E R T R O P H Y  
O XID A N T INJURY  
INFLAM MAT ION  
ISCH EM IA
A N T I-N E O P L A S T IC  C H E M I C A L S  
VIRAL INFE CT ION
O N C O G E N E S  AND  
P R O T O - O N C O G E N E S
3. NON-STRESSFUL ! 
CONDITIONS
D E V E L O P M E N T
AND
DIFFERENTIA TION
CELL
CY C L E
G R O W T H
F A C T O R S
References for figure 82
1. Heat shock: Chin etal, 1990b
2. Transition heavy metals: Chin et al, 1990b
3. Hypertrophy: Fairchild et al, 1987; Thorgeirsson et al, 1987
4. Inflammation: Marino et al, 1990; Thorgeirsson et al, 1987
5. Anti-neoplastic chemicals: Chin et al, 1990a; Licht et al, 1991
6. Viral infection: Gollapudi & Gupta, 1990
7. Oncogenes: Burt etal, 1988
8. Development and differentiation: Bates et al 1989, Meyers et al. 1991
9. Growth factors: Chapekar et al. 1990
Figure 8.2 illustrates that induction of mdrl expression is not limited to agents 
which are potential MDR substrates. Indeed the connection between some of the 
factors and the proposed function of P-gp as an efflux pump is obscure. In rat liver in 
vivo, noxious chemicals (which are not P-gp substrates) have been shown to induce 
liver mdrl in conjunction with inciting changes in cytochrome P450 enzymes and 
glutathione transferases (Fairchild et al„ 1987; Burt and Thorgeirsson, 1988). This 
apparently co-ordinated response suggests that mdrl induction can occur as part of a
generalised detoxification reaction in liver cells (Gottesman 1988). The mechanism 
underlying this coordinated response is not known. Initial experiments indicated that 
the Ah receptor may be involved in the coordinated response (Burt and Thorgeirsson, 
1988) but further work has suggested otherwise (Gant et al, 1991).
The presence of a conserved AP-1 site in both human mdrl and mouse mdrl a 
promotors (Ueda et al, 1987b; Hsu et al, 1990) make the c-fos and c-jun proto­
oncogene products contenders for controlling events in mdrl induction. The 
coinduction of glutathione S-transferase and mdrl in rat liver supports this role; 
glutathione S-transferase is known to be induced via AP-1 elements in the placenta 
(Sakai et al, 1988) and c-jun and c-fos levels are known to be elevated during 
chemical hepatocarcinogenesis (Sakai et al, 1989). The role of the heat shock 
proteins themselves in mdrl induction is unknown.
Returning to the APC model of a P-gp expressing cell, one of the alternate 
class I presentation pathways which occurs in serum-starved cells involves a 70kd 
hsp which translocates cytosolic proteins into the lysosomal pathway of degradation. 
Brodsky and Guagliardi (1991) propose that this association with hsp70 could mean 
that any stressed cell could upregulate its lysosomal degradative pathway. If P-gp is 
also needed for some unknown function in these acidic compartments then it would 
be logical that the hsp70 and P-gp should have coordinate regulation.
8.3 IS MDR DRUG TREATMENT CRITICAL FOR P-GP ACQUISITION IN 
LYMPHOMAS?
The connection between non-specific cellular stress and P-gp induction 
returns this discussion to the original aim of this thesis; to investigate the role of P-gp 
in mediating in vivo resistance to anthracyclines. This study has shown that treatment 
with an anthracycline only protocol was no more likely to result in P-gp positive 
disease at relapse than a COP protocol in which cyclophosphamide (a non-MDR 
drug) was the predominant drug. However, the COP protocol does have an MDR 
component and so it is still feasible that MDR drug selection has allowed the 
preferential outgrowth of a P-gp positive sub-population.
The experimental evidence from the rat liver carcinogenesis model has shown 
that certain chemicals (which are not mdr substrates) can elicit a detoxification 
response which includes upregulation of mdrl (Gant et al, 1991). This would suggest 
that it could be possible for cyclophosphamide to select lymphoma cells which have 
multiple resistance mechanisms, one of which is P-gp expression.
The Goldie-Coldman hypothesis proposes that resistant variants arise at a 
frequency compatible with the spontaneous mutation rate of the cell population. 
Based on purely stochastic model of drug resistance, the appearance of mutants with
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resistance to multiple agents should be a very rare event. However acquisition of 
multiple agent resistance does not always appear to be stochastic. Cells selected with 
doxorubicin and methotrexate produce dual resistant variants at a higher rate than 
would be predicted from the frequency of single drug resistance variants (Rice et al, 
1987).
In cell lines prior exposure to carcinogens can increase the frequency of drug 
resistant variants in the population (McLaughlin et al, 1991). In the rat liver model, 
chemical carcinogen treatment led to increased P-gp expression. Hepatocytes isolated 
from rats exposed to 2-acetylaminofluorine (AAF) and other carcinogens are more 
resistant to doxorubicin and methotrexate than normal hepatocytes (Carr, 1987). In a 
similar fashion, mouse skin papillomas which have been promoted by the chronic 
application of chemical carcinogens are more doxorubicin resistant than virally 
induced papillomas (Keith et al, 1990b). This suggests that exposure to chemical 
carcinogens results in the development of a population of cells resistant to the 
cytotoxic effects of the carcinogen (Farber, 1980).
What relevance does this have to canine and human NHL which do not have a 
strong link to chemical carcinogenesis? The pleotropic effects of the chemical 
carcinogens in rat liver cells can be mimicked by oncogenic activation events. Burt et 
al. (1988) transformed rat liver epithelial cells with v-H-ras or v-raf ; this 
transformation was found to be accompanied by the acquisition of an MDR 
phenotype and increased mdr gene expression. So in this particular model, neoplastic 
transformation of liver epithelial cells resulted in mdrl expression independent of 
chemical exposure.
That mdr expression could arise as part of the neoplastic process would 
concur with the observations made in the introductory chapter regarding P-gp 
expression in leukaemias. Mature leucocytes do not seem to express P-gp and yet 
untreated leukaemias, especially the blast crises of CML are not infrequently P-gp 
positive. It is also relevant to remember that P-gp expression is more likely to occur 
in canine lymphomas which present in an advanced stage of disease. These tumours, 
which have metastasized outwith the lympho-reticular system, are presumed to have 
undergone more cell doublings to have reached their extensive tumour bulk and to 
have gained a metastatic potential. The association of P-gp with clinically advanced 
disease has been noted in other tumour types including neuroblastomas and 
retinoblastomas (Chan etal, 1991a and 1991b).
The association of P-gp expression with advanced stage malignancies is 
explicable by the Goldie-Coldman hypothesis. The biologically advanced tumours 
would be presumed to contain a more heterogeneous population upon which drug 
treatment selects resistant variants. The treatment with mutagenic chemotherapeutic
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agents (MDR and non-MDR) may even increase the number of resistant variants in 
the total population.
It is accepted that NHL is a progressive disease in which phenotypic changes 
occur. NHL in humans commonly displays histologic and cytogenetic evidence of 
tumour progression. Histologically, follicular tumours can transform into diffuse 
tumours both in treated and untreated malignancies (Homing et al, 1985). This has 
also been reported in the dog (Gray et al, 1984). The cytogenetic abnormalities which 
amass in NHL were described in sections 1.5 and 1.6. It was noted that 
morphologically diverse tumours acquired different genetic abnormalities suggestive 
of inexorable, defined, tumour progression.
Recent observations are beginning to shed light on the connection between 
tumour progression events and the frustrating emergence of a resistant phenotype. 
One of the most common genetic abnormalities associated with human malignancy is 
the loss or mutation of the p53 tumour suppressor gene on chromosome 17q. Wild- 
type p53 appears to be potent transcription factor for as yet unidentified genes 
(Farmer et al, 1992) and can prevent the transforming activity of mutant p53 in co- 
transfection studies. Lane (1992) proposes that the tumour suppressor activity of p53 
may be related to its ability to prevent DNA replication in the presence of DNA 
damage. This is based on observations that DNA damaging agents cause 
accumulation of wild-type p53 and a concurrent cell cycle block in G1 (Kastan et al, 
1991). Prolonged elevation of wild type p53, presumably in the face of irrepairable 
DNA damage, can result in apoptosis (Yonish-Rouach etal, 1991) . In this way p53 
guards against heritable genetic abnormalities.
Wild type p53 function can be compromised by complexing with mutant p53 
and other cellular proteins which are involved in neoplastic progression such as 
MDM2 (Oliner et al, 1992). The net result is that many malignancies do not have 
normal p53 function and therefore do not effectively shut down DNA replication in 
the presence of DNA damage. This would allow tumour cells to continue dividing 
despite the DNA damage imposed by chemotherapeutic agents. Some tumour cells 
would die because the resultant genetic defects are incompatible with survival but 
inevitably the tumour cells would accumulate genetic abnormalities which would 
provide a wealth of variants upon which drug selection could act.
Recently, preliminary observations suggest there may be a direct connection 
between p53 tumour progression events and the acquisition of P-gp expression. The 
MDR1 gene promoter is a target for p53 modulating activity. Chin et al (1992) 
examined the effects of wild-type and mutant p53 on the MDR1 promoter activity by 
cotransfecting MDR1 promoter-CAT constructs with expression vectors containing 
the oncogene and the tumour suppressor genes. The mutant p53 stimulated
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MDRCAT expression in the NIH3T3 transfectants and this enhancement was 
completely abolished by cotransfection with wild-type p53. Obviously, these findings 
using promoter constructs have to be confirmed in the intact mdrl gene. Essential 
experiments, which are presumed to be underway, would include the effects of 
removing normal p53 activity in cell lines with constitutive versus inducible mdrl 
expression.
A fairly direct link between p53 function and P-gp expression may account 
for the rather inexplicable connection between X-irradiation of cell lines and 
consequent stable expression of P-gp (Hill et al, 1990). Temporary expression of P- 
gp following DNA damage could occur due to the ill-defined "stress" related 
induction of mdrl but stable expression would require a different mechanism, 
perhaps mutation of p53. However, even this does not entirely fit all the available 
information; irradiation led to increased P-gp but no significant alteration in mdrl 
mRNA. So perhaps the mutagenic event involves translational control rather than 
transcription or message stabilisation.
Abnormalities which could result in loss of one p53 allele have been 
identified as adversely affecting prognosis of NHL in three studies (Levine et al, 
1990; Yunis et al, 1989; Rodriguez et al, 1991). However, the involvement of other 
cellular proteins that can complex with p53 and prevent normal function means that 
tumours which have retained normal p53 may still be defective in p53 function due to 
amplifications at another loci (Oliner et al. 1992). These findings suggest that the 
emergence of mdrl drug resistant disease may not simply be due to drug selection of 
randomly occurring resistant mutants but be an integral part of the neoplastic process 
in which the emergence of P-gp positive clones is a genetically favoured event due to 
the lack of normal p53 activity. If this is indeed the case, then drug resistance may be 
an inevitable consequence of the genetic instability of malignancy and drug treatment 
merely acts as a catalyst to speed up the process.
8.4 CANINE MLSA AS A MODEL FOR NHL: CLINICAL CONCLUSIONS
The results of this longitudinal study mirror the emerging picture of P-gp in 
NHL (Miller et al, 1991). P-gp is rarely expressed in pre-treatment disease but is 
considerably more common at relapse, but this expression is definitely not 
ubiquitous. The relatively small percentage of canine patients who expressed P-gp at 
relapse confirms the fact that studies with P-gp modulators have to be interpreted 
following establishment of the P-gp status of the tumour. In human, and especially 
canine NHL, it cannot be assumed that MDR drug resistant disease will be P-gp 
positive.
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As discussed in the first section of this chapter, modulators can have effects 
even in P-gp negative cell lines and so apparent amelioration of clinical drug 
resistance cannot be construed as proof of P-gp activity. Similarly, this study does not 
prove that the resistance to MDR drugs in the minority of relapse tumours which 
expressed mdrl was actually P-gp mediated. In fact given that the majority (75%) of 
relapse tumours did not express P-gp and were equally drug refractory, the 
dominance of other resistance factors has to be proposed. Among the most likely 
candidates for anthracycline resistance would be alterations in the amount or activity 
of the topoisomerase II genes which are one of the targets of the anthracyclines 
(Zhang et a l 1990). However, this cannot explain the coincident resistance of these 
lymphomas to the alkylating agent cyclophosphamide.
Stage of disease had the most profound effect on P-gp expression, more than 
the dose of MDR drug or the length of treatment. This validates some of the central 
dogmas of medical oncology. It is often repeated in textbooks that chemotherapy 
should be instituted at the earliest oppurtunity, that the highest tolerated dose of drugs 
should be used and that wherever possible the least mutagenic agents should be 
chosen; this is of course all based on the recognised fact that the best chance of a cure 
is at first presentation (Sobrero and Bertino, 1986). From the discussion in the 
previous section, the molecular basis for these clinical guidelines are at last being 
discovered.
P-gp expression was connected with clinical stage at presentation but several 
other trends were also evident, which because of low numbers involved, did not reach 
statistical significance. Among these were a lack of P-gp in all tumours with TCR 
gene rearrangements and a propensity for P-gp in males rather than females. This 
latter point may appear trivial, but the hamster provides a precedence for male 
restricted P-gp expression in the adult adrenal gland (Bradley et al, 1990) and so it 
should not be excluded that sex-specific effects in P-gp expression in tumours could 
occur.
The lack of P-gp in T cell tumours is definitely worthy of further 
investigation; earlier chapters have discussed the evidence that P-gp, of different 
isoforms, can be expressed in normal and malignant B cells and section 8.2 discussed 
the connection between P-gp and antigen presenting cells. Germinal centre B cells 
can be very efficient APC (Brodsky and Guagliardi, 1991) and given that the 
centrocytic histologic class of NHL is presumed to arise from these germinal centre 
cells (Lennert et al, 1975) it could be that certain B cell tumours have a propensity to 
express P-gp because the oncogenic process is mimicking a normal lymphocyte 
activation process. The association of P-gp with B cells could be simply and quickly 
confirmed or refuted in human NHL. Immunophenotyping is routinely carried out in
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many centres and could easily be incorporated into study design. It is imperative that 
human NHL studies start to assess P-gp status in conjunction with basic prognostic 
factors such as histological subtype and immunophenotype if the biology and 
relevance of P-gp are to be better understood.
The first chapter noted that human HTLV-I lymphomas had a higher 
frequency of P-gp expression than other NHL. These are exclusively T cell tumours; 
this does not nullify the above observations that immunophenotype should be defined 
in P-gp studies. The connection between specific oncogenic events and P-gp 
expression in tumours could account for the higher incidence of P-gp in the HTLV 
lymphomas. Unfortunately, at this stage, it is still impossible to rule out that the 
differences between NHL and ATL could be due to sample size and methodologic 
variation.
It is also worthy of note that in the series of five bull mastiffs lymphomas, 
four cases did not have any TCR P gene rearrangements and only BOA had evidence 
of one TCR P chain allele rearrangement. There was dubiety about whether BOA had 
both alleles rearranged and so this sample could quite possibly not be a phenotypic T 
cell. As mentioned in the introduction, the clustering of lymphomas in three families 
of Bull Mastiffs could be construed as evidence of a possible infectious aetiology. 
The leukaemogenic retrovirus' feline leukaemia virus and HTLV-I produce almost 
exclusively T cell tumours. In the case of HTLV-I, these lymphomas are 
histologically high grade and clinically aggressive. This does not parallel the clinical 
picture of Bull Mastiff lymphomas which clinically are often quite indolent. Indeed 
one of the bull mastiffs, CMD, was the only low grade tumour, according to the 
Working Formulation, in the entire series of all lymphomas (Sean Callanan, personal 
communication). This clinical and histopathological discrepancy from HTLV-I 
lymphomas does not rule out a retroviral aetiology. Bovine leucosis virus, which is 
related to HTLV-I, produces chronic B-cell proliferation in infected cattle and in a 
small percentage leads to (pre)-B cell tumour formation (Bumy et al, 1987). The 
susceptibility to B cell lymphocytosis is heritable and is related to the bovine 
lymphocyte antigen (BoLA) haplotype (Lewin and Bemoco, 1986). Non-retrovirus' 
are also implicated in B cell lymphoproliferative diseases in man. The herpes virus 
Epstein Barr virus can immortalise B cells (through an undefined mechanism) and it 
has been proposed, that this immortalisation then allows B cells carrying a random 
second event (such as chromosomal translocations of c-myc) to survive and expand 
(Thomas et al 1991; Rogers et al, 1992). Thus there are several natural models upon 
which to base investigation of an infectious origin of the Bull Mastiff lymphomas.
This study confirms the observations of Price et al (1991) in which steroid 
pretreatment adversely affected clinical performance. Fortunately, humans with
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lymphoma will not often have been prescribed steroids prior to the initiation of 
chemotherapy. However, the association of corticosteroids with poor complete 
response rate does have some relevance to human oncology. None of the dogs which 
received considerable corticosteroids prior to chemotherapy were P-gp positive at 
diagnosis. The promoter region of the murine mdrlb has been reported to contain 
steroid responsive elements (Cohen et al, 1991) and in the secretory epithelium of the 
mouse uterus, mdrl expression is reported to be under the control of steroid 
hormones (Arceci et al, 1990). Hence a direct relationship between steroid 
administration and P-gp induction could be envisaged. This study would suggest that 
this does not often occur in lymphomas.
The biochemical basis for steroid induced anthracycline resistance is not- 
known. From the clinical presentation of the pre-treated dogs it is not likely to be due 
to major changes in the cell-cycling status of the tumour population because the 
referred dogs showed rapid regrowth of the lymphomatous nodes either following 
cessation of the steroids or while still receiving steroids. Continued tumour growth 
was usually the underlying reason for the case referral. Corticosteroids induce 
apoptosis in normal lymphocytes and most lymphomas are steroid-sensitive initially; 
loss of steroid sensitivity in human lymphomas is usually linked to down regulation 
of steroid receptors (Norgaard and Poulsen, 1991). But what could be the connection 
between down-regulation of the steroid receptors and anthracycline resistance? This 
may be another area where a better understanding of the events which promote and 
block apoptosis would be highly beneficial.
One of the main suggestions that the preceding section on p53 and tumour 
progression makes is that tumour cells may not necessarily become drug resistant in 
the sense of avoiding all damage from the agent. It is perhaps more accurate to 
describe them as drug-tolerant in that DNA replication of damaged DNA is allowed 
to proceed. If this is true, to investigate the phenomenon of clinical multiple agent 
resistance, it may be more worthwhile concentrating efforts on the understanding of 
DNA repair and apoptosis than on mechanisms peculiar to only a small group of 
drugs. Topoisomerases (as the targets for etoposide and the anthracyclines) are 
exceptional in that these enzymes are intimately involved with DNA metabolism and 
abnormal function of these enzymes probably contributes to the genetic instability of 
malignancy.
As a natural model for acquired resistance, canine MLSA has proved very apt 
and could profitably be used again. For instance, the hypothesis that MDR drugs are 
not a pre-requisite for acquired P-gp positive disease could be confirmed using 
MLSA cases treated with asparaginase. Single agent treatment with asparaginase 
(which is not an MDR substrate) gives remission and survivals which are directly
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comparable with this study (Teske et al, 1990) and so the time-span of treatment 
would be similar.
It is unfortunate that the chromosomal translocations and cytogenetic 
abnormalities in canine MLSA are completely unknown. However, as a model of 
tumour progression, this disease is still worthy of attention. Monoclonal antibodies 
used to detect wild-type and mutant p53 can work across species barriers and it is 
feasible that this could be exploited to investigate alterations in p53 which 
accompany drug resistant relapse.
The power of this longitudinal study was jeopardised by the loss of follow-up 
samples, the inconsistency of clinical results in the first year and by lack of detailed 
histopathological reports. Such problems could be minimised in future studies by 
diligent client communication, use of a single designated clinician and full 
collaboration with the pathology department. In this way, canine MLSA could 
continue to be a useful natural tumour model.
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